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Oncogenic KRAS signaling is the main driving force behind pancreatic ductal 
adenocarcinoma (PDAC); however, targeting this pathway has proven to be difficult. 
Conversely, the PI3K/Akt pathway represents an exciting new target, because it has 
been associated with poor prognosis and chemoresistance, and several inhibitors are 
under development. In particular, perifosine prevents Akt traslocation to the cell 
membrane, while MK-2206 is an Akt allosteric inhibitor and BEZ-235 is a dual 
PI3K/mTOR inhibitor. Therefore, we investigated the prognostic role of phospho 
(p)-Akt1 in PDAC tissues, as well as the molecular mechanisms underlying the 
interaction of Akt inhibitors with gemcitabine, using PDAC cells, primary cultures 
and spheroids. 
Immunohistochemistry of tissue microarrays with specimens from radically-resected 
patients (n=100) revealed a correlation between high p-Akt1 expression and worse 
outcome. Patients with low p-Akt1 expression (as detected by digital scoring) had a 
median overall survival (OS) of 16.2 months (95% CI, 14.8-20.1), while patients 
with high expression had a median OS of 12.0 months (95% CI, 9.0-14.9, P=0.03). 
Parallel immunocytochemistry studies revealed high expression levels in LPC028 
primary cells, while LPC006 where characterized by low p-Akt1.  
Akt inhibitors reduced cancer cell growth in monolayers and spheroids, and 
synergistically enhanced the antiproliferative activity of gemcitabine in LPC028 
(e.g., combination index CI of 0.2, in the gemcitabine-perifosine combination for 
72h, at fixed IC50 ratio)., while this combination was antagonistic in LPC006 cells. 
The synergistic effect was paralleled by a 5-fold reduction in the expression of the 
main gemcitabine target ribonucleotide reductase. Inhibition of Akt decreased cell 
migration and invasion, which was additionally reduced by the combination with 
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gemcitabine. However, the combination of Akt inhibitors with gemcitabine increased 
apoptosis, associated with induction of caspasi-3/6/8/9, PARP and BAD, and 
inhibition of Bcl-2 and NF-KB in LPC028, but not in LPC006 cells. 
The Akt signaling is involved in the expression/localization of the key glucose 
transporter Glut1, and increased glucose metabolism was associated to resistance to 
axitinib (Hudson et al., Cell Death Dis, 2014). Remarkably, the resistant LPC006 
cells were characterized by overexpression of Glut1, which was not reduced after 
exposure to Akt inhibitors. However, the novel Glut1 inhibitor PGL-13 enhanced 
perifosine and perifosine/gemcitabine-induced cell death. 
In conclusion, our findings support the analysis of phosphor-Akt1 expression as both 
a prognostic and predictive biomarker, for the rationale development of new 
combination therapies targeting the Akt pathway in PDAC. Finally, inhibition of 
Glut1 might overcome resistance to these therapies and warrants further studies.   
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PI3K/AKT/mTOR SIGNALING PATHWAY 
PI3K/Akt/mTOR (PAM) pathway is often altered in patients with cancer. This 
pathway controls several biological activities within the cell, and its activation is one 
of the fundamental downstream molecular events following tyrosine kinase growth 
factor receptor activation [1,2,3]. 
  
 
              FIGURE 1: Activation mechanism of PI3K/AKT/mTOR signaling pathway 
 
 
The first event is the activation of PI3K; The PI3Ks, a family of lipid kinases, can be 
divided into three classes according to the structure, mode of regulation and lipid 
substrate specificity, of which the class I PI3K is related to cancer [4]. 
8 
 
Within class IA, the genes PIK3CA, PIK3CB, and PI3KCD, encode the homologous 
p110α, p110β, and p110δ isozymes respectively. Class IB consists of PIK3CG, 
which encodes p110γ. p110α and p110β are ubiquitously expressed while the 
expression of p110δ and p110γ is generally restricted to hematopoietic and immune 
cells. Class IA PI3Ks are heterodimeric proteins made up of a p110 catalytic subunit 
and a p85 regulatory subunit, and are involved in carcinogenesis.  
PI3K is activated upstream by the binding of a growth factor or ligand to its cognate 
growth factor receptor tyrosine kinases (RTKs), which include members of the 
human epidermal growth factor receptor (HER) family, and the insulin and insulin-
like growth factor 1 (IGF-1) receptor, among others [5]. PI3K phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
triphosphate (PIP3), which in turn leads to phosphorylation of Akt, a serine/threonine 
kinase. PIP3 acts as a docking site for AKT, which is the central mediator of the 
PI3K pathway and phosphoinositide-dependent kinase 1 (PDK1). Phosphorylation of 
AKT stimulates protein synthesis and cell growth by activating mTOR via effects on 
the intermediary tuberous sclerosis 1/2 complex (TSC1/2) [6,7]. 
Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a tumor 
suppressor, which has inhibitory effects on the pathway by dephosphorylating PIP3 
to PIP2 [8]. PIP3 levels are hence closely regulated by the opposing activities of 
PTEN and PI3K [9]. The role of inositol polyphosphate 4-phosphatase type II 
(INPP4B), another tumor suppressor, is increasingly recognized. INPP4B is also 
involved in dephosphorylation of PIP3 to PIP2 [10].  
mTOR, a serine/threonine protein kinase, is a downstream effector of PI3K and Akt. 
It comprises two different complexes, mTOR complex 1 (mTORC1) and mTOR 
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complex 2 (mTORC2), which are structurally similar but functionally different. 
mTORC1 is the target of rapamycin and rapamycin analogues, such as everolimus, 
and leads to cell anabolic growth by promoting mRNA translocation and protein 
synthesis [11] and also has roles in glucose metabolism and lipid synthesis. Its 
downstream substrate S6 kinase 1 can phosphorylate the activation function domain 
1 of the ER, which is responsible for ligand-independent receptor activation [12]. 
mTORC2 on the other hand, organizes the cellular actin cytoskeleton and regulates 
AKT phosphorylation. Rapalogues exert their effect mainly on mTORC1 and the 
incomplete inhibition can lead to feedback loops causing paradoxical activation of 
Akt and proliferative effects via other downstream targets. 
 
PAM PATHWAY IN PANCREATIC DUCTAL ADENOCARCINOMA 
In pancreatic ductal adenocarcinoma (PDAC) PAM pathway plays a crucial role 
because deregulation of components involved in this pathway could confer resistance 
to chemotherapy, while blockage of Akt signaling results in programmed cell death 
and inhibition of tumor growth. Activation of Akt is a frequent event in PDAC and 
has been correlated to its poor prognosis [13,14]. 
The serine/threonine kinase Akt, which is coded in three highly homologous 
isoforms (Akt1, Akt2 and Akt3), is overexpressed in more than 40% of PDAC 
patients [15]. 
Mechanisms underlying aberrant Akt activation in cancer include direct alterations 
such as mutations, amplification or overexpression, but also activation of upstream 
signaling events, such as activation of HER-2/neu signaling or PTEN mutation/loss 
[16]. 
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PANCREATIC DUCTAL ADENOCARCINOMA 
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal solid tumors. 
Despite extensive preclinical and clinical research, the prognosis of this disease has 
not significantly improved, with a 5-year survival rate around 7% [17].  
This dismal outcome can partially be explained by the lack of biomarkers for 
screening and diagnosis at earlier stages, and by the resistance to most currently 
available chemotherapy regimens. This resistance has been attributed to both the 
desmoplastic tumor microenvironment and to the strong inter- and intra-tumor 
heterogeneity in terms of complexity of genetic aberrations and the resulting 
signaling pathway activities, as well as to resistance mechanisms that quickly adapt 
the tumor to drugs [18]. 
Therefore, there is an urgent need to better understand the molecular pathology of PC 
in order to improve patient selection for current treatment options, and to develop 
novel therapeutic strategies. Genomic analyses of pancreatic cancer reveal a complex 
mutational landscape with four common oncogenic events in well-known cancer 
genes (KRAS, TP53, SMAD4 and CDKN2A), among of genes mutated at low 
prevalence. Despite this heterogeneity, oncogenic point mutations of individual 
genes aggregate into core molecular pathways including DNA damage repair, cell 
cycle regulation, TGF-β signalling, chromatin regulation and axonal guidance 
[19,20]. Increasingly sophisticated analyses are revealing biologically important 
events with clinical significance, including whole-genome sequencing, which sub-
classifies PC into 4 on the basis of the differential expression of transcription factors 
and downstream targets important in lineage specification and differentiation during 
pancreas development and regeneration:  
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9 Squamous 
9 Pancreatic progenitor 
9 Immunogenic 
9 Aberrantly differentiated endocrine exocrine 
 
AKT INHIBITORS 
Several inhibitors of Akt are under investigation, but three are the farthest along and 
showed the most promise in early clinical research: the pan-Akt and PI3K inhibitor 
perifosine (KRX-0401, Aeterna Zentaris/Keryx), the allosteric pan-Akt inhibitor 
MK-2206 (Merck), and the dual PI3K/mTOR inhibitor dactolisib (NVP-BEZ235, 
Novartis).  
In particular, the synthetic oral alkylphospholipid perifosine [21,22] has been 
evaluated in clinical trials for several tumors, including colon, breast, head and neck 
and prostate cancer [23,24,25,26]. Unfortunately, it failed the phase III clinical trials 
for treatment of colon cancer and relapsed refractory multiple myeloma 
(www.clinicaltrials.gov). These failures together with the disappointing response 
rates to perifosine as a single agent in most solid tumors, including PDAC, prompt 
further studies into its mechanism of action [27]   as well as on synergistic 
combinations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Perifosine prevents translocation of Akt to the cell membrane by blocking the 
pleckstrin homology (PH) domain of Akt [28] leading to inactivation of downstream 
pathway and inhibition of cell proliferation. Previous studies demonstrated perifosine 
activity against different cancer types, in vitro and in vivo [29]. 
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Recently, Pinton and collaborators showed that perifosine inhibited cell growth of 
malignant pleural mesothelioma cells by affecting EGFR and c-Met phosphorylation 
[30]. Another study showed that perifosine decreased the AEG-1 gene expression 
along with inhibition of Akt/GSK3/c-Myc signaling pathway in gastric cancer [31]. 
Perifosine and curcumin synergistically increased the intracellular level of reactive 
oxygen species and ceramide, and downregulated the expression of cyclin-D1 and 
Bcl-2 in colorectal cancer cells [32]. 
Finally, perifosine also inhibits the anti-apoptotic mitogen-activated protein kinase 
(MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic 
stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis 
[33]. 
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The aim of my project is to investigate the expression of phospho-Akt1 in PDAC 
tissues and cells, and to evaluate the effects of growth inhibition by Akt inhibitors, 
using PDAC cell lines and primary cultures growing as monolayer or as spheroids. 
Moreover, characterize several key factors, affecting cell cycle perturbation, 
apoptosis induction, as well as inhibition of cell migration and invasion and 
modulation of key factors in glucose metabolism in PDAC cells exposed to 
perifosine and perifosine/gemcitabine combination. 
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DRUGS AND CHEMICALS  
Perifosine was provided by Æterna Zentaris Inc. (Frankfurt am Main, Germany), 
NVP-BEZ235 was purchased from Selleck Chemicals (Houston, TX) while 
gemcitabine and MK-2206 were generous gifts from Eli-Lilly (Indianapolis, IN), and 
Merck (Whitehouse Station, NJ), respectively. The drugs were dissolved in Dimethyl 
sulfoxide (DMSO) or sterile water, and diluted in culture medium before use. RPMI-
1640 medium, foetal bovine serum (FBS), penicillin (50 IU/ml) and streptomycin (50 
µg/ml) were from Gibco (Gaithersburg, MD). All other chemicals were purchased 
from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
CELL CULTURE   
Seven PDAC cell lines (PL45, MIA-PaCa2, HPAF-II, CFPAC-1, Bxpc3, HPAC and 
PANC-1) and the human immortalized pancreatic duct epithelial-like cell line 
hTERT-HPNE were obtained from the American Type Culture Collection, whereas 
seven primary PDAC cultures (LPC006, LPC028, LPC033, LPC067, LPC111, 
LPC167 and PP437) were isolated from patients at the University Hospital of Pisa 
(Pisa, Italy), as described previously [28]. The cell lines were tested for their 
authenticity by PCR profiling using short tandem repeats by BaseClear (Leiden, The 
Netherlands). The cells were cultured in RPMI-1640, supplemented with 10% heat-
inactivated FBS and 1% streptomycin/penicillin at 37 °C, and harvested with trypsin- 
EDTA in their exponentially growing phase. 
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GROWTH INHIBITION STUDIES  
The cell growth inhibitory effects of perifosine, MK-2206 and NVP-BEZ235 were 
evaluated in the PANC-1 and LPC028 cells. Further studies evaluated perifosine and 
gemcitabine combination in CFPAC-1, PANC-1, LPC028 and LPC006 cells. These 
cells were treated for 72 hours with perifosine (1-500 μM), gemcitabine (1-500 nM), 
and simultaneous combination at a fixed ratio based on IC50 (i.e. concentration of a 
drug required for 50% inhibition of cell growth) of each drug. The plates were then 
processed for the sulforhodamine-B assay, as described. 
TISSUE MICROARRAYS (TMAS), IMMUNOHISTOCHEMISTRY (IHC) 
AND IMMUNOCYTOCHEMISTRY (ICC) 
Phospho-Akt protein expression was evaluated in slides from four formalin-fixed, 
paraffin-embedded PDAC-specific TMAs build with neoplastic cores from a cohort 
of radically-resected patients (n=100), using the TMA Grand Master (3DHistec, 
Budapest, Hungary) instrument, and stained according to standard procedures with 
the 587F11 rabbit monoclonal antibody (1:50 dilution; Cell-Signaling, Beverly, 
MA). Visualization was obtained with BenchMark Special Stain Automation system 
(Ventana Medical Systems, Tucson, AZ). Two pathologists reviewed all the slides, 
assessing the amount of tumor and tissue loss, background staining and overall 
interpretability before the phospho-Akt reactivity evaluation. Staining results were 
evaluated using a computerized high-resolution acquisition system (D-Sight, 
Menarini, Florence, Italy), including the analysis of positive cells number and 
staining intensity which resulted in values expressed as arbitrary units” (a.u.). All 
patients have provided a written in- formed consent. This study was approved by the 
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Local Ethics Committee of the University of Pisa. Date of approval: July 3, 2013 
(file number 3909). 
For ICC, the cells were grown in a Chamber Slides System (Lab-Tek, Collinsville, 
IL). After 24 hours, the cells were fixed with 70% ethanol for 10 minutes, followed 
by incubation with the antibody described above (4°C overnight, 1:30 dilution in 
PBS). Cells were stained with the avidin-biotin-peroxidase complex (UltraMarque 
HRP Detection, Greenwood, AR). Negative controls were obtained by replacing the 
primary antibody with PBS. The sections were reviewed and scored using a digital 
system based on staining intensity and on the number of positively stained cells. 
QUANTITATIVE REVERSE-TRANSCRIPTASE POLYMERASE-CHAIN-
REACTION (QRT-PCR) 
 
Total RNAs were extracted from cells using the TRI REAGENT-LS (Invitrogen, 
Carlsbad, CA), according to the manufacturers’ protocol. RNA was also extracted 
from seven primary tumors, after laser micro-dissection with a Leica-LMD7000 
instrument (Leica, Wetzlar, Germany), using the QIAamp RNA Micro Kit (Qiagen, 
Hilden, Germany). RNA yield and purity were checked at 260 to 280 nm with 
NanoDrop-1000 Detector (NanoDrop Technologies, Wilmington, DE). One 
microgram of RNA was reverse-transcribed using the DyNAmo Synthesis Kit 
(Thermo Scientific, Vantaa, Finland). qRT-PCR was performed with specific 
TaqMan® primers and probes for Akt1, human equilibrative nucleoside transporter-
1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), ribonucleotide 
reductase subunit-M1 (RRM1), and subunit-M2 (RRM2), E-cadherin, and the 
glucose transporter 1 (SLC2A1/Glut1) which were obtained from Applied 
Biosystems TaqMan Gene expression products (Hs00920503_m1, Hs01085706_m1, 
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Hs00984403_m1, Hs01040726_m1, Hs00156401_m1, Hs00168784_m1, 
Hs01072069_g1,  Hs01023894_m1, and Hs00892681_m1 respectively). The cDNA 
was amplified using the ABI-PRISM 7500 instrument (Applied Biosystems, Foster 
City, CA). Gene expression values were normalized to β-actin, using a standard 
curve of cDNAs obtained from Quantitative PCR Human Reference RNA 
(Stratagene, La Jolla, CA). 
WESTERN BLOTTING (WB) 
In order to evaluate the modulation of Akt, phospho-Akt, PARP, BAD, Bcl-2, NF-kB 
and Glut1 protein expression in PDAC cells treated for 24 hours with perifosine, 
gemcitabine and their combination, Western blot analyses were executed as 
described previously [30]. Briefly, 40 μg of proteins was separated on a 10% SDS-
polyacrylamide gel and transferred onto PVDF membrane (Immobilion®-FL, 
Millipore, Billerica, MA). The membrane was incubated overnight with rabbit anti-
Akt, anti-phospho-Akt, described above, as well as with rabbit anti-BAD, anti-Bcl-2, 
anti-PARP, and anti-NF-kB (1:1000, diluted in the blocking solution; all from Santa 
Cruz Biotechnology, Santa Cruz, CA) and the rabbit anti-Glut-1 (ab652, 1:500, 
diluted in the blocking solution, from Abcam, Cambridge, UK) and mouse anti-β-
actin (1:10000; Sigma–Aldrich). The secondary antibodies were goat anti-rabbit-
InfraRedDye® 800 Green and goat anti-mouse-InfraRedDye® 680 Red (1:10000, 
Westburg, Leusden, The Netherlands). Fluorescent proteins were monitored by an 
Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE), equipped with 
Odyssey 2.1 software to perform a semi-quantitative analysis of the bands. 
 
20 
 
EVALUATION OF SYNERGISTIC/ANTAGONISTIC INTERACTION WITH 
GEMCITABINE  
The pharmacological interaction between perifosine and gemcitabine was evaluated 
by the median drug effect analysis method. In this regard, the combination index (CI) 
was calculated to compare cell growth inhibition of the combination and each drug 
alone. Data analysis was carried out using CalcuSyn software (Biosoft, Oxford, UK). 
EFFECTS ON MULTICELLULAR SPHEROIDS 
LPC006 and LPC028 spheroids were established by seeding 104 cells per ml in 
DMEM/F12+GlutaMAX-I (1:1) with insulin-transferrin-selenium (1:1000, 
Invitrogen), in 24-well ultra low attachment plates (Corning Incorporated, NY). The 
cytotoxic effects were evaluated by measuring the size and number of spheroids with 
the inverted phase contrast microscope Leica-DMI300B (Leica, Wetzlar, Germany), 
taking 9 pictures for each well. Spheroid volume (V) was calculated from the 
geometric mean of the perpendicular diameters D=(Dmax+Dmin)/2, as follows: 
V=(4/3)×π (D/2)3. 
AKT AND PHOSPHO-AKT ANALYSIS BY ENZYME LINKED 
IMMUNOSORBENT (ELISA) ASSAY 
To investigate the inhibitory effects of perifosine on Akt [pS473] phosphorylation, a 
specific ELISA assay was performed using the Pierce AKT Colorimetric In-cell 
ELISA Kit (Thermo Scientific, Rockford, IL), which has a sensitivity approximately 
2 fold greater than Western blotting. The levels of Akt and phospho-Akt were 
measured in cells seeded in a 96 well-plate at a density of 105 cells per well, and 
treated for 2, 4 or 24 hours with perifosine, gemcitabine and their combination at 
IC50 values. The absorbance was measured in a Synergy HT Multi-Detection 
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Microplate Reader (BioTek, Bad Friedrichshall, Germany) at a wavelength of 450 
nm. 
IN VITRO MIGRATION AND INVASION ASSAYS 
The ability of perifosine and its combination with gemcitabine to inhibit the 
migratory behaviour of PDAC cells was investigated by in vitro migration assay. The 
cells were exposed to the drugs at their IC50s. Images were taken at the beginning of 
the exposure (time 0), with those taken after 4, 6, 8, 20, and 24 hours. Transwell 
chambers with polycarbonate membranes and 8 µm pores were used for invasion 
assays. These assays were carried out through coated transwell filters, with 100 µl of 
0.1 mg/mL collagen I solution. A total of 105 cells were plated on the upper side of 
the filter and incubated with the drugs at IC50 concentrations in RPMI-1640 
medium. After 24 hours cells migrated into the lower side were fixed with 
paraformaldehyde and stained with Giemsa in 20% methanol. The filters were 
photographed and cells were counted. 
ANALYSIS OF CELL-CYCLE AND CELL DEATH  
To investigate the effect of drugs on modulation of cell cycle, LPC028, LPC006, 
CFPAC-1 and PANC-1 cells were treated for 24 hours with gemcitabine, perifosine 
and their combination at IC50 concentrations. Cells were stained by propidium 
iodide (PI) and cell cycle modulation was evaluated using a FACSCalibur flow 
cytometer (Becton Dickinson, San José, CA), equipped with the CELLQuest 
software for data analysis.  
The ability of gemcitabine, perifosine and its combination with gemcitabine to 
induce cell death was evaluated by measuring sub-G1 regions during cell cycle 
22 
 
analysis, as described above. Apoptosis induction was also assessed by 3,3'-
dihexyloxacarbocyanine iodide (DiOC) labelling. DiOC is a lipophilic and green 
fluorescent dye, which can pass the plasma membrane, without being metabolized by 
the cell, and accumulate at the membrane of mitochondria of living cells. Shortly, the 
cells were stained with DiOC for 30 min, and analysed by FACSCalibu. Additional 
studies were performed with the Annexin-V/PI assay, plating the cells in 6-well 
plates at a density of 1.5u105. After 24 hours, the cells were treated with the drugs at 
their IC50, followed by 24-hour incubation. Then, the cell pellets were re-suspended 
in 100 mL of ice-cold binding buffer (0.1 M Hepes/NaOH (pH=7.4), 1.4 M NaCl, 25 
mm CaCl2). The staining was performed according to the manufacturer’s instructions 
(Annexin-V/PI detection Kit-I, Becton Dickinson). Cells were stained by 5 µL 
Annexin V-FITC and 5 µL PI. Samples were gently vortexed and incubated for 15 
minutes at room temperature. Then, 400 µL of binding buffer was added to the cells. 
The samples were analyzed by FACSCalibur using excitation/emission wavelengths 
of 488/525 and 488/675 nm for Annexin-V and PI, respectively. 
CASPASE ACTIVITY ASSAY 
The effects of perifosine, gemcitabine and their combination on the activity of 
caspase-3, -6, -7, -8, -9 were determined by specific fluorometric assay kits (Zebra 
Bioscience, Enschede, The Netherlands), according to the manufacturer’s 
instructions. Briefly, 106 LPC006, LPC028, CFPAC-1 and PANC-1 cells were 
exposed to the drugs for 24 hours at their IC50s. Fluorescence was measured at 350 
nm excitation and 460 nm emission (Spectrafluor Tecan, Salzburg, Austria). Relative 
caspase activity was normalized with respect to the untreated cells.  
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ANALYSIS OF MODULATION OF GLUT1 BY FLOW CYTOMETRY 
To quantitatively detect the expression of membrane-bound Glut1, cells were fixed 
with 80% ethanol, incubated with anti-Glut1 antibody (Abcam), and then stained 
with the appropriate FITC-conjugated anti-rabbit IgG antibody (BD Pharmingen™, 
BD Biosciences, San Jose, CA). Quantification of FITC fluorescence intensity was 
performed using a FACSCanto flow cytometer (BD Biosciences). 
EVALUATION OF THE CYTOTOXIC AND PRO-APOPTOTIC EFFECTS 
INHIBITION OF GLUT1 INHIBITION COMBINED WITH AKT 
INHIBITORS 
The Akt signaling is involved in the modulation of Glut1 expression/localization, and 
a recent study showed that increased glucose metabolism was associated to resistance 
to the tyrosine kinase inhibitor axitinib, and this resistance was overcame by Glut1 
silencing. Therefore, we performed additional cytotoxicity studies using the novel 
Glut1 inhibitor PGL13. This compound was tested in the LPC006 cells, at a 
concentration of 30 PM, which effectively reduced glucose influx. The cells were 
exposed to PGL13 for 72 hours, alone or in combination with IC50 concentration 
values of perifosine, gemcitabine, and their combination. Cell growth inhibition was 
then assessed by counting the cells after staining with trypan blue, in comparison to 
untreated cells. Parallel evaluation of apoptosis induction was performed by 
fluorescence microscopy with bisbenzimide staining. 
STATISTICAL ANALYSIS 
All experiments were performed in triplicate and repeated at least twice. Data were 
expressed as mean values±SEM. and analyzed by Student’s t-test or ANOVA 
followed by Tukey's multiple comparison test. For the analysis of the correlation of 
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phospho-Akt expression and clinical data, the overall-survival (OS) and progression-
free-survival (PFS) were calculated from the date of pathological diagnosis (i.e. the 
date of surgery) to the date of death and tumor progression, respectively. OS and PFS 
curves were constructed using Kaplan-Meier method, and differences were analyzed 
using log-rank test. Data were analyzed using SPSS v.20 statistical software (IBM, 
Chicago). Statistical significance was set at P<0.05. 
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Results 
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CORRELATION WITH OUTCOME AND PHOSPHO-AKT AND AKT1 
MRNA EXPRESSION IN PDAC TISSUES AND CELLS 
The protein expression of phospho-Akt was successfully evaluated by IHC in 100 
human PDACs collected in two TMAs. The main clinical characteristics of these 
patients are reported in the Table 1. 
 
IHC has showed a variable protein expression with some specimens characterized by 
a strong and diffuse staining, while other tissues had only a few scattered positive 
cells with a weak staining, as respectively exemplified by the middle and left panels 
in figure2. 
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Figure 2: Representative examples (original magnification, 40X) showing the variable expression of phospho-Akt 
in paraffin-embedded PDAC samples collected in 4 TMAs (with 4 cores for each of the 100 patients). N.C., 
negative control. 
 
Patients were categorized according to their high vs. low phospho-Akt expression 
compared to the median value (30 a.u.) calculated by digital scoring (Fig.3, black 
line). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Expression values of phospho-Akt observed across the cohort of PDAC patients, obtained by digital 
quantification. Phospho-Akt showed positive cytoplasmatic and nuclear staining in most tissue sections, with 
intense staining in 14 out of 100 samples. The staining intensities of the LPC028 and LPC006 cells were included 
in the “very high” and “low” Akt expression groups, respectively 
 
No association was observed between phospho-Akt and age, sex, grading, resection, 
and lymph node infiltration (data not shown). Patients with low phospho-Akt 
expression had a median OS of 16.2 months (95%CI, 14.8-20.1), while patients with 
a high expression had a median OS of 12.0 months (95%CI, 9.0-14.9, P=0.03, fig 4). 
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Figure 4: Kaplan–Meier survival curves according to the expression of phospho-Akt in 100 radically-resected 
PDACs showing that patients with high expression of phospho-Akt had a significantly shorter survival compared 
to patients with low phospho-Akt expression 
 
However, only a trend toward a significant association was found between phospho-
Akt expression and PFS (P=0.08, Fig.5). 
 
 
Figure 5: Kaplan-Meier PFS curves according to the expression of phospho-Akt in 100 radically-resected PDACs 
 
An additional analysis was performed categorizing the patients with respect to a 
threshold expression of 57 a.u., which identified 14 cases with higher expression 
compared to all the others (defined as “very-high” phospho-Akt expression, Fig.3, 
blue square). 
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Using these categories, we observed a significant correlation between high phospho-
Akt protein expression and both significantly shorter OS (P<0.01, fig. 6), and PFS 
(fig. 7). 
 
 
Figure 6: Kaplan–Meier survival curves according to the expression of phospho-Akt in 100 radically-resected 
PDACs, showing that patients with “very high” expression of phospho-Akt had a significantly shorter survival 
compared to patients with low phospho-Akt expression 
 
 
Figure 7: Kaplan-Meier  PFS curves according to the expression of phospho-Akt in 100 radically-resected 
PDACs, showing that patients with “very high” expression had a significantly  worste a PFS compared to patients 
with low phospho-Akt expression. 
 
Parallel ICC studies revealed that the LPC006 cells had a significantly lower 
phospho-Akt expression compared to LPC028 cells, which were indeed included in 
the category of “low” and “very-high” phospho-Akt expression, respectively (Fig.3, 
blue and red circles). The mRNA expression of Akt1 was detectable in all PDAC 
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cells by qRT-PCR, as well as in the originator tissues of the primary tumor cell 
cultures. This expression value differed among the cells, ranging from 0.9 arbitrary 
unit (a.u.) in LPC006 cells to 24.0 a.u. in LPC028 and PANC-1 cells (Fig. 8).  
 
 
Figure 8: Akt1 mRNA expression in ATCC cell lines (black-bars), primary tumor cultures (white-bars), and their 
originator tissues (gray-bars). Dashed bars identify the cells that were selected for further in vitro studies 
 
The mean and median expression in the tumor cells (8.7±0.2 and 8.4 a.u., 
respectively) were significantly higher (P<0.01) than the expression detected in 
hTERT-HPNE cells (0.3 a.u.). Notably, Akt1 gene expression in the 7 primary tumor 
cells and their laser-microdissected originator tumors showed a similar pattern and 
were highly correlated with Spearman analysis (R2>0.9, P<0.05), suggesting that 
these cells represent optimal preclinical models for our pharmacological studies. 
Moreover, Western blot analysis revealed that the LPC006 and CFPAC-1 cells had a 
lower Akt and phospho-Akt expression compared to PANC-1 and LPC028 cells 
(fig.9). 
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Figure 9: Representative Western blot pictures of phospho-Akt and Akt expression in LPC006, CFPAC-1, 
PANC-1 and LPC028 cells 
 
Therefore, we selected for further studies two primary cell cultures (LPC006 and 
LPC028) which were representative of “low” and “very-high” expression values, as 
well as two cell lines, PANC-1 and CFPAC-1, with high and intermediate expression 
values of Akt1 mRNA, respectively. 
PERIFOSINE INHIBITS CELL GROWTH AND INTERACTS 
SYNERGISTICALLY WITH GEMCITABINE IN PDAC CELLS WITH 
HIGH EXPRESSION OF PHOSPHO-AKT 
The cytotoxic activity of three different Akt inhibitors (perifosine, MK-2206, and 
NVP-BEZ235) was evaluated in the PANC-1 cell line (fig.10). 
 
 
 
 
 
 
Figure 10: Growth inhibitory effects in PANC-1 cells after 72 h exposure to perifosine, MK-2206 and NVP-
BEZ235 
All these compounds caused a concentration-dependent inhibition of proliferation, 
with IC50 values ranging from 5.1 PM (perifosine) to 15.8 PM (NVP-BEZ235). 
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Higher IC50 values were obtained in the LPC006 cells, with IC50 of 22.5, 31.7 and 
45.5 PM for perifosine, NVP-BEZ235 and MK-2206, respectively. According to the 
lowest IC50 values detected in these assays we selected perifosine for the following 
studies on the pharmacological interaction of Akt inhibitors with gemcitabine. The 
cell growth inhibitory effects of perifosine, gemcitabine and their combination in 
LPC028 and LPC006 cells are shown in figure 11, while the data for CFPAC-1 and 
PANC-1 are reported in the Supplemental figure 12. 
 
 
Figure 11: Growth inhibitory effects after 72 hours exposure to perifosine, gemcitabine or their combination at a 
fixed ratio based on IC50 values in LPC028 and LPC006 cells. On the X-axis the drug concentrations for the 
combination are referred to gemcitabine 
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Figure 12: Growth inhibitory effects after 72 hours exposure to perifosine, gemcitabine or their combination at a 
fixed ratio based on IC50 values in CFPAC-1 and PANC-1 cells. On the X-axis the drug concentrations for the 
combination are referred to gemcitabine 
 
Since the CI method recommends a ratio of concentrations at which drugs are 
equipotent, combination studies were performed using fixed ratios with IC values at 
IC50s. Perifosine enhanced the antiproliferative activity of gemcitabine, especially in 
the LPC028 and PANC-1 cells, by decreasing the IC50s of gemcitabine from 4.3±1.1 
nM and 17.2±2.1 nM to 1.4±0.5 nM and 4.0±1.1 nM, respectively. The median drug-
effect analysis revealed a slight-to-moderate synergism in CFPAC-1, and a strong 
synergism in the PANC-1 and LPC028 cells, with CI values of 0.8, 0.5 and 0.2, 
respectively (fig.13). 
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Figure 13: Mean CI of the perifosine/gemcitabine combination. CI values at FA of 0.5, 0.75 and 0.9 were 
averaged for each experiment, and this value was used to calculate the mean between experiments 
 
Conversely, the combination of perifosine and gemcitabine was antagonistic in the 
LPC006 cells (CI>1.2). To evaluate whether these effects were observed also in 
three-dimensional (3-D) models and investigate the mechanisms underlying these 
different interactions, several biochemical analyses were performed, as detailed 
below. 
PERIFOSINE AND ITS COMBINATION WITH GEMCITABINE REDUCE 
THE SIZE OF PDAC SPHEROIDS 
 
Previous studies illustrated that 3-D culture models are generally more chemo-/radio-
resistant than two-dimensional monolayer cell cultures, supporting their use for drug 
testing [34].  In order to explore whether perifosine would be active in 3-D PDAC 
models, we evaluated this drug in spheroids of LPC006 and LPC028 cells, 
characterized by low and high phospho-Akt expression respectively.  
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Perifosine remarkably increased the disintegration of LPC028 spheroids, which were 
significantly (P<0.05) reduced in size compared to the untreated spheroids (fig 14-
15). 
 
 
Figure 14: Effect of perifosine and gemcitabine and their combination, at IC50 values, on the volumes of PDAC 
spheroids after 72 hours exposure 
 
 
Figure 15:  Representative images of untreated spheroid versus spheroid treated with perifosine and gemcitabine 
(original magnification, 40X) 
 
The combination of perifosine with gemcitabine additionally reduced the size of the 
LPC028 spheroids with respect to the spheroids treated with the single drugs. In 
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contrast, no changes were observed in the LPC006 spheroids, further supporting the 
antagonistic interaction of perifosine with gemcitabine in this PDAC model.  
MODULATION OF PHOSPHO-AKT AND GEMCITABINE 
DETERMINANTS IN PDAC CELLS 
Perifosine inhibits the phosphorylation of Akt by blocking the PH-domain in 
different cancer cell lines [35], but no data have been reported yet on PDAC cells. 
Therefore, we evaluated the expression of phospho-Akt (at serine residue 473), 
normalized to the total Akt levels, both in untreated cells and in cells treated with 
perifosine, gemcitabine, and their combination, after 2, 4 or 24 hours exposure. 
Perifosine was more effective after 24 hours than after 2 or 4 hours (data now 
shown). As shown in figure 16, perifosine significantly reduced the expression of p-
Akt in LPC028, CFPAC-1 and PANC-1 cells (e.g 40%, 25%, and 30% reduction, 
respectively). Similarly, the combinations of perifosine and gemcitabine markedly 
suppressed Akt phosphorylation, with a degree of inhibition ranging from -35% 
(CFPAC-1 cells) to -45% (LPC028 cells). Conversely, phospho-Akt levels were not 
affected by perifosine, gemcitabine or their combination in the LPC006 cells (fig.16). 
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Figure 16: Standard curves for pAKT (pS473) and total AKT obtained using a specific ELISA assay 
 
RRM1 and RRM2 encode for the catalytic and the regulatory subunits of 
ribonucleotide reductase and is a key molecular target of gemcitabine [36]. 
Previous studies demonstrated that the expression of RRM2 is modulated by the 
Akt/c- MYC pathway [37]. However, the alterations in the expression or function of 
other enzymes, involved in the transport, metabolism and catabolism of gemcitabine 
can also lead to resistance (e.g., decreased dCK or increased CDA expression). 
Therefore, we evaluated the mRNA expression of several gemcitabine determinants 
in the LPC006 and LPC028 cells. The expression of RRM1 and RRM2 was 
significantly reduced (approximately 2-fold) in LPC028 cells treated with perifosine 
versus untreated cells, while only minimal variations were observed for hCNT1, 
hENT1, dCK and CDA expression. No significant changes were observed in the 
LPC006 cells (fig.17).  
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Figure 17: Expression of gemcitabine key determinants in LPC028 (left panel) and LPC006 (right panel) cells 
treated with perifosine at IC50 versus untreated cells, as determined by qRT-PCR 
 
These results can at least in part explain the synergistic interaction of perifosine with 
gemcitabine in PDAC cells with high phospho-Akt expression.  
PERIFOSINE AND ITS COMBINATION WITH GEMCITABINE INHIBIT 
CELL MIGRATION/INVASION AND UP-REGULATE THE EXPRESSION 
OF E-CADHERIN 
 
To determine the effects of perifosine, gemcitabine and their combination on 
migratory behavior, a scratch mobility assay was performed in LPC028, LPC006, 
CFPAC-1 (fig.18) and PANC-1 (fig.19).  
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Figure 18: Results of wound-healing assay in LPC028 and LPC006 cells exposed to perifosine, gemcitabine or to 
their combination, at IC50 values for 24 hours 
 
 
 
Figure 19: Results of wound-healing assay in CFPAC-1 and PANC-1 cells exposed to perifosine, gemcitabine or 
to their combination, at IC50 values for 24 hours 
 
LPC028 showed a significant reduction of migration starting after 8 hours exposure 
to perifosine with a reduction of the scratch-area of about 50%, and the 
perifosine/gemcitabine combination additionally reduced cell migration (P<0.05, 
fig.19 left panel), while gemcitabine alone did not affect cell migration. No 
modulation of cell migration was observed in the LPC006 cells (fig.19 right panel). 
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LPC028, CFPAC-1 and PANC-1 cells treated with perifosine showed also a 
significantly reduced invasive potential, compared to untreated cells (fig. 20). 
 
Figure 20: Results of invasion studies in the PDAC cells exposed for 24 hours to perifosine, gemcitabine or to 
their combination, at IC50 values (insert: representative pictures of LPC028 cells at 24 hours, original 
magnification 40X 
 
In particular, the perifosine/gemcitabine combination was more effective in 
inhibiting invasion than perifosine-alone in LPC028 and PANC-1 cells, as shown by 
the significantly lower number of invading cells with Giemsa's stain. However, no 
modulation of cell invasion was observed in the LPC006 cells.  
Since previous studies suggested that Akt signaling pathway suppressed E-cadherin 
expression [38], we investigated whether perifosine could affect the level of this 
target at both mRNA and protein level. Perifosine and its combination with 
gemcitabine significantly enhanced E-cadherin mRNA expression in LPC028, 
CFPAC-1 and PANC-1 (P<0.05), while no changes were detected in LPC006 cells. 
Similarly, immunocytochemistry analysis in LPC028 cells illustrated a significant 
increase of E-cadherin protein staining after exposure to both perifosine and 
perifosine/gemcitabine combination (data not shown). 
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PERIFOSINE AND ITS COMBINATION WITH GEMCITABINE AFFECT 
CELL CYCLE 
Perifosine, gemcitabine and their combination affected cycle distribution of PDAC 
cells, as summarized in the table 2.  
 
Perifosine significantly (P<0.05) increased the percentages of LPC028 cells in S and 
G2/M phases (e.g., from 18.7 in the control to 26.1% in the S phase) after 72 hours, 
while reducing the percentage of the cells in G0/G1. Similarly, the 
perifosine/gemcitabine combination significantly decreased the cells in G1 phase, 
while increasing the cells in S phase, up to 48.9%. Comparable perturbations of cell 
cycle were observed in the CFPAC-1 and PANC-1 cells, suggesting that perifosine 
might favor gemcitabine activity through a significant increase of cells in the S 
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phase. Opposite modulation of cell cycle was observed in LPC006 cells, with only a 
slight increase of the cells in the G0/G1 phase and minimal modulations of the S and 
G2/M phase in cells exposed to perifosine/gemcitabine combination.  
PERIFOSINE AND ITS COMBINATION WITH GEMCITABINE ENHANCE 
CELL DEATH AND APOPTOSIS 
Analysis of the sub-G1 region of cell cycle perturbation demonstrated that the 
treatment with perifosine enhanced cell death (table 2). In particular, the LPC028 
cells treated with the combination exhibited the largest sub-G1 signal (e.g., ≈20% in 
cells treated with perifosine/gemcitabine combination versus untreated cells).  
Furthermore, we evaluated the variation of mitochondrial membrane potential in 
LPC028, LPC006, PANC-1 and CFPAC-1. As shown in Figure 21, the combination 
perifosine gemcitabine causes an increase of mitochondrial membrane potential in 
LPC028, PANC-1 and CFPAC-1 cells. 
 
 
Figure 21: Mitochondrial membrane potential (as assessed by (DiOC) labelling) in LPC028, LPC006, PANC-1 
and CFPAC-1 cells 
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Further analysis of cell death by the Annexin-V/PI assay confirmed the induction of 
apoptosis by perifosine. Perifosine increased both early and late apoptosis, as shown 
in Fig.22 for the LPC028 cells.  
 
 
Figure 22: Annexin-V assay in LPC028 
Moreover, the combination of perifosine and gemcitabine significantly increased the 
percentage of late apoptotic cells up to 26%. Similar results were observed in 
CFPAC-1 and PANC-1 cells (fig.23), whereas no apoptosis induction was detected 
in LPC006 cells (fig.24). 
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Figure 23: Annexin-V assay in LPC028 and LPC006 cells 
 
 
Figure 24: Annexin-V assay in LPC006 
 
PERIFOSINE AND ITS COMBINATION WITH GEMCITABINE 
ACTIVATE CASPASES AND PROAPOPTOTIC FACTORS, AND DOWN-
REGULATE BCL-2 AND NF-KB 
In order to investigate the molecular mechanisms underlying apoptosis induction, we 
explored several potential cellular targets of perifosine, focusing on activation of the 
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“initiator” caspases, caspase-8 and -9, and the “effector” caspases, caspase-3, and -6. 
Moreover, we studied the expression of various pro-apoptotic and anti-apoptotic 
proteins.  As a shown figure 25, perifosine and its combination with gemcitabine 
were able to increase the activity of caspase-3/-6/-8/-9 in LPC028 but not in LP006. 
 
 
Figure 25: Modulation of caspase-3, caspase-6/-8/ and caspase-9 in LPC028 and LPC006 cells, as determined by 
a specific fluorometric assay described in the Materials and Methods section; 
 
Also in CFPAC-1 and PANC-1 the levels of caspases were increased (fig.26).  
 
 
Figure 26: Modulation of caspase-3, caspase-6/-8/ and caspase-9 in CFPAC-1 and PANC-1 cells, as determined 
by a specific fluorometric assay 
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However, Western blot analyses demonstrated the modulation of other important 
apoptotic markers. In particular, perifosine and perifosine/gemcitabine combination 
increased the expression of PARP and BAD, while reducing Bcl-2 and NF-kB 
expression in LPC028 cells. Conversely, none of these proteins was affected by the 
exposure to perifosine and its combination with gemcitabine in the LPC006 cells 
(fig.28). 
 
Figure 28: Representative Western blot pictures of apoptosis determinants in LPC006 and LPC028 cells 
 
GLUT1 IS OVEREXPRESSED IN THE CELLS RESISTANT TO AKT 
INHIBITION, WHILE ITS INHIBITION SIGNIFICANTLY REDUCES CELL 
GROWTH AND INDUCES APOPTOSIS AFTER 
GEMCITABINE/PERIFOSINE TREATMENT 
Since major oncogenic signaling pathways have been linked to increased glucose 
metabolism, and previous studies showed that stimulation of Akt1 induces Glut1 
mRNA and protein accumulation [39]  we evaluated the expression of this key 
glucose transporter in the LPC028 and LPC006 cells. As shown in the figure 29, 
Glut1 mRNA levels were significantly reduced after treatment with perifosine alone 
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and in combination with gemcitabine in the LPC028 cells, whereas no modulation 
was detected in the LPC006 cells.  
 
Figure 29: Modulation of Glut1 mRNA levels in LPC028 and LPC006 cells after 24-hour exposure to perifosine, 
gemcitabine or to their combination, at IC50 values, as determined by qRT-PCR 
However, since PI3K/AKT/mTOR signaling seems to play an essential role in 
trafficking of Glut1 from recycling endosomes and/or retention of Glut1 at the 
plasma membrane [40] , we performed further studies to evaluate the amount of 
membrane-bound Glut1 with FACS analysis (fig.30).  
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Figure 30: Representative of Glut1 membrane-bound expression in LPC006 and LPC028 cells exposed for 24 
hours to perifosine at IC50s 
Further studies with Western blot clearly demonstrated the overexpression of Glut1 
in the LPC006 compared to the LPC028 and PANC-1 cells. Moreover Glut1 
expression was not reduced by Akt inhibition (fig.31).  
 
Figure 31: Representative Western blot pictures of Glut1 expression in LPC028, LPC006 and PANC-1 cells 
exposed for 24 hours to perifosine, gemcitabine or their combination at IC50s 
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We therefore investigated whether inhibition of Glut1 by the novel specific 
compound PGL13  can at least in part overcome the inherent resistance of the 
LPC006 cells to perifosine and other Akt inhibitors (fig.32). 
 
 
                                                                    Figure 32: PGL13 structure 
Remarkably, the Glut1 inhibitor alone caused only a slight reduction of cell growth 
(<10%), but its combination with perifosine reduced significantly the percentage of 
surviving cells compared to perifosine alone (fig.33).  
 
Figure 33: Cell growth inhibition in LPC006 cells after 72-hour exposure to perifosine, gemcitabine or to their 
combination, at IC50 values, together with DMSO or with the Glut1 inhibitor PGL13, at 30 M. 
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Furthermore, the combination of PGL13 with both perifosine and gemcitabine led to 
a more dramatic drop in the number of surviving cells, up to –81%, compared to 
control which was associated with strong apoptosis induction, as detected by 
characteristic apoptotic nuclear morphological features with fluorescence 
microscopy. In particular the LPC006 cells exposed to PGL13 with both perifosine 
and gemcitabine had an apoptotic index of 27%, which was similar to the apoptotic 
index of the LPC028 cells treated with perifosine and gemcitabine (fig.34). The 
effect of a combined Akt inhibitor/anti-Glut1 treatment was further tested with MK-
2206 and NVP-BEZ235, where it led to a -14% and -20% decrease in cell viability 
compared with these drugs alone. Thus, inhibition of Glut1 promoted anti-Akt-
mediated cell death and this combined treatment shows promise for future 
investigation in the treatment of PDAC. 
 
 
Figure 34: Apoptosis induction by perifosine, gemcitabine and their combination as assessed by bisbenzimide 
staining 
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Discussion 
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The present study supports a role for phospho-Akt as a prognostic factor in PDAC 
patients, and unravels its potential role as a target for the synergistic interaction of 
anti-Akt agents and gemcitabine through modulation of apoptotic and invasive 
processes. 
Several studies demonstrated that PDAC tissues have increased activation of the 
PI3K/Akt, as assessed with the phosphorylation of Akt, and this has been associated 
with higher histological tumor grade [41] and worse prognosis [42,43].  
In this project we further explored the clinical relevance of phospho-Akt by 
screening its expression in a homogeneous cohort of 100 surgically resected PDACs. 
In agreement with the previous studies, even considering several clinicopathological 
parameters, phospho-Akt expression was the only factor correlated to differential 
clinical outcome. However, a systematic review and meta-analysis of prognostic 
tissue biomarkers for PDAC, including phospho-Akt among the 22 markers 
associated with limitless replicative potential eligible for examination, showed that 
only Ki-67 maintained statistically significant associations with outcome [44]. These 
discrepancies might be attributed to the different experimental procedures used, 
including antigen retrieval technique, antibody characteristics and dilution, as well as 
observer variability in staining pattern description and cutoff point selection. 
Therefore, in the present study we have chosen an antibody that was previously 
validated in an immunohistochemical study on 102 colorectal cancer FFPE samples 
[45]  and we have used image analysis software to calculate expression as a 
continuous parameter, in order to facilitate the identification of cutoff points. 
However, because of the typical dense stromal reaction and diffusely infiltrative 
growth pattern the data were always checked also by two experienced researchers. 
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This method allowed the assignment of the specimens to different categories, 
including a subset of tissues (about 14%) characterized by extremely high expression 
of phospho-akt, which could clearly influence the prognostic value. Indeed this 
cutoff point identified a group of patients with very poor outcome, who should be 
treated with more aggressive, novel therapeutic approaches. Of note, recent genomic 
studies showed that the PI3K/Akt signaling is among the core signaling pathways 
leading the intrinsic aggressiveness of PDAC, suggesting that in the “PDAC 
actionable genome” about 9 and 6% of the cases are Akt- and PI3K-dependent, 
respectively [46]. These data underline the potential importance of specific inhibitors 
of PI3K/Akt as novel effective therapeutics in a selected subpopulation of PDAC 
patients. Moreover, activation of this signaling pathway is associated with PDAC 
chemoresistance [47,48], supporting the hypothesis that Akt inhibitors might also be 
used to overcome resistance towards conventional cytotoxic agents. Several 
Akt/PI3K inhibitors are being developed. The ﬁrst-generation of these inhibitors 
includes LY294002 and wortmannin, which were tested to elucidate the value of 
Akt/PI3K as therapeutic target [49]. 
However, due to the unfavorable pharmaceutical properties, toxicity, and crossover 
inhibition of other lipid and protein kinases, these compounds were not used in 
clinical studies [48]. More recently, several small molecules that inhibit the 
PI3K/Akt signaling entered clinical development, but more information on their 
activity in the preclinical setting is warranted. Our results demonstrate that perifosine 
is the targeted anti-PI3K/Akt antitumor agent demonstrating the most potent growth 
inhibitory effects in a panel of human PDAC cells characterized by distinct 
molecular properties. Limited published preclinical research focusing on this issue in 
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PDAC reported similar cytotoxic activity of perifosine in PANC-1, MIA PaCa-2, and 
AsPC-1 cells [28]. Sensitivity to perifosine in the PDAC cells also fell within the 
range of IC50 values previously reported in PDAC cell lines and spheroids for other 
Akt inhibitors, such as NVP-BEZ-235 [50,51]. Furthermore, perifosine interacted 
synergistically with gemcitabine in PDAC cells with high phospho-Akt expression, 
but antagonistic in cells with low phospho-Akt expression. Synergism was associated 
with inhibition of migration/invasion and induction of apoptosis. These results are in 
agreement with previous studies showing synergistic interaction of gemcitabine with 
perfifosine in PANC-1 cells and xenografts [28] as well as enhanced apoptotic cell 
death after combined treatment with paclitaxel in chemoresistant ovarian cancer cells 
[52]. However, most previous studies were performed in ATCC cell lines, which 
showed similar results [53], while, to more effectively develop targeted compounds, 
it will be helpful to understand why these agents fail when they do. Thus, in the 
present study, cell growth inhibitory effects of perifosine, gemcitabine and their 
combination were evaluated in several representative PDAC cells, including two 
primary PDAC cell cultures, LPC028 and LPC006, characterized by high and low 
Akt expression, respectively. For the LPC0028 model we demonstrated that 
perifosine inhibited cell growth, both in monolayer cell cultures and in cells growing 
as spheroids, whereas LPC006 cells and spheroids were not affected. Similarly the 
perifosine/gemcitabine combination had synergistic effects only in the cells with 
high phospho-Akt or intermediate/high values of Akt1 mRNA, as determined by RT-
PCR. Conversely this combination was antagonistic in the cells with low Akt1, and 
phospho-Akt expression. These data suggest that the expression and activation of 
Akt might therefore be used to tailor perifosine therapy.  
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Importantly, a specific ELISA showed that perifosine effectively reached and 
inhibited its targets only in the LPC028 cells, and the combination with gemcitabine 
additionally inhibited Akt activation in these cells. The present study demonstrated 
also that perifosine interfered with pivotal determinants for the activity of 
gemcitabine. In particular, we observed that perifosine and its combination with 
gemcitabine significantly reduced the expression of RRM1 and RRM2 in the cells 
with a high expression of Akt, while this effect was not statistically significant in the 
cells with low Akt expression. RR is a key target of gemcitabine activity and 
previous studies correlated the expression of its subunits to gemcitabine sensitivity in 
PDAC cells [54,55]. 
Therefore, the synergistic interaction between perifosine and gemcitabine might be 
explained, at least in part, by the modulation of gemcitabine sensitivity through 
RRM1 and RRM2 suppression.   
However, our results suggested that the synergistic interaction of perifosine with 
gemcitabine is associated with other important molecular mechanisms affecting 
PDAC aggressiveness. In agreement with previous observations showing the 
reduction of cell migration/invasion through Akt inhibition [56,57], we observed that 
perifosine and its combination with gemcitabine markedly reduced cell migration 
and invasion in PDAC cells. Several classes of proteins are involved in this invasive 
behavior, including cell-cell adhesion molecules like members of immunoglobulin 
and calcium-dependent cadherin families and integrins. In line with previous 
evidence on inverse relationship between Akt and E-cadherin expression [38], we 
demonstrated that perifosine increased the expression of E-cadherin in LPC028, 
CFPAC-1 and PANC-1 cells. Since the Akt signaling pathway plays an important 
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role in cell survival process, its blockage can result in activation of programmed cell 
death [58]. Thus, we further evaluated the effect of perifosine on cell cycle 
perturbation and apoptosis induction. In agreement with previous findings on the 
effect of perifosine on cell cycle perturbation at the G1-S boundary [59], our results 
showed that perifosine increased the percentage of cells in the S phase, potentially 
favoring the cytotoxic activity of gemcitabine. This modulation of the cell cycle was 
associated with significant induction of apoptosis, as determined by multiple 
methods, such as analysis of sub-G1, mitochondria membrane potential and 
Annexin-V/PI. In order to investigate the mechanisms underlying the activation of 
programmed cell death, we checked the modulation of critical factors involved in the 
apoptotic cascades. Previous studies showed that drug-induced Akt deactivation was 
associated with activation of pro-apoptotic factors, including caspase-9 and BAD, as 
well as with a parallel decrease in the expression of the anti-apoptotic factors Bcl-2 
and NF-kB [60,24]. Our studies showed similar results after exposure of the PDAC 
cells to perifosine. Despite increasing evidence on the pivotal role of PI3K/Akt 
signaling in cancer, the strategies to hit PI3K/Akt/mTOR pathway have failed to 
demonstrate therapeutic activity in most ongoing clinical trials, and a previous phase 
II study testing perifosine in previously untreated patients with locally advanced, 
unresectable, or metastatic pancreatic adenocarcinoma, was terminated as a result of 
unacceptable adverse events [61]. 
Therefore, there is an urgent need to improve alternative strategies that might tailor 
these therapies to the individual characteristics of the patients and favor synergistic 
combination, reducing toxic doses, as well as prevent feedback loops involved in 
PDAC progression upon pan-PI3K treatment. For example, it is already known that 
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in PDAC cells, dual PI3K-mTOR inhibition induces rapid over-activation of MAPK 
pathway through a PI3K-independent pathway [62] and that drug resistance may be 
overcome by inhibition of parallel oncogenic-dependent pathways, such as with the 
dual MEK and PI3K/mTOR blockade [51].  
One strategy to overcome resistance consists into identifying key molecular 
differences in the tumors that are less likely to respond. Oncogenic KRAS drives 
metabolic reprogramming in tumor cells by increasing aerobic glycolysis, and recent 
studies showed that subtypes of PDAC cells with distinct metabolite levels 
associated with glycolysis, lipogenesis, and redox pathways, confirmed at the 
transcriptional level. The glycolytic and lipogenic subtypes showed striking 
differences in glucose and glutamine utilization, as well as mitochondrial function, 
and corresponded to differences in cell sensitivity to inhibitors of glycolysis, 
glutamine metabolism, lipid synthesis, and redox balance [63].  
In the present study we demonstrated that the resistant LPC006 cells were 
characterized by overexpression of Glut1, which was not reduced after exposure to 
perifosine. Remarkably, the inhibition of Glut1 dramatically enhanced perifosine and 
perifosine/gemcitabine-induced cell death. Agents directly inhibiting Glut1 are in 
early-phase evaluations, and a few preclinical studies have demonstrated that Glut 
inhibitors led to diminish tumor growth in vitro and in vivo [64]. However, the 
altered expression of Glut1 might also influence the sensitivity of tumor cells to 
chemotherapy, since a recent study showed that the knockdown of Glut1 sensitizes 
head and neck cancer cells to the chemotherapy drug cisplatin [65]. 
To our knowledge this is the first study showing that Glut1 inhibitors can restore the 
repression of aerobic glycolysis induced by PI3K/mTOR inhibitors in resistant cells, 
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and favor their synergistic interaction with cytotoxic compounds. These results 
should prompt further studies to understand how PDAC cell metabolism might affect 
sensitivity to new anti-signaling therapies and to identify promising therapeutic 
targets that might be exploited by combination therapies. 
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Conclusions 
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Our data support the analysis of phospho-Akt expression as both a prognostic and a 
predictive biomarker, for the rational development of novel therapies targeting the 
Akt pathway in PDAC. In particular we observed that phospho-Akt expression levels 
influence the antitumor activity of perifosine, as well as the synergistic interaction 
with gemcitabine, through its ability to attack key mechanisms involved in the 
proliferation, cell cycle control, apoptosis and migration/invasion properties. Finally, 
we demonstrated that inhibition of Glut1 overcame resistance to this combination 
treatment and might provide the basis for the development of new therapeutic 
approaches with Akt inhibitors in patients with PDAC. 
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Abstract
Background: There is increasing evidence of a constitutive activation of Akt in pancreatic ductal adenocarcinoma
(PDAC), associated with poor prognosis and chemoresistance. Therefore, we evaluated the expression of phospho-Akt
in PDAC tissues and cells, and investigated molecular mechanisms influencing the therapeutic potential of Akt
inhibition in combination with gemcitabine.
Methods: Phospho-Akt expression was evaluated by immunohistochemistry in tissue microarrays (TMAs) with
specimens tissue from radically-resected patients (n = 100). Data were analyzed by Fisher and log-rank test. In vitro
studies were performed in 14 PDAC cells, including seven primary cultures, characterized for their Akt1 mRNA and
phospho-Akt/Akt levels by quantitative-RT-PCR and immunocytochemistry. Growth inhibitory effects of Akt inhibitors
and gemcitabine were evaluated by SRB assay, whereas modulation of Akt and phospho-Akt was investigated by
Western blotting and ELISA. Cell cycle perturbation, apoptosis-induction, and anti-migratory behaviors were studied by
flow cytometry, AnnexinV, membrane potential, and migration assay, while pharmacological interaction with
gemcitabine was determined with combination index (CI) method.
Results: Immunohistochemistry of TMAs revealed a correlation between phospho-Akt expression and worse outcome,
particularly in patients with the highest phospho-Akt levels, who had significantly shorter overall and progression-free-
survival. Similar expression levels were detected in LPC028 primary cells, while LPC006 were characterized by low
phospho-Akt. Remarkably, Akt inhibitors reduced cancer cell growth in monolayers and spheroids and synergistically
enhanced the antiproliferative activity of gemcitabine in LPC028, while this combination was antagonistic in LPC006
cells. The synergistic effect was paralleled by a reduced expression of ribonucleotide reductase, potentially facilitating
gemcitabine cytotoxicity. Inhibition of Akt decreased cell migration and invasion, which was additionally reduced by
the combination with gemcitabine. This combination significantly increased apoptosis, associated with induction of
caspase-3/6/8/9, PARP and BAD, and inhibition of Bcl-2 and NF-kB in LPC028, but not in LPC006 cells. However,
targeting the key glucose transporter Glut1 resulted in similar apoptosis induction in LPC006 cells.
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Conclusions: These data support the analysis of phospho-Akt expression as both a prognostic and a predictive
biomarker, for the rational development of new combination therapies targeting the Akt pathway in PDAC. Finally,
inhibition of Glut1 might overcome resistance to these therapies and warrants further studies.
Keywords: Pancreatic ductal adenocarcinoma, Akt, Synergism, Gemcitabine
Background
Pancreatic ductal adenocarcinoma (PDAC) is among the
most lethal solid tumors. Despite extensive preclinical
and clinical research, the prognosis of this disease has
not significantly improved, with a 5-year survival rate
around 7% [1]. This dismal outcome can partially be
explained by the lack of biomarkers for screening and
diagnosis at earlier stages, and by the resistance to most
currently available chemotherapy regimens. This resist-
ance has been attributed to both the desmoplastic tumor
microenvironment and to the strong inter- and intra-
tumor heterogeneity in terms of complexity of genetic
aberrations and the resulting signaling pathway activ-
ities, as well as to resistance mechanisms that quickly
adapt the tumor to drugs [2].
Oncogenic KRAS signaling is the main driving force
behind PDAC. Activating KRAS mutations occur early,
followed by loss of p16, and then later, inactivation of
TP53 and SMAD4 [3, 4]; however, targeting these events
has proven to be very difficult. Conversely, the
phosphatidylinositol-3 kinase (PI3K)/Akt downstream
pathway represents an exciting new target for thera-
peutic intervention, especially because it emerged among
the core signaling pathways in PDAC [5, 6], and several
known inhibitors are currently in clinical trials
(www.clinicaltrials.gov).
In particular, the serine/threonine kinase Akt, which is
coded in three highly homologous isoforms (Akt1, Akt2,
and Akt3), is overexpressed in more than 40% of PDAC
patients [7]. Mechanisms underlying aberrant Akt activa-
tion in cancer include direct alterations such as mutations,
amplification, or overexpression, but also activation of
upstream signaling events, such as activation of HER-2/
neu signaling or PTEN mutation/loss [8–11].
The PI3K/Akt pathway plays a key role in cell prolifer-
ation, survival, and motility [12]. Deregulation of com-
ponents involved in this pathway could confer resistance
to chemotherapy [13, 14], while blockage of Akt signal-
ing results in programmed cell death and inhibition of
tumor growth [15, 16]. Activation of Akt is a frequent
event in PDAC and has been correlated to its poor prog-
nosis [17, 18].
Several inhibitors of Akt are under investigation, but
three are the farthest along and showed the most prom-
ise in early clinical research: the pan-Akt and PI3K
inhibitor perifosine (KRX-0401, Aeterna Zentaris/Keryx),
the allosteric pan-Akt inhibitor MK-2206 (Merck), and
the dual PI3K/mTOR inhibitor dactolisib (NVP-BEZ235,
Novartis).
In particular, the synthetic oral alkylphospholipid peri-
fosine [19, 20] has been evaluated in clinical trials for
several tumors, including colon [21], breast [22], head
and neck, and prostate cancer [23, 24]. Unfortunately, it
failed the phase III clinical trials for treatment of colon
cancer and relapsed refractory multiple myeloma
(www.clinicaltrials.gov). These failures, together with the
disappointing response rates to perifosine as a single
agent in most solid tumors, including PDAC, prompt
further studies into its mechanism of action [6] as well
as on synergistic combinations.
Perifosine prevents translocation of Akt to the cell
membrane by blocking the pleckstrin homology (PH)
domain of Akt [25] leading to inactivation of downstream
pathway and inhibition of cell proliferation. Previous stud-
ies demonstrated perifosine activity against different
cancer types, in vitro and in vivo [26]. Recently, Pinton
and collaborators showed that perifosine inhibited cell
growth of malignant pleural mesothelioma cells by affect-
ing EGFR and c-Met phosphorylation [27]. Another study
showed that perifosine decreased the AEG-1 gene expres-
sion along with inhibition of Akt/GSK3/c-Myc signaling
pathway in gastric cancer [28]. Perifosine and curcumin
synergistically increased the intracellular level of reactive
oxygen species and ceramide, and downregulated the
expression of cyclin-D1 and Bcl-2 in colorectal cancer
cells [29]. Finally, perifosine also inhibits the anti-
apoptotic mitogen-activated protein kinase (MAPK) path-
way and modulates the balance between the MAPK and
pro-apoptotic stress-activated protein kinase (SAPK/JNK)
pathways, thereby inducing apoptosis [30].
The aims of current study were to investigate the
expression of phospho-Akt in PDAC tissues and cells,
and to evaluate the effects of growth inhibition by Akt
inhibitors, using PDAC cell lines and primary cultures
growing as monolayer or as spheroids. Moreover, we
characterized several key factors, affecting cell cycle
perturbation, apoptosis induction, as well as inhibition
of cell migration and invasion and modulation of key
factors in glucose metabolism in PDAC cells exposed to
perifosine and perifosine/gemcitabine combination.
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Methods
Tissue microarrays (TMAs), immunohistochemistry (IHC),
and immunocytochemistry (ICC)
Phospho-Akt protein expression was evaluated in slides
from four formalin-fixed, paraffin-embedded PDAC-
specific TMAs build with neoplastic cores from a cohort
of radically resected patients (n = 100), using the TMA
Grand Master (3DHistec, Budapest, Hungary) instru-
ment, and stained according to standard procedures with
the EP2109Y rabbit monoclonal antibody (1:50 dilution;
Abcam, Cambridge, UK). Visualization was obtained
with BenchMark Special Stain Automation system
(Ventana Medical Systems, Tucson, AZ). Two patholo-
gists reviewed all the slides, assessing the amount of
tumor and tissue loss, background staining, and overall
interpretability before the phospho-Akt reactivity
evaluation. Staining results were evaluated using a com-
puterized high-resolution acquisition system (D-Sight,
Menarini, Florence, Italy), including the analysis of
positive cells number and staining intensity which re-
sulted in values expressed as arbitrary units (a.u.). All
patients have provided a written informed consent. This
study was approved by the Local Ethics Committee of
the University of Pisa. Date of approval: July 3, 2013 (file
number 3909).
For ICC, the cells were grown in a Chamber Slides
System (Lab-Tek, Collinsville, IL). After 24 h, the cells
were fixed with 70% ethanol for 10 min, followed by in-
cubation with the antibody described above (4 °C over-
night, 1:30 dilution in PBS). Cells were stained with the
avidin-biotin-peroxidase complex (UltraMarque HRP
Detection, Greenwood, AR). Negative controls were
obtained by replacing the primary antibody with PBS.
The sections were reviewed and scored using a digital
system based on staining intensity and on the number of
positively stained cells, as described above.
Drugs and chemicals
Perifosine was provided by Æterna Zentaris Inc. (Frank-
furt am Main, Germany), NVP-BEZ235 was purchased
from Selleck Chemicals (Houston, TX), while gemcita-
bine and MK-2206 were generous gifts from Eli-Lilly
(Indianapolis, IN) and Merck (Whitehouse Station, NJ),
respectively. The drugs were dissolved in Dimethyl sulf-
oxide (DMSO) or sterile water and diluted in culture
medium before use. RPMI-1640 medium, foetal bovine
serum (FBS), penicillin (50 IU/ml), and streptomycin
(50 μg/ml) were from Gibco (Gaithersburg, MD). All
other chemicals were purchased from Sigma-Aldrich
(Zwijndrecht, The Netherlands).
Cell cultures
Eight PDAC cell lines (PL45, MIA-PaCa2, HPAF-II,
CFPAC-1, Bxpc3, HPAC, and PANC-1) and the human
immortalized pancreatic duct epithelial-like cell line
hTERT-HPNE were obtained from the American Type
Culture Collection, whereas seven primary PDAC
cultures (LPC006, LPC028, LPC033, LPC067, LPC111,
LPC167, and PP437) were isolated from patients at the
University Hospital of Pisa (Pisa, Italy), as described
previously [31]. The cell lines were tested for their
authenticity by PCR profiling using short tandem repeats
by BaseClear (Leiden, The Netherlands). The cells were
cultured in RPMI-1640, supplemented with 10% heat-
inactivated FBS and 1% streptomycin/penicillin at 37 °C,
and harvested with trypsin- EDTA in their exponentially
growing phase.
Quantitative reverse-transcriptase polymerase-chain-
reaction (qRT-PCR)
Total RNAs were extracted from cells using the TRI
REAGENT-LS (Invitrogen, Carlsbad, CA), according to
the manufacturer’s protocol. RNA was also extracted
from seven primary tumors, after laser micro-dissection
with a Leica-LMD7000 instrument (Leica, Wetzlar,
Germany), using the QIAamp RNA Micro Kit (Qiagen,
Hilden, Germany), as described [31].
RNA yield and purity were checked at 260 to 280 nm
with NanoDrop-1000 Detector (NanoDrop Technolo-
gies, Wilmington, DE). One microgram of RNA was
reverse-transcribed using the DyNAmo Synthesis Kit
(Thermo Scientific, Vantaa, Finland). qRT-PCR was per-
formed with specific TaqMan® primers and probes for
Akt1, human equilibrative nucleoside transporter-1
(hENT1), deoxycytidine kinase (dCK), cytidine deami-
nase (CDA), ribonucleotide reductase subunit-M1
(RRM1), and subunit-M2 (RRM2), E-cadherin, and the
glucose transporter 1 (SLC2A1/Glut1) which were
obtained from Applied Biosystems TaqMan Gene
expression products (Hs00920503_m1, Hs01085706_m1,
Hs00984403_m1, Hs01040726_m1, Hs00156401_m1,
Hs00168784_m1, Hs01072069_g1, Hs01023894_m1, and
Hs00892681_m1). The cDNA was amplified using the
ABI-PRISM 7500 instrument (Applied Biosystems,
Foster City, CA). Gene expression values were normal-
ized to β-actin, using a standard curve of cDNAs
obtained from Quantitative PCR Human Reference RNA
(Stratagene, La Jolla, CA), as described earlier [32].
Growth inhibition studies
The cell growth inhibitory effects of perifosine, MK-
2206 and NVP-BEZ235 were evaluated in the PANC-1,
LPC028, and LPC006 cells. Further studies evaluated
perifosine and gemcitabine combination in CFPAC-1,
PANC-1, LPC028, and LPC006 cells. These cells were
treated for 72 h with perifosine (1–500 μM), gemcitabine
(1–500 nM), and simultaneous combination at a fixed
ratio based on IC50 (i.e., concentration of a drug
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required for 50% inhibition of cell growth) of each drug.
The plates were then processed for the sulforhodamine-
B assay, as described [32].
Evaluation of synergistic/antagonistic interaction with
gemcitabine
The pharmacological interaction between perifosine and
gemcitabine was evaluated by the median drug effect
analysis method as described previously [32]. In this
regard, the combination index (CI) was calculated to
compare cell growth inhibition of the combination and
each drug alone. Data analysis was carried out using
CalcuSyn software (Biosoft, Oxford, UK).
Effects on multicellular spheroids
LPC006 and LPC028 spheroids were established by
seeding 104 cells per ml in DMEM/F12 + GlutaMAX-I
(1:1) with insulin-transferrin-selenium (1:1000, Invitro-
gen), in 24-well ultra-low attachment plates (Corning In-
corporated, NY). The cytotoxic effects were evaluated by
measuring the size and number of spheroids with the
inverted phase contrast microscope Leica-DMI300B
(Leica, Wetzlar, Germany), taking 9 pictures for each
well. Spheroid volume (V) was calculated from the
geometric mean of the perpendicular diameters D = (Dmax
+ Dmin)/2, as follows: V = (4/3) × π (D/2)3.
Western blot
In order to evaluate the modulation of Akt1, phospho-
Akt1, PARP, BAD, Bcl-2, NF-kB, and Glut1 protein
expression in PDAC cells treated for 24 h with perifo-
sine, gemcitabine, and their combination, Western blot
analyses were executed as described previously using the
Akt1 sc-5298 mouse monoclonal (Santa Cruz,
Biotechnology, Santa Cruz, CA) and the EP2109Y rabbit
monoclonal antibody (1:500 dilution; Abcam), PARP
sc-8007 mouse monoclonal (1:500 dilution; Santa Cruz),
BAD sc-8044 mouse monoclonal (1:500 dilution;Santa
Cruz), Bcl-2 sc-7382 mouse monoclonal (1:500 dilution;
Santa Cruz), NF-kB sc-114 rabbit polyclonal (1:500 dilu-
tion; Santa Cruz), and Glut1 sc-1605 goat polyclonal
(1:500 dilution; Santa Cruz) [33]. Briefly, 40 μg of pro-
teins was separated on a 10% SDS-polyacrylamide gel
and transferred onto polyvinylidene difluoride (PVDF)
membrane (Immobilion®-FL, Millipore, Billerica, MA).
The membrane was incubated overnight with mouse
and rabbit anti-Akt1, anti-phospho-Akt1, as described
above, as well as with mouse anti-BAD, anti-Bcl-2, anti-
PARP, with rabbit anti-NF-kB (1:1000, diluted in the
blocking solution; all from Santa Cruz Biotechnology,
Santa Cruz, CA), goat anti-Glut-1 (ab652, 1:500, diluted
in the blocking solution, from Abcam, Cambridge, UK),
and mouse anti-β-actin (1:10000; Sigma–Aldrich). The
secondary antibodies were goat anti-rabbit-InfraRedDye®
800 Green and goat anti-mouse InfraRedDye® 680 Red
(1:10000, Westburg, Leusden, The Netherlands). Fluor-
escent proteins were monitored by an Odyssey Infrared
Imager (LI-COR Biosciences, Lincoln, NE), equipped
with Odyssey 2.1 software to perform a semi-
quantitative analysis of the bands.
Akt and phospho-Akt analysis by enzyme linked immuno-
sorbent (ELISA) assay
To investigate the inhibitory effects of perifosine on Akt
[pS473] and [Thr308] phosphorylation, specific ELISA
assays were performed using the Pierce AKT Colorimet-
ric In-cell ELISA Kit (Thermo Scientific, Rockford, IL),
which has a sensitivity approximately twofolds greater
than Western blotting. The levels of Akt and phospho-
Akt were measured in cells seeded in a 96-well-plate at a
density of 105 cells per well, and treated for 4 or 24 h
with perifosine, gemcitabine, and their combination at
IC50 values. The absorbance was measured in a Synergy
HT Multi-Detection Microplate Reader (BioTek, Bad
Friedrichshall, Germany) at a wavelength of 450 nm.
In vitro migration and invasion assays
The ability of perifosine and its combination with gemci-
tabine and MK-2206 and its combination with gemcita-
bine to inhibit the migratory behaviour of PDAC cells
was investigated by in vitro migration assay, as described
[31]. The cells were exposed to the drugs at their IC50s.
Images were taken at the beginning of the exposure
(time 0), with those taken after 4, 6, 8, 20, and 24 h.
Transwell chambers with polycarbonate membranes,
and 8 μm pores were used for invasion assays. These
assays were carried out through coated transwell filters,
with 100 μl of 0.1 mg/mL collagen I solution. A total of
105 cells were plated on the upper side of the filter and
incubated with the drugs at IC50 concentrations in
RPMI-1640 medium. After 24 h, cells migrated into the
lower side were fixed with paraformaldehyde and stained
with Giemsa in 20% methanol. The filters were photo-
graphed and cells were counted.
Analysis of cell-cycle and cell death
To investigate the effect of drugs on modulation of cell
cycle, LPC028, LPC006, CFPAC-1, and PANC-1 cells
were treated for 24 h with gemcitabine, perifosine, and
their combination at IC50 concentrations. Cells were
stained by propidium iodide (PI) and cell cycle modula-
tion was evaluated using a FACSCalibur flow cytometer
(Becton Dickinson, San José, CA), equipped with the
CELLQuest software for data analysis.
The ability of gemcitabine, perifosine, and its combin-
ation with gemcitabine to induce cell death was evalu-
ated by measuring sub-G1 regions during cell cycle
analysis, as described above. Apoptosis induction was
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also assessed by 3,3′-dihexyloxacarbocyanine iodide
(DiOC) labelling. DiOC is a lipophilic and green fluores-
cent dye, which can pass the plasma membrane, without
being metabolized by the cell, and accumulate at the
membrane of mitochondria of living cells. Shortly, the
cells were stained with DiOC for 30 min, and analysed
by FACSCalibur, as described [34]. Additional studies
were performed with the Annexin-V/PI assay, plating
the cells in 6-well-plates at a density of 1.5 × 105. After
24 h, the cells were treated with the drugs at their IC50,
followed by 24-h incubation. Then, the cell pellets were
re-suspended in 100 mL of ice-cold binding buffer
(0.1 M Hepes/NaOH (pH = 7.4), 1.4 M NaCl, 25 mm
CaCl2). The staining was performed according to the
manufacturer’s instructions (Annexin-V/PI detection
Kit-I, Becton Dickinson). Cells were stained by 5 μL
Annexin V-FITC and 5 μL PI. Samples were gently
vortexed and incubated for 15 min at room temperature.
Then, 400 μL of binding buffer was added to the cells.
The samples were analyzed by FACSCalibur using exci-
tation/emission wavelengths of 488/525 and 488/675 nm
for Annexin-V and PI, respectively.
Caspase activity assay
The effects of perifosine, gemcitabine and their combin-
ation on the activity of caspase-3, -6, -7, -8, -9 were
determined by specific fluorometric assay kits (Zebra
Bioscience, Enschede, The Netherlands), according to
the manufacturer’s instructions. Briefly, 106 LPC006,
LPC028, CFPAC-1, and PANC-1 cells were exposed to
the drugs for 24 h at their IC50s. Fluorescence was
measured at 350 nm excitation and 460 nm emission
(Spectrafluor Tecan, Salzburg, Austria). Relative caspase
activity was normalized with respect to the untreated
cells.
Analysis of modulation of Glut1 by flow cytometry
To quantitatively detect the expression of membrane-
bound Glut1, cells were fixed with 80% ethanol,
incubated with anti-Glut1 antibody (Abcam), and then
stained with the appropriate FITC-conjugated anti-
rabbit IgG antibody (BD Pharmingen™, BD Biosciences,
San Jose, CA). Quantification of FITC fluorescence
intensity was performed using a FACSCanto flow
cytometer (BD Biosciences).
Evaluation of the cytotoxic and pro-apoptotic effects in-
hibition of Glut1 inhibition combined with Akt inhibitors
The Akt signaling is involved in the modulation of Glut1
expression/localization, and a recent study showed that
increased glucose metabolism was associated to resistance
to the tyrosine kinase inhibitor axitinib, and this resistance
was overcame by Glut1 silencing [35]. Therefore, we per-
formed additional cytotoxicity studies using the novel
Glut1 inhibitor PGL13. This compound was tested in the
LPC006 cells, at a concentration of 30 μM, which effect-
ively reduced glucose influx in previous studies [36, 37].
The cells were exposed to PGL13 for 72 h, alone or in
combination with IC50 concentration values of perifosine,
gemcitabine, and their combination. Cell growth inhib-
ition was then assessed by counting the cells after staining
with trypan blue, in comparison to untreated cells. Parallel
evaluation of apoptosis induction was performed by fluor-
escence microscopy with bisbenzimide staining, as
described previously [33].
Statistical analysis
All experiments were performed in triplicate and repeated
at least twice. Data were expressed as mean values ± SEM
and analyzed by Student’s t test or ANOVA followed by
Tukey’s multiple comparison test. For the analysis of the
correlation of phospho-Akt expression and clinical data,
the overall survival (OS), and progression-free-survival
(PFS) were calculated from the date of pathological diag-
nosis (i.e., the date of surgery) to the date of death and
tumor progression, respectively. OS and PFS curves were
constructed using Kaplan-Meier method, and differences
were analyzed using log-rank test. Data were analyzed
using SPSS v.20 statistical software (IBM, Chicago). Statis-
tical significance was set at P < 0.05.
Results
Correlation with outcome and phospho-Akt and Akt1
mRNA expression in PDAC tissues and cells
The protein expression of phospho-Akt was successfully
evaluated by IHC in 100 human PDACs collected in two
TMAs. The main clinical characteristics of these patients
are reported in the Table 1. IHC showed a variable pro-
tein expression with some specimens characterized by a
strong and diffuse staining, while other tissues had only
a few scattered positive cells with a weak staining (as
exemplified by the middle and lower panels in the Fig. 1a,
respectively). Patients were categorized according to
their high versus low phospho-Akt expression compared
to the median value (30 a.u.) calculated by digital scoring
(Fig. 1b, black line). No association was observed
between phospho-Akt and age, sex, grading, resection,
and lymph node infiltration (data not shown). Patients
with low phospho-Akt expression had a median OS of
16.2 months (95% CI, 14.8–20.1), while patients with a
high expression had a median OS of 12.0 months (95%
CI, 9.0–14.9, P = 0.03, Fig. 1c, upper panel). However,
only a trend toward a significant association was found
between phospho-Akt expression and PFS (P = 0.08,
Additional file 1: Figure S1a).
An additional analysis was performed categorizing the
patients with respect to a threshold expression of
57 a.u., which identified 14 cases with higher expression
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compared to all the others (defined as very high
phospho-Akt expression, Fig. 1b, blue square). Using
these categories, we observed a significant correlation
between high phospho-Akt protein expression and both
significantly shorter OS (P < 0.01, Fig. 1c, lower panel),
and PFS (Additional file 1: Figure S1b).
Parallel ICC studies revealed that the LPC006 cells
had a significantly lower phospho-Akt expression com-
pared to LPC028 cells, which were indeed included in
the category of low and very high phospho-Akt expres-
sion, respectively (Fig. 1b, blue and red circles). The
mRNA expression of Akt1 was detectable in all PDAC
cells by qRT-PCR, as well as in the originator tissues of
the primary tumor cell cultures. This expression value
differed among the cells, ranging from 0.9 arbitrary unit
(a.u.) in LPC006 cells to 24.0 a.u. in LPC028 and PANC-
1 cells (Fig. 1d). The mean and median expression in the
tumor cells (8.7 ± 0.2 and 8.4 a.u., respectively) were sig-
nificantly higher (P < 0.01) than the expression detected
in hTERT-HPNE cells (0.3 a.u.). Notably, Akt1 gene ex-
pression in the seven primary tumor cells and their
Table 1 Outcome according to clinical characteristics in the 100
PDAC patients enrolled in the present study
Characteristics N (=%) OS months
(95% CI)
P
No. patients All 100 14.0 (12.1–15.8)
Age, years ≤65 43 15.2 (13.3–16.8) 0.361
>65 57 14.1 (11.1–17.0)
Sex Male 47 13.0 (11.1–14.9) 0.814
Female 53 15.0 (11.9–18.1)
Resection status R0 56 15.2 (12.3–21.6) 0.474
R1 44 13.5 (11.2–31.0)
Lymph node No 10 18.5 (7.6–32.4) 0.521
Yes 90 14.2 (12.2–15.9)
Grading 1–2 36 15.5 (11.5–18.1) 0.097
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Fig. 1 Akt/phospho-Akt expression in PDAC tissues and cells. a Representative examples (original magnification, ×40) showing the variable
expression of phospho-Akt in paraffin-embedded PDAC samples collected in four TMAs (with 4 cores for each of the 100 patients). N.C., negative
control. b Expression values of phospho-Akt observed across the cohort of PDAC patients, obtained by digital quantification. Phospho-Akt showed
positive cytoplasmic and nuclear staining in most tissue sections, with intense staining in 14 out of 100 samples. The staining intensities of the
LPC028 and LPC006 cells were included in the very high and low Akt expression groups, respectively. c Kaplan–Meier survival curves according to
the expression of phospho-Akt in 100 radically resected PDACs, showing that patients with high expression (upper panel) and very high expression
(lower panel) of phospho-Akt had a significantly shorter survival compared to patients with low phospho-Akt expression. d Akt1 mRNA expression in
ATCC cell lines (black bars), primary tumor cultures (white bars), and their originator tissues (gray bars). Dashed bars identify the cells that were selected
for further in vitro studies; e Representative Western blot pictures of phospho-Akt1 and Akt1 expression in LPC006, CFPAC-1, PANC-1, and LPC028 cells.
Columns, mean values obtained from three independent experiments, bars, SEM
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laser-microdissected originator tumors showed a similar
pattern and were highly correlated with Spearman analysis
(R2 > 0.9, P < 0.05), suggesting that these cells represent
optimal preclinical models for our pharmacological stud-
ies. Moreover, Western blot analysis revealed that the
LPC006 and CFPAC-1 cells had a lower phospho-Akt1/
Akt1 ratio (0.3 and 0.6 a.u., respectively) expression com-
pared to PANC-1 (0.8) and LPC028 (1.1) cells (Fig. 1e).
Therefore, we selected for further studies two primary
cell cultures (LPC006 and LPC028) which were represen-
tative of low and very high expression values, as well as
two cell lines, PANC-1 and CFPAC-1, with high and inter-
mediate expression values of Akt1 mRNA, respectively.
Perifosine inhibits cell growth and interacts synergistically
with gemcitabine in PDAC cells with high expression of
phospho-Akt
The cytotoxic activity of three different Akt inhibitors
(perifosine, MK-2206, and NVP-BEZ235) was evaluated
in the PANC-1 cell line (Fig. 2a). All these compounds
caused a concentration-dependent inhibition of prolifer-
ation, with IC50 values ranging from 5.1 (perifosine) to
15.8 μM (NVP-BEZ235). Higher IC50 values were
obtained in the LPC006 cells, i.e., 22.5, 31.7 and 45.5 μM
for perifosine, NVP-BEZ235, and MK-2206 (Additional
file 1: Figure S2), respectively. According to the lowest
IC50 values detected in these assays, we selected perifo-
sine for the following studies on the pharmacological
interaction of Akt inhibitors with gemcitabine.
The cell growth inhibitory effects of perifosine,
gemcitabine, and their combination in LPC028 and
LPC006 cells are shown in Fig. 2b, while the data for
CFPAC-1 and PANC-1 are reported in the Additional
file 1: Figure S3. Since the CI method recommends a
ratio of concentrations at which drugs are equipotent,
combination studies were performed using fixed ratios
with IC values at IC50s. Perifosine enhanced the anti-
proliferative activity of gemcitabine, especially in the
LPC028 and PANC-1 cells, by decreasing the IC50s of
gemcitabine from 4.3 ± 1.1 and 17.2 ± 2.1 nM to 1.4 ± 0.5
and 4.0 ± 1.1 nM, respectively. The median drug-effect
analysis revealed a slight-to-moderate synergism in
CFPAC-1, and a strong synergism in the PANC-1 and
LPC028 cells, with CI values of 0.8, 0.5, and 0.2, respect-
ively (Fig. 2c). Conversely, the combination of perifosine
and gemcitabine was antagonistic in the LPC006 cells
(CI > 1.2). To evaluate whether these effects were
observed also in three-dimensional (3D) models and
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investigate the mechanisms underlying these different
interactions, several biochemical analyses were performed,
as detailed below.
Perifosine and its combination with gemcitabine reduce
the size of PDAC spheroids
Previous studies illustrated that 3D culture models are gen-
erally more chemo-/radio-resistant than two-dimensional
monolayer cell cultures, supporting their use for drug test-
ing [38]. In order to explore whether perifosine would be
active in 3D PDAC models, we evaluated this drug in
spheroids of LPC006, LPC028, and PANC-1 cells.
Perifosine remarkably increased the disintegration of
LPC028 and PANC-1 spheroids, which were significantly
(P < 0.05) reduced in size compared to the untreated
spheroids (Fig. 2d–e). The combination of perifosine
with gemcitabine additionally reduced the size of the
LPC028 and PANC-1 spheroids with respect to the
spheroids treated with the single drugs. In contrast, no
changes were observed in the LPC006 spheroids, further
supporting the antagonistic interaction of perifosine with
gemcitabine in this PDAC model.
Modulation of phospho-Akt and gemcitabine determinants
in PDAC cells
Perifosine inhibits the phosphorylation of Akt by blocking
the PH-domain in different cancer cell lines [39], but no
data have been reported yet on PDAC cells. Therefore, we
evaluated the expression of phospho-Akt (at serine residue
473 (Ser473) and at threonine residues 308 (Thr308)),
normalized to the total Akt levels, both in untreated cells
and in cells treated with Akt inhibitors (perifosine and
MK-2206), gemcitabine, and their combination. We
observed a similar inhibition of the phosphorylation status
after 4 or 24 h (Fig. 3a and Additional file 1: Figure S4) as
well as in both residues (Additional file 1: Figure S5a, b).
Perifosine significantly reduced the expression of p-Akt in
LPC028, CFPAC-1, and PANC-1 cells (e.g., 40, 25, and
30% reduction, respectively). Regarding Ser473 phosphor-
ylation, the combination of perifosine and gemcitabine
was also able to significantly suppress Akt phosphoryl-
ation, with a degree of inhibition ranging from −35
(CFPAC-1 cells) to −45% (LPC028 cells). Conversely, both
Ser473 and Thr308 phospho-Akt levels were not affected
by perifosine, MK-2206, and their combination with
gemcitabine in the LPC006 cells.
RRM1 and RRM2 encode for the catalytic and the
regulatory subunits of ribonucleotide reductase and is a
key molecular target of gemcitabine [40]. Previous stud-
ies demonstrated that the expression of RRM2 is modu-
lated by the Akt/c- MYC pathway [41]. However, the
alterations in the expression or function of other
enzymes, involved in the transport, metabolism, and
catabolism of gemcitabine can also lead to resistance
(e.g., decreased dCK or increased CDA expression
[40]). Therefore, we evaluated the mRNA expression of
several gemcitabine determinants in the LPC006,
LPC028 and PANC-1 cells. As shown in Fig. 3b, the ex-
pression of RRM1 and RRM2 was significantly reduced
(approximately 2-fold) in LPC028 and also in PANC-1
cells (Additional file 1: Figure S6) treated with perifo-
sine versus untreated cells, while only minimal varia-
tions were observed for hCNT1, hENT1, dCK, and
CDA expression. No significant changes were observed
in the LPC006 cells (Fig. 3b). These results can at least
in part explain the synergistic interaction of perifosine
with gemcitabine in PDAC cells with high phospho-Akt
expression.
Perifosine and its combination with gemcitabine inhibit
cell migration/invasion and upregulate the expression of
E-cadherin
To determine the effects of perifosine, gemcitabine, and
their combination on migratory behavior, a scratch mo-
bility assay was performed in LPC028, LPC006 (Fig. 4a),
CFPAC-1, and PANC-1 (Additional file 1: Figure S7).
LPC028 showed a significant reduction of migration
starting after 8 h exposure to perifosine with a reduction
of the scratch-area of about 50%, and the perifosine/
gemcitabine combination additionally reduced cell mi-
gration (P < 0.05; Fig. 4a left panel), while gemcitabine
alone did not affect cell migration. No modulation of cell
migration was observed in the LPC006 cells (Fig. 4a
right panel). Similarly, the migration of these cells was
not affected by MK-2206 alone and in combination with
gemcitabine (Additional file 1: Figure S8).
LPC028, CFPAC-1, and PANC-1 cells treated with
perifosine showed also a significantly reduced invasive
potential, compared to untreated cells (Fig. 4b). In
particular, the perifosine/gemcitabine combination was
more effective in inhibiting invasion than perifosine-
alone in LPC028 and PANC-1 cells, as shown by the
significantly lower number of invading cells with
Giemsa’s stain. However, no modulation of cell invasion
was observed in the LPC006 cells.
Since previous studies suggested that the Akt signaling
pathway suppressed E-cadherin expression [42], we
investigated whether perifosine could affect the level of
this target at both mRNA and protein level. Perifosine
and its combination with gemcitabine significantly
enhanced E-cadherin mRNA expression in LPC028,
CFPAC-1, and PANC-1 (P < 0.05; Fig. 4c), while no
changes were detected in LPC006 cells. Similarly,
immunocytochemistry analysis in LPC028 cells
illustrated a significant increase of E-cadherin protein
staining after exposure to both perifosine and perifosine/
gemcitabine combination (data not shown).
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Perifosine and its combination with gemcitabine affect
cell cycle
Perifosine, gemcitabine and their combination affected
cycle distribution of PDAC cells, as summarized in
Additional file 2: Table S1. Perifosine significantly (P <
0.05) increased the percentages of LPC028 cells in S and
G2/M phases (e.g., from 18.7 in the control to 26.1% in
the S phase) after 72 h, while reducing the percentage of
the cells in G0/G1. Similarly, the perifosine/gemcitabine
combination significantly decreased the cells in G1
phase, while increasing the cells in S phase, up to 48.9%.
Comparable perturbations of cell cycle were observed in
the CFPAC-1 and PANC-1 cells, suggesting that perifo-
sine might favor gemcitabine activity through a signifi-
cant increase of cells in the S phase. Opposite
modulation of cell cycle was observed in LPC006 cells,
with only a slight increase of the cells in the G0/G1
phase and minimal modulations of the S and G2/M phase
in cells exposed to perifosine/gemcitabine combination.
Perifosine and its combination with gemcitabine enhance
cell death and apoptosis
Analysis of the sub-G1 region of cell cycle perturbation
demonstrated that the treatment with perifosine
enhanced cell death (Additional file 2: Table S1). In
particular, the LPC028 cells treated with the combin-
ation exhibited the largest sub-G1 signal (e.g., ≈20% in
cells treated with perifosine/gemcitabine combination
versus untreated cells).
Moreover, we evaluated the variation of mitochondrial
membrane potential in LPC028, LPC006, PANC-1, and
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CFPAC-1. As shown in Fig. 5a, the combination
perifosine gemcitabine causes an increase of mitochon-
drial membrane potential in LPC028, PANC-1, and
CFPAC-1 cells.
Further analysis of cell death by the Annexin-V/PI
assay confirmed the induction of apoptosis by perifosine.
Perifosine increased both early and late apoptosis, as
shown in Fig. 5b (left panel) for the LPC028 cells. More-
over, the combination of perifosine and gemcitabine
significantly increased the percentage of late apoptotic
cells up to 26%. Similar results were observed in
CFPAC-1 and PANC-1 cells (Additional file 1: Figure S9),
whereas no apoptosis induction was detected in LPC006
cells (Fig. 5b right panel).
Perifosine and its combination with gemcitabine activate
caspases and pro-apoptotic factors, and downregulate
Bcl-2 and NF-kB
In order to investigate the molecular mechanisms under-
lying apoptosis induction, we explored several potential
cellular targets of perifosine, focusing on activation of
the initiator caspases, caspase-8 and -9, and the effector
caspases, caspase-3, and -6. Moreover, we studied the
expression of various pro-apoptotic and anti-apoptotic
proteins. As shown in Fig. 5c, perifosine and its combin-
ation with gemcitabine were able to increase the activity
of caspase-3/-6/-8/-9 in LPC028 as well as CFPAC-1
and PANC-1 (Additional file 1: Figure S10) but not in
the LPC006 cells, as determined by specific fluorometric
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caspase activity assays. However, Western blot analyses
demonstrated the modulation of other important apop-
totic markers. In particular, perifosine and perifosine/
gemcitabine combination increased the expression of
PARP and BAD, while reducing Bcl-2 and NF-kB expres-
sion in LPC028 cells. Conversely, none of these proteins
was affected by the exposure to perifosine and its com-
bination with gemcitabine in the LPC006 cells (Fig. 5d).
Glut1 is overexpressed in the cells resistant to Akt
inhibition, while its inhibition significantly reduces cell
growth and induces apoptosis after gemcitabine/
perifosine treatment
Since major oncogenic signaling pathways have been
linked to increased glucose metabolism, and previous
studies showed that stimulation of Akt1 induces Glut1
mRNA and protein accumulation, [43] we evaluated the
expression of this key glucose transporter in the LPC028
and LPC006 cells. As shown in the Fig. 6a, Glut1 mRNA
levels were significantly reduced after treatment with
perifosine alone and in combination with gemcitabine in
the LPC028 and PANC-1 cells, whereas no modulation
was detected in the LPC006 cells. However, since PI3K/
AKT/mTOR signaling seems to play an essential role in
trafficking of Glut1 from recycling endosomes and/or
retention of Glut1 at the plasma membrane [44], we
performed further studies to evaluate the amount of
membrane-bound Glut1 with FACS analysis (Fig. 6b).
In the LPC028 cells, we observed a significant reduc-
tion (P < 0.05) of the membrane-bound expression of
Glut1 after treatment with perifosine (56% compared to
untreated cells). Further studies with Western blot
clearly demonstrated the overexpression of Glut1 in the
LPC006 compared to the LPC028 and PANC-1 cells. A
high expression of Glut-1 was also observed in PANC-1
cells (Fig. 6c). Moreover, Glut1 expression was not
reduced by Akt inhibition (Fig. 6c). We therefore inves-
tigated whether inhibition of Glut1 by the novel specific
compound PGL13 (Fig. 6d) can at least in part
overcome the inherent resistance of the LPC006 cells
to perifosine and other Akt inhibitors. Remarkably, the
Glut1 inhibitor alone caused only a slight reduction of
cell growth (<10%), but its combination with perifosine
reduced significantly the percentage of surviving cells
compared to perifosine alone (Fig. 6e). Furthermore,
the combination of PGL13 with both perifosine and
gemcitabine led to a more dramatic drop in the number
of surviving cells, up to −81%, compared to control
which was associated with strong apoptosis induction, as
detected by characteristic apoptotic nuclear morphological
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features with fluorescence microscopy. In particular the
LPC006 cells exposed to PGL13 with both perifosine and
gemcitabine had an apoptotic index of 27%, which was
similar to the apoptotic index of the LPC028 cells treated
with perifosine and gemcitabine (Fig. 6f). The effect of a
combined Akt inhibitor/anti-Glut1 treatment was further
tested with MK-2205 and NVP-BEZ235, where it led to a
−14% and −20% decrease in cell viability compared with
these drugs alone (Additional file 1: Figure S11). Thus,
inhibition of Glut1 promoted anti-Akt-mediated cell
death, and this combined treatment shows promise for
future investigation in the treatment of PDAC.
Discussion
The present study supports a role for phospho-Akt as a
prognostic factor in PDAC patients, and unravels its
potential role as a target for the synergistic interaction
of anti-Akt agents and gemcitabine through modulation
of apoptotic and invasive processes.
Several studies demonstrated that PDAC tissues have
increased activation of the PI3K/Akt, as assessed with
the phosphorylation of Akt, and this has been associated
with higher histological tumor grade [45] and worse
prognosis [46, 47]. In the present study, we further
explored the clinical relevance of phospho-Akt by
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screening its expression in a homogeneous cohort of 100
surgically resected PDACs. In agreement with the previ-
ous studies, even considering several clinicopathological
parameters, phospho-Akt expression was the only factor
correlated to differential clinical outcome. However, a
systematic review and meta-analysis of prognostic tissue
biomarkers for PDAC, including phospho-Akt among
the 22 markers associated with limitless replicative
potential eligible for examination, showed that only
Ki-67 maintained statistically significant associations
with outcome [48]. These discrepancies might be attrib-
uted to the different experimental procedures used,
including antigen retrieval technique, antibody charac-
teristics, and dilution, as well as observer variability in
staining pattern description and cutoff point selection.
Therefore, in the present study we have chosen an anti-
body that was previously validated in an immunohisto-
chemical study on 102 colorectal cancer FFPE samples
[49] and we have used image analysis software to calcu-
late expression as a continuous parameter, in order to
facilitate the identification of cutoff points. This method
allowed the assignment of the specimens to different
categories, including a subset of tissues (about 14%)
characterized by extremely high expression of phospho-
akt, which could clearly influence the prognostic value.
Indeed this cutoff point identified a group of patients
with very poor outcome, who should be treated with
more aggressive, novel therapeutic approaches.
Of note, recent genomic studies showed that the PI3K/
Akt signaling is among the core signaling pathways lead-
ing the intrinsic aggressiveness of PDAC, suggesting that
in the PDAC actionable genome about 9 and 6% of the
cases are Akt- and PI3K-dependent, respectively [50].
These data underline the potential importance of specific
inhibitors of PI3K/Akt as novel effective therapeutics in a
selected subpopulation of PDAC patients. Moreover, acti-
vation of this signaling pathway is associated with PDAC
chemoresistance [13, 51], supporting the hypothesis that
Akt inhibitors might also be used to overcome resistance
towards conventional cytotoxic agents.
Several Akt/PI3K inhibitors are being developed. The
first generation of these inhibitors includes LY294002 and
wortmannin, which were tested to elucidate the value of
Akt/PI3K as therapeutic target [52]. However, due to the
unfavorable pharmaceutical properties, toxicity, and cross-
over inhibition of other lipid and protein kinases, these
compounds were not used in clinical studies [51].
More recently, several small molecules that inhibit the
PI3K/Akt signaling entered clinical development, but
more information on their activity in the preclinical
setting is warranted. For instance, a recent study showed
the potential inhibition of autophagy by perifosine dem-
onstrating that this drug impairs the autophagic flux in
HepG2 and U87 MG cells, which is related to defects in
intracellular cholesterol transport [53]. These results
might be relevant for PDAC because some research lines
point at autophagy as a tumor-promoting mechanism.
Although a better understanding of the complexity of
autophagy is needed, the modulation of this process
might therefore open new opportunities for the
therapeutic use of autophagy inhibitors [54]. Further
research to identify the precise mechanisms of autoph-
agy maturation may therefore provide a new insight into
the antiproliferative action of perifosine.
Our results demonstrate that perifosine is the targeted
anti-PI3K/Akt antitumor agent demonstrating the most
potent growth inhibitory effects in a panel of human
PDAC cells characterized by distinct molecular proper-
ties. Limited published preclinical research focusing on
this issue in PDAC reported similar cytotoxic activity of
perifosine in PANC-1, MIA PaCa-2, and AsPC-1 cells
[55]. Sensitivity to perifosine in the PDAC cells also fell
within the range of IC50 values previously reported in
PDAC cell lines and spheroids for other Akt inhibitors,
such as NVP-BEZ-235 [56, 57].
Furthermore, perifosine interacted synergistically with
gemcitabine in PDAC cells with high phospho-Akt
expression, but antagonistic in cells with low phospho-
Akt expression. Synergism was associated with inhibition
of migration/invasion and induction of apoptosis. These
results are in agreement with previous studies showing
synergistic interaction of gemcitabine with perifosine in
PANC-1 cells and xenografts [55] as well as enhanced
apoptotic cell death after combined treatment with
paclitaxel in chemoresistant ovarian cancer cells [58].
However, most previous studies were performed in
ATCC cell lines, which showed similar results [59], while,
to more effectively develop targeted compounds, it will be
helpful to understand why these agents fail when they do.
Thus, in the present study, cell growth inhibitory effects
of perifosine, gemcitabine, and their combination were
evaluated in several representative PDAC cells, including
primary PDAC cell cultures. For the LPC028 model, we
demonstrated that perifosine inhibited cell growth, both
in monolayer cell cultures and in cells growing as
spheroids, whereas LPC006 cells and spheroids were not
affected. Similarly, the perifosine/gemcitabine combin-
ation had synergistic effects only in the cells with high
phospho-Akt or intermediate/high values of Akt1 mRNA,
as determined by RT-PCR. Conversely, this combination
was antagonistic in the cells with low Akt1, and phospho-
Akt1 expression. An important limitation of our findings
is the use of a single-cell culture (LPC006) as a model of
low phospho-Akt1. However, the results in two PDAC
models (LPC028 and PANC-1) with high phospho-Akt1
levels were similar. These data suggest that the expression
and activation of Akt might therefore be used to tailor
perifosine therapy.
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Importantly, two specific ELISA for the Akt Ser473
and the Thr308 phosphorylation showed that perifosine
effectively reached and inhibited its targets in the
LPC028 and PANC-1 cells, and the combination with
gemcitabine additionally inhibited Akt activation in
these cells. The present study demonstrated also that
perifosine interfered with pivotal determinants for the
activity of gemcitabine. In particular, we observed that
perifosine and its combination with gemcitabine signifi-
cantly reduced the expression of RRM1 and RRM2 in
the cells with a high expression of Akt, while this effect
was not statistically significant in the cells with low Akt
expression. RR is a key target of gemcitabine activity and
previous studies correlated the expression of its subunits
to gemcitabine sensitivity in PDAC cells [60, 61]. There-
fore, the synergistic interaction between perifosine and
gemcitabine might be explained, at least in part, by the
modulation of gemcitabine sensitivity through RRM1
and RRM2 suppressions.
However, our results suggested that the synergistic
interaction of perifosine with gemcitabine is associated
with other important molecular mechanisms affecting
PDAC aggressiveness (Fig. 7). In agreement with previ-
ous observations showing the reduction of cell migra-
tion/invasion through Akt inhibition [16, 62], we
observed that perifosine and its combination with gem-
citabine markedly reduced cell migration and invasion in
PDAC cells. Several classes of proteins are involved in
this invasive behavior, including cell-cell adhesion mole-
cules like members of immunoglobulin and calcium-
dependent cadherin families and integrins. In line with
previous evidence on inverse relationship between Akt
and E-cadherin expression [42], we demonstrated that
perifosine increased the expression of E-cadherin in
LPC028, CFPAC-1, and PANC-1 cells. This can at least
in part explain our findings on the reduction of migra-
tion determined by perifosine. Furthermore, Toll et al.
[63] showed that decreased E-cadherin was associated
with poor prognosis of PDAC patients, supporting the
studies on novel compound which can modulate the
expression of this protein.
Since the Akt signaling pathway plays an important
role in cell survival process, its blockage can result in
activation of programmed cell death [15]. Thus, we
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further evaluated the effect of perifosine on cell cycle
perturbation and apoptosis induction. Previous findings
on the effect of perifosine after 24 h treatment showed
induction of G2/M arrest, potentially favoring the activ-
ity of 6-thioguanine [64]. Our results showed that after
72 h, perifosine treatment was associated with an in-
crease in the percentage of cells in the G0/G1, and S
phase, potentially favoring the cytotoxic activity of gem-
citabine. This modulation of the cell cycle was associated
with significant induction of apoptosis, as determined by
multiple methods, such as analysis of sub-G1, mitochon-
dria membrane potential and Annexin-V/PI. In order to
investigate the mechanisms underlying the activation of
programmed cell death, we checked the modulation of
critical factors involved in the apoptotic cascades. Previ-
ous studies showed that drug-induced Akt deactivation
was associated with activation of pro-apoptotic factors,
including caspase-9 and BAD, as well as with a parallel
decrease in the expression of the anti-apoptotic factors
Bcl-2 and NF-kB [22, 65]. Our studies showed similar
results after exposure of the PDAC cells to perifosine.
Despite increasing evidence on the pivotal role of
PI3K/Akt signaling in cancer, the strategies to hit PI3K/
Akt/mTOR pathway have failed to demonstrate thera-
peutic activity in most ongoing clinical trials, and a pre-
vious phase II study testing perifosine in previously
untreated patients with locally advanced, unresectable,
or metastatic PDAC, was terminated as a result of
unacceptable adverse events [66].
It is already known that in PDAC cells, dual PI3K-
mTOR inhibition induces rapid overactivation of MAPK
pathway through a PI3K-independent pathway [67], and
that drug resistance may be overcome by inhibition of
parallel oncogenic-dependent pathways, such as with the
dual MEK and PI3K/mTOR blockade [57].
One strategy to overcome resistance consists into
identifying key molecular differences in the tumors that
are less likely to respond. Oncogenic KRAS drives meta-
bolic reprogramming in tumor cells by increasing aer-
obic glycolysis, and recent studies showed that subtypes
of PDAC cells with distinct metabolite levels associated
with glycolysis, lipogenesis, and redox pathways, con-
firmed at the transcriptional level. The glycolytic and
lipogenic subtypes showed striking differences in glucose
and glutamine utilization, as well as mitochondrial func-
tion, and corresponded to differences in cell sensitivity
to inhibitors of glycolysis, glutamine metabolism, lipid
synthesis, and redox balance [68]. In the present study
we demonstrated that the resistant LPC006 cells were
characterized by overexpression of Glut1. Remarkably,
the inhibition of Glut1 dramatically enhanced perifosine
and perifosine/gemcitabine-induced cell death, suggest-
ing a cooperativity between Akt inhibitors and Glut1 in-
hibition. Agents directly inhibiting Glut1 are in early
phase evaluations, and a few preclinical studies have
demonstrated that Glut inhibitors led to diminish tumor
growth in vitro and in vivo [69]. However, the altered ex-
pression of Glut1 might also influence the sensitivity of
tumor cells to chemotherapy, since a recent study
showed that the knockdown of Glut1 sensitizes head
and neck cancer cells to the chemotherapy drug cisplatin
[70]. To our knowledge, this is the first study showing
that Glut1 inhibitors can restore the repression of aer-
obic glycolysis induced by PI3K/mTOR inhibitors in re-
sistant cells, and favor their synergistic interaction with
cytotoxic compounds. These results should prompt fur-
ther studies to understand how PDAC cell metabolism
might affect sensitivity to new anti-signaling therapies
and to identify promising therapeutic targets that might
be exploited by combination therapies.
Conclusions
Our data support the analysis of phospho-Akt expression as
both a prognostic and a predictive biomarker, for the rational
development of novel therapies targeting the Akt pathway in
PDAC. In particular, we observed that phospho-Akt expres-
sion levels influence the antitumor activity of perifosine, as
well as the synergistic interaction with gemcitabine, through
its ability to attack key mechanisms involved in the prolifera-
tion, cell cycle control, apoptosis and migration/invasion
properties. Finally, we demonstrated that inhibition of Glut1
overcame resistance to this combination treatment andmight
provide the basis for the development of new therapeutic ap-
proaches with Akt inhibitors in patients with PDAC.
Additional files
Additional file 1: Figure S1. PFS curves according to phospho-Akt
expression in radically-resected PDACs, showing that patients with high
and “very high” phospho-Akt (right panel) had a significantly worse PFS.
Figure S2. Growth inhibitory effects after MK-2206 exposure in LPC006
(72-hours). Figure S3. Growth inhibitory effects after 72 hours exposure
to perifosine, gemcitabine or their combination at a fixed ratio based on
IC50 values in CFPAC-1 and PANC-1 cells. On the X-axis the drug
concentrations for the combination are referred to gemcitabine.
Figure S4. Phospho-Akt (serine residue-473) expression, normalized to
total Akt, after 4-hour exposure, as determined by ELISA. Figure S5. A
Phospho-Akt (serine residue-473) expression, normalized to total Akt, after
24-hour exposure. B Phospho-Akt (threonine residue-308) expression,
normalized to total Akt, after 24-hour exposure, as determined by ELISA.
Figure S6. Expression of gemcitabine determinants in PANC-1 cells
treated with perifosine, as determined by qRT-PCR. Dashed line, values in
untreated samples. Figure S7. Wound-healing assay in CFPAC-1 and
PANC-1 exposed to perifosine, gemcitabine or their combination (IC50
values, 24 hours). Figure S8. Wound-healing assay in LPC006 exposed to
MK-2206, gemcitabine or to their combination (IC50 values, 24 hours).
Figure S9. Annexin-V assay in LPC028 and LPC006. Figure S10:
Modulation of caspase-3, caspase-6/-8/ and caspase-9 in CFPAC-1 and
PANC-1, as determined by a specific fluorometric assay. Figure S11. Cell
growth inhibition in LPC006 cells after 72-hour exposure to MK-2205,
NVP-BEZ235 at IC50 values, together with DMSO or with the Glut1
inhibitor PGL13, at 30 μM. Points, or Columns, mean values obtained from
three independent experiments; bars, SEM. *Significantly different from
controls. (PPTX 328 kb)
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Additional file 2: Table S1. Effects of gemcitabine and perifosine and
their combination on cell cycle distribution and on cell death (sub-G1).
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AbstrAct
Breast cancer is one of the most widespread carcinoma and one of the main 
causes of cancer-related death worldwide, especially in women aged between 
35 and 75 years. Among the different subtypes, triple negative breast cancer 
(TNBC) is characterized by the total absence of the estrogen-receptor (ER) and 
progesteron-receptor (PR) expression as well as the lack of human epidermal growth 
factor receptor 2 (HER2) overexpression or gene amplification. These biological 
characteristics confer to TNBC a higher aggressiveness and relapse risk along with 
poorer prognosis compared to other subtypes. Indeed, 5-years survival rate is still 
low and almost all patients die, despite any adjuvant treatment which at moment 
represents the heading pharmacological approach. To date, several clinical trials 
have been designed to investigate the potential role of some molecular markers, 
such as VEGF, EGFR, Src and mTOR, for targeted treatments in TNBC. In fact, many 
inhibitors of the PI3K/AKT/mTOR pathway, frequently de-regulated in TNBC, are 
acquiring a growing interest and several inhibitors are in preclinical development 
or already in early phase clinical trials. In this Review, we investigated the role 
of the PI3K/AKT/mTOR pathway in TNBC patients, by summarizing the molecular 
features that led to the distinction of different histotypes of TNBC. Furthermore, 
we provided an overview of the inhibition mechanisms of the mTOR and PI3K/AKT 
signaling pathways, highlighting the importance of integrating biological and clinical 
data for the development of mTOR inhibitors in order to implement targeted therapies 
for TNBC patients.
INtrODUctION
Breast cancer (BC) is one of the most widespread 
carcinoma and one of the main causes of cancer-related 
death worldwide especially in women aged between 35 
and 75 years [1]. In the last few years new molecular 
markers have been studied to provide new insights on 
BC heterogeneity but also to better understand and 
predict tumor behavior during treatment. It is now well 
established that BC can be classified into different groups 
according to gene expression profiles [2-5]. This new 
classification will certainly provide new insights into the 
BC biology and will probably drive treatment decisions 
in the near future by microarray analysis that soon will 
switch the clinical approach to different illnesses by giving 
a huge support to conventional pathology (morphology 
and immunohistochemistry) [6].
The different BC subgroups detected by their 
different gene expression profiling are below described as 
discussed in San Gallen Expert Consensus report: 
                                             Review
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Luminal A subgroup is characterized by estrogen/
progesterone receptor (ER/PR) positivity, lower 
expression of Ki-67 ( < 20%) and HER2 lack, accounting 
for the 50% of all invasive BCs; Luminal B subgroup 
results characterized by ER/PR positivity or variable 
expression of HER2 (+ or -), accounting for the 10-20% 
of all invasive BCs [7]; HER2 overexpression subtype 
is characterized by ER/PR negativity and HER2 strong 
positivity. This subtype accounts for 15% of all invasive 
breast cancer; Basal like breast cancer (BLBC) subtype 
exhibits an expression profile similar to that of the 
epithelial cell mammary tissue and includes triple negative 
breast cancer (TNBC) [8-10].
Among the different subgroups, TNBC presents 
biological characteristics that confer higher aggressiveness 
and relapse risk along with worse outcome in comparison 
to other subgroups. Several studies showed that PI3K/
AKT/mTOR signaling is often altered in TNBC patients 
[11].
sELEctION crItErIA
We have searched trials using Medline (PUBMED), 
EMBASE and COCHRAINE database, the following 
search strategy (“TNBC” [MESH] AND (“PI3K” [tiab] 
OR “mTOR” [tiab]) AND (“ER” [tiab] OR “PgR” [tiab]) 
and free text terms as “PI3K” [tiab], “triple negative breast 
cancer” [tiab] and “mTOR” [tiab].
trIPLE NEGAtIVE brEAst cANcEr
TNBC is characterized by lack of ER and PR 
expression as well as the absence of HER2 [12, 13]. 
The percentage of new TNBC diagnosis is variable, but 
it mainly ranges between 9% and 16% with a higher 
frequency in young women carrying BRCA1 gene 
mutation, showing a strong correlation with ethnic origin 
(in particular, African-American and Hispanic women) 
[14-17]. TNBC also shows greater size and tumor burden, 
and often is a more aggressive high grade tumor [18, 19]. 
TNBC patients show a higher susceptibility to 
develop metastases, resulting in an unfavorable clinical 
outcome compared to other subgroups [20-22].
Although TNBC patients initially respond to 
neoadjuvant treatments, only 30% of them will exhibit a 
survival higher than 5-years following the first diagnosis, 
reflecting the aggressiveness of this subtype [23, 24]. 
Patients with BRCA1 mutation are often diagnosed 
with TNBC but not all TNBC are BRCA1 positive. 
Nevertheless, it been shown that TNBC not carrying 
BRCA1 mutation, behave similarly to BRCA1-deficient 
tumors, showing also similar gene expression profiles [25, 
26].
The growing interest in the TNBC biology allowed 
to develop trials investigating new drug targeting potential 
biomarkers such as VEGF, EGFR, Src and mTOR [27]. 
Moreover, the introduction of tumor molecular features in 
the characterization of TNBC has led to a further subtype 
labeling. Indeed, 6 new TNBC subtypes have been 
identified [28]: 
Basal-like 1 (BL1) and Basal-like 2 (BL2) subtypes: 
both are characterized by up-regulation of gene and 
cellular markers mainly implicated in cell growth. In fact, 
Ki-67 expression and nuclear fraction staining are higher 
(BL1+BL2 = 70%) if compared to other subtypes (42%). 
All these features combined together indicate that more 
efficient treatment for BL TNBCs could be that directed 
against the mitotic apparatus such as a taxane-based 
therapy [29-32]. Furthermore, BL2 shows the involvement 
of a different plethora of growth factors and receptors 
(EGF, EGFR, NGF, MET, Wnt/β-catenin, IGF1R and 
EPHA2). 
Immunomodulatory subtype: it is characterized by 
immune system gene signature similar to that of medullar 
BC determining its better clinical outcome.
Mesenchymal and mesenchymal stem-like subtypes: 
both are characterized by increased expression of gene 
and cellular markers involved in cell motility (Rho 
pathway), extracellular matrix-receptor interaction and 
differentiation (Wnt/β-catenin, ALK, TGF-β pathways). 
The mesenchymal stem-like subtype shows reduced 
expression of proliferative genes and enrichment of 
genes involved in several signaling pathways, including 
the inositol phosphate-dependent signaling pathway, 
EGFR, PDGF, and ERK1/2 signaling. Moreover, notable 
is the contribute of the adipocytokine signaling and ABC 
transporter. Both subtypes exhibit gene expression pattern 
and chemoresistance similar to metaplastic BC [28].
Luminal androgen receptor (LAR) subtype: this 
TNBC subgroup is ER-negative and is characterized by 
high deregulation of hormone-dependent pathways. In 
particular, the androgen receptor pathway seems to play a 
pivotal role in inducing expression of specific genes of the 
LAR subtype [33-35]. 
Indeed, androgen receptor mRNA expression 
has been shown to be considerably increased (9-fold) 
with respect to the other subtypes. Furthermore, tumors 
here classified show the up-regulation of a plethora of 
downstream targets and co-activators of the androgen 
receptor signaling [36-38].
tArGEt tHErAPY IN tNbc
The major issue for targeted therapy against TNBC 
is the lack of specific oncogene drivers due to wide BC 
heterogeneity [39-41].
To date, the main approach in TNBC treatment 
remains the chemotherapy, in particular the administration 
of anthracyclines, taxanes and/or platinum compounds 
able to target dividing cells. Unfortunately, not all 
chemotherapy treated patients show a favorable outcome 
and is still unclear whether treatment choices should be 
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personalized among the different TNBC subtypes [42, 43]. 
Maybe a possible solution would be represented 
by the new proposed genetic signature tools as suggested 
by the recent MINDACT trial results, in the order 
to avoid the aggressive treatment to non-responder 
patients. MammaPrint genetic study allowed to identify 
a large group of patients which showed a good five-year 
progression-free survival (PFS) good though they have 
not received adjuvant treatment (AACR Annual Meeting 
2016).
Indeed, for pre-operative treatment pCR 
(pathological Complete Response) would represent the 
best surrogate survival end-point for TNBC patients and 
it results doubled if platinum compounds are added to 
conventional therapy compared to the worse outcome 
achieved by TNBC patients showing residual disease [44, 
45]. 
Given the aforementioned issues for management of 
TNBC patients, studies are urgently needed to improve the 
use of target therapies. The major difficulty is to discover 
actionable target because of wide heterogeneity of the 
disease. In fact, clinical trials on TNBCs that aim to point 
out a particular receptor fail to demonstrate an evident 
clinical benefit. One of the most important involved 
receptors is EGFR, that is upregulated in about 60% of 
TNBCs, whose trial investigating chemotherapy plus 
EGFR targeted agent versus chemotherapy alone showed 
a modest advantage in terms of response rate (RR) (33% 
vs 28%) [46]. Among the reasons why studies were not 
able to underline a significant clear advantage of these 
new proposed drugs, we should not take into account the 
heterogeneity of the disease that probably masks the real 
effect of the drug in a smaller population carrying the right 
target [47]. Recent studies are investigating a number of 
promising molecules and, thanks to some favourable 
hopeful results, a growing interest is developing about 
some specific signaling pathways such as PI3K/AKT/
mTOR. [48-50]. 
PI3K/AKt/mtOr signaling pathway
PI3K/AKT/mTOR (PAM) represents the main 
signaling pathway responsible for cell proliferation, 
survival, metabolism and motility regulation and is often 
activated in BC [51-54] (Figure 1). A heterodimeric 
molecule belonging to the lipid kinases, phosphoinositide 
3-kinase (PI3K), is the major component of this pathway. 
Based on structure, regulation mechanism and lipid 
substrate specificity, they can be categorized in three 
classes, but the class I PI3K is the more dysregulated in 
cancer [55]. 
PI3K signaling pathway starts following the binding 
of a growth factor or ligand to a variety of tyrosine kinase 
(TK) receptors, including HER proteins and IGF-1 
receptors [56-58]. 
In its activated form PI3K phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3) which 
represents the docking site for AKT kinase. AKT 
activation leads to protein synthesis and cell growth by 
activating mTOR through TSC1/2 [59-61].
The main PI3K counteracting protein is the PTEN 
phosphatase, which acts by converting PIP3 to PIP2 [62]. 
Therefore, PIP3 results activated by PI3K and negatively 
controlled by PTEN [63]. 
Moreover, PIP3 levels seem to be also tightly 
modulated by another tumor suppressor, inositol 
polyphosphate 4-phosphatase type II (INPP4B), which 
dephosphorylates PIP3 to PIP2 [64]. 
Many research works report a higher incidence of 
PTEN and PI3K mutations in TNBC patients with respect 
to other histological subtypes [65]. 
A downstream component of PI3K/AKT pathway 
is mTOR which exists in two functionally different 
complexes, mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). mTORC1 is responsible for the 
activation of protein translation process by promoting 
mRNA translocation and is also involved in metabolism 
and lipid synthesis [66]. mTOR downstream substrate 
is S6K1 which in turn can phosphorylate estrogen 
determining its activation with a mechanism independent 
of the ligand [67-69]. 
On the other hand, mTOR complex 2 is involved 
in the organization of actin cytoskeleton and, at the same 
time, regulates AKT phosphorylation. The importance 
of mTOR complexes and their pathways is fundamental 
in clinics due to the ability of many drugs to target 
selectively mTORC1 [70]. Indeed, studies conducted 
on TNBC murine models highlighted the effects of the 
inhibitor Dactolisib in controlling the whole mTOR 
pathway [71]. The frequency of mTOR pathway activation 
is higher in TNBC compared to other subtypes and is often 
correlated with poor prognosis [22, 72, 73]. Moreover, 
the up-regulation of PAM signaling induces resistance 
to hormone treatment, HER2-targeted treatment and 
cytotoxic therapy [74]. 
MAMMALIAN tArGEt OF rAPAMYcIN 
INHIbItOrs
Everolimus (RAD001) is a mTOR inhibitor 
exhibiting vast anticancer activity in preclinical studies 
[75]. The combined treatment of rapamycin with 
paclitaxel in cell lines altered in the PI3K/AKT/mTOR 
signaling has been shown to increase effectiveness of 
treatment in TNBC [76]. This rationale has been explored 
in different clinical experiences. In a phase II study, Meyer 
and collaborators investigated the addition of everolimus 
5 mg/day for 12 weeks to a short course pre-operative 
chemotherapy regimen containing weekly cisplatin (25 
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mg/m²) + paclitaxel (80 mg/m²) in patients affected by 
stage II / III TNBC demonstrating that no improvement 
was detected in the pCR after surgery and RR, following 
the addition of RAD001 [77]. Another phase II randomized 
study aimed to investigate the addition of everolimus to 
paclitaxel in neoadjuvant sequential regimen containing 
anthracyclines. Fifty women affected by stage II/III TNBC 
were subjected to a therapy with paclitaxel 80 mg/mq for 
12 weeks or paclitaxel 80 mg/mq + everolimus 30 mg/day 
orally for 12 weeks followed by an FEC scheme (5-FU 
500 mg/mq, epirubicin 100 mg/mq and cyclophosphamide 
500 mg/mq every 3 weeks for four cycles) [78]. The 
addition of everolimus, although well tolerated, did not 
add any significant benefit in terms of 12-week-RR (48% 
versus 30% in favour of everolimus) and pCR (30% versus 
26% in favour of everolimus) [79]. 
For the same principles, everolimus was tested 
in combination with carboplatin. In particular, Singh 
et al. enrolled 25 patients affected by metastatic TNBC 
who underwent to a 3-weekly chemotherapy regimen 
containing carboplatin AUC6 (or decreased to AUC5/4) + 
everolimus 5 mg/day. The treatment has shown significant 
hematologic toxicity especially with regimens containing 
carboplatin AUC6/5, but was well tolerated with AUC4, 
table 1: Ongoing trials studying the role of mtOr inhibitors in tNbc
trIAL rEGIstrAtION NUMbEr INVEstIGAtOr INstItUtION
Phase Ib/II Trials of RDA001 in Triple 
Negative Metastatic Breast Cancer NCT01939418 National Cancer Center, Korea
A study of Lapatinib in combination 
with Everolimus in patients with 
Advanced, Triple Negative Breast 
Cancer
NCT01272141 Emory University Winship Cancer Institute
Liposomal Doxorubicin, Bevacizumab 
and Temsirolimus (DAT) in Triple-
Negative Breast Cancer (TNBC) 
Insensitive  to Standard Neoadjuvant 
chemotherapy
NCT02456857 M.D. Anderson Cancer Center
Comparison of Single-Agent 
Carboplatin vs the Combination of 
Carboplatin and Everolimus for the 
Treatment of Advanced Triple-Negative 
Breast Cancer
NCT02531932 Icahn School of Medicine at Mount Sinai
Eribulin Mesylate and Everolimus in 
Treating Patients With Triple-Negative 
Metastatic Breast Cancer
NCT02120469 City of Hope Medical Center
NECTAR Everolimus Plus Cisplatin (-) 
Breast Cancer (NECTAR) NCT01931163 The Methodist Hospital System
Safety and Tolerability of Everolimus 
in Combination With Eribulin in Triple-
negative Breast Cancer
NCT02616848 Istituti Ospitalieri di Cremona
A Study of AZD2014 in Combination 
With Selumetinib in Patients With 
Advanced Cancer (TORCMEK)
NCT02583542 Queen Mary University of London
table 2: Ongoing trials studying the role of PI3K inhibitors in tNbc
trIAL rEGIstrAtION NUMbEr INVEstIGAtOr INstItUtION
Capecitabine +BKM120 TNBC Brain 
Mer NCT02000882 US Oncology Research
Phase I Study of the Oral PI3kinase 
Inhibitor BKM120 or BYL719 and the 
Oral PARP Inhibitor Olaparib in Patients 
With Recurrent Triple Negative Breast 
Cancer or High grade Serous Ovarian 
Cancer
NCT01623349 Dana-Farber Cancer Institute
Phosphatidylinositol 3-kinase (PI3K) 
Alpha iNhibition In Advanced Breast 
Cancer (PIKNIC)
NCT02506556 Peter MacCallum Cancer Centre, Australia
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demonstrating a clinical benefit rate > = 6 months of 28% 
with a total mOS of 16.6 months and mPFS of 3 months 
[80].
Despite TNBC is HER2- [81], RAD001 has also 
been tested in a regimen with anti-HER2 drugs since 
EGFR is overexpressed and upregulated in about 50% 
of TN tumors [82, 83], providing a strong rationale to 
investigate the association between an anti-EGFR and a 
mTOR inhibitor in order to overlap the resistance to anti-
EGFR agents [84, 85]. Although the mTOR inhibitors 
paradoxically trigger the AKT pathway [86], this 
activation could probably serve as resistance mechanism 
to mTOR inhibitors thus explaining the poor performance 
of these drugs when used as a single agent [78, 87]. On 
this basis, Liu et al. in their experience have shown that 
the addition of everolimus could sensitize BC cells to 
anti-EGFR drugs (lapatinib) [88], demonstrating that this 
association may be responsible for an increased apoptosis 
in some TNBC cell lines and murine xenograft progression 
compared to the same drugs used in monotherapy [89]. 
The main clinical studies concerning the function of 
mTOR inhibitors in TNBC and currently under evaluation 
are reported in Table 1. 
In another important work, Zhang et al. created 
a panel of seven patient-derived orthotopic xenografts 
from primary and metastatic neoplastic tissue having 
histological and immunohistochemical features matched 
between patient and their corresponding xenografts. 
Neoplasms were divided on the basis of the above 
characteristics in different TNBC subtypes and the 
authors created a response signature to mTOR inhibitors 
demonstrating that BLBC also possessed the highest 
expression rate of the genes belonging to the PI3K/AKT 
pathway and the highest extent of phosphorylation of 
4EBP1 [90]. 
Despite these promising results, it is not yet 
known the synergistic mechanism of action between the 
anti-EGFR and mTOR inhibitors and, furthermore, the 
Figure 1: PI3K/AKt/mtOr signaling pathway. The PI3K signaling pathway is triggered by activation of receptor tyrosine kinase 
(RTK) in cell membrane. After binding to the growth factors, the intracellular domain of RTK is phosphorylated, and PI3K is activated. 
Activated PI3K phosphorylates PIP2 to produce PIP3. The tumor suppressor phosphatase and tensin homolog (PTEN) could negatively 
regulate this process via dephosphorylation of PIP3. Activated PIP3 could prompt the phosphorylation of Akt and further stimulate the 
Akt- mediated activation of downstream targets, including the Bcl-2 family members, Mdm2 and tuberous sclerosis complex 2 (TSC2). 
Activated Akt inhibits the Rheb GTPase activity of TSC1/2 complex by phosphorylating TSC2. Then, activated Rheb promotes mTOR 
complex 1 (mTORC1) to phosphorylate p70S6 and 4E binding protein1 (4EBP1), resulting in dysregulation of protein synthesis and cell 
survival.
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importance of EIF4EBP1 gene is not completely clear. 
This topic was recently treated by Madden et al. that, using 
gefitinib (anti-EGFR) and temsirolimus (anti-mTOR) on 
TNBC cell lines, discovered the presence of a cross-talk 
mechanism between EGFR and mTOR also engaging the 
eukaryotic translation initiation factor 4B (eIF4B) [91]. 
Moreover, the action of these two molecules would seem 
to block phosphorylation of eIF4B, finally resulting in a 
growth and survival reduction in TNBC cell lines and then 
suggesting to investigate mTOR inhibition in association 
with other drugs [92, 93]. 
Recently, Bhola et al. [70] have suggested that 
resistance to TORC1/2 inhibitors may be exceeded via 
inhibition of the FGFR-mitochondrial metabolism-Notch1 
axis that allows to eradicate therapy-resistant cancer stem 
cells in TNBC.
PI3K/AKt INHIbItOrs
The PAM pathway may be targeted trough a 
different strategy involving the inhibition of its upstream 
targets such as PI3K and Akt [94]. While there are 
inhibitors inactivating both PI3K and mTOR, further 
development may be limited by issues, including increased 
toxicity [95]. Kalinski et al. have shown that subjecting 
patients affected by stage I/III BC (including 3 women 
TN) at different doses of MK-2206, an allosteric inhibitor 
of AKT, they experienced rash and pruritus G3, mucositis 
G2, fever G2 and hyperglycemia G2, leading to the trial 
suspension, despite two dose reductions [96]. 
A further setting in which the PI3K/AKT inhibitors 
could prove their usefulness could be in association 
to PARP inhibitors (PARPis) in TNBC patients who 
did not exhibited BRCA1/2 function loss [97]. This is 
because, as it is already known, PARPis result active in 
tumors deficient in the homologous recombination (HR) 
mechanisms due to alterations in the BRCA1/2 genes [98-
101], whereas their action is very negligible in non-BRCA 
mutant cancers [102].
Since the PI3K/AKT pathway stabilizes the function 
of HR, Ibrahim and collaborators have demonstrated 
that the use of AKT inhibitors in TNBC cell lines 
without BRCA1/2 alterations could cause HR function 
changes, and then sensitize to PARPis. In particular, 
the study showed that TNBC cancer cells treated with 
buparlisib (AKT inhibitor) were subject to a subsequent 
hyperactivation of ERK and MEK1, two essential 
component of the MAP kinase signal transduction 
pathway, resulting in downregulation of BRCA1 and then 
favoring the action of olaparib (PARPi) with subsequent 
reduction of cell proliferation and survival [103]. An 
interesting in vitro study showed that targeting multiple 
kinases such as IGF-1R, PI3K, mTORC or MEK may 
suppress cell proliferation and induce apoptosis in MDA-
MB-231 cells, increasing also the inhibition of Akt 
phosphorylation [104].
A similar experience has been carried out by 
Kimbung et al. which evaluated the association between 
Rucaparib (PARPi) and LY294002 (PI3Ki) in BRCA1-
deficient cells with the intent to improve the response to 
PARPis. This study showed promising results with sub-
micromolar doses of both drugs, providing then a strong 
rationale for further research especially in TNBC [105].
The main clinical trials concerning the function of 
PI3K inhibitors in TNBC and currently under evaluation 
are reported in Table 2. 
cONcLUsIONs
TNBC is a heterogeneous subtype of BC showing 
aggressiveness and high risk of relapse [106]. 
In the last years, the treatment of metastatic breast 
cancer has seen the development of new systemic 
treatments. Despite this progress, TNBC still has 
limited therapeutic options: cytotoxic chemotherapy 
is the standard of care; systemic treatment tipically has 
transitory efficacy and the response is early followed by 
disease progression.
TNBC patients exhibit, indeed, an unfavorable 
outcome compared to those with other subtypes.
Only recently driver mutations have been identified 
with encouraging results in preclinical models and have 
allowed to investigate new specific drugs for each different 
subtype of the disease.
The PI3K-AKT-mTOR pathway is an exciting target 
for developing new anticancer therapeutics [107]. Since 
several pathways may be involved, therefore, the best 
results are achieved by combining different molecules 
on various targets paying attention to toxicity. For these 
reasons, it will be necessary in the near future to rescue 
pathological tissue taken before and after therapy in order 
to better understand the mechanisms of drug resistance and 
new concepts on tumor pathogenesis. Using increasingly 
refined techniques, liquid biopsies could have an important 
role, allowing us to obtain a lot of information in a short 
time and in a minimally invasive manner and maintaining 
a high concordance rate with the primary tumor and/
or metastases. Therefore, is desirable enrolling TNBC 
patients with different subtypes in new specific trials to 
ensure them the most suitable treatment.
One of the main difficulties in the field of targeted 
therapies is represented by the extreme heterogeneity of 
the disease. This condition produces a number of different 
cases, each constituted by the presence of a rare mutation 
mostly detected in cases of exceptional responders in the 
context of negative trials. Consequently, although the 
discovery of these rare mutations is leading to the approval 
of many new antitumor therapies, it is necessary to design 
new studies showing benefits, avoiding all the problems 
related to the extreme heterogeneity of the disease 
contained in other conventional trials. A possible solution 
could be derived from the use of the so called basket 
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trials that find their maximum indication where neoplasia 
depends on the pathway of the target and whether the 
therapy can effectively inhibit the action of the target 
itself. This would make possible to consider a marker as a 
probable predictor regardless of tumor histology.
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Abstract Dietary restrictions, including fasting (or long-term
starvation), calorie restriction (CR), and short-term starvation
(STS), are considered a strong rationale that may protect against
various diseases, including age-related diseases and cancer.
Among dietary approaches, STS, in which food is not con-
sumed during designed fasting periods but is typically not re-
stricted during designated feeding periods, seems to be more
suitable, because other dietary regimens involving prolonged
fasting periods could worsen the health conditions of cancer
patients, being they already naturally prone to weight loss.
Until now, the limited amount of available data does not point
to a single gene, pathway, or molecular mechanism underlying
the benefits to the different dietary approaches. It is well known
that the healthy effect is mediated in part by the reduction of
nutrient-related pathways. The calorie restriction and starvation
(long- and short-term) also suppress the inflammatory response
reducing the expression, for example, of IL-10 and TNF-α,
mitigating pro-inflammatory gene expression and increasing
anti-inflammatory gene expression. The dietary restriction
may regulate both genes involved in cellular proliferation and
factors associated to apoptosis in normal and cancer cells.
Finally, dietary restriction is an important tool that may influ-
ence the response to chemotherapy in preclinical models.
However, further data are needed to correlate dietary ap-
proaches with chemotherapeutic treatments in human models.
The aim of this review is to discuss the effects of various dietary
approaches on the cancer progression and therapy response,
mainly in preclinical models, describing some signaling path-
ways involved in these processes.
Keywords Cancer cells . Cellular stress response .
Chemotherapy . Diet . Fasting . Short-term starvation
Introduction
BLet food be thy medicine and medicine be thy food.^ This
sentence of Hippocrates explains excellently the importance
that feeding assumes in the establishment of a healthy life. In
particular, various dietary approaches, such as calorie restric-
tion and long- and short-term starvations, seem to be involved
in the protection from aging and age-related diseases.
Fasting (or long-term starvation) is commonly defined as a
prolonged deprivation of nutrients from a system that can be
represented by cells in culture (normal or immortalized) or by
multicellular organisms (from fruit flies to humans). In vitro
serum deprivation, for example, is often considered as a rou-
tine procedure to reduce basal cellular activity [1] and to make
the population homogeneous of proliferating cells that, in this
condition, can enter in the quiescent G0/G1 phase [2]. Its utility
includes the metabolic research in which the establishment of
serum starvation-based protocols submits the physiological
response to a hormonal change [3]. Moreover, other re-
searchers have used serum starvation as a system to analyze
molecular mechanisms involved in cellular stress response
[4], apoptosis, and autophagy [5, 6]. That is why serum star-
vation has also been referred to as Benvironmental stress^ [7]
and Bapoptotic trigger^ [8]. Recently, starvation is assuming a
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part of protagonist. In particular, it has been spreading the idea
that fasting cycles can prevent the onset of age-related dis-
eases [9] and to improve the response to certain therapies like
the oncological ones [10].
Like fasting, the reduction in calorie intake or calorie restric-
tion (CR), without malnutrition, has been indicated as a strong
non-genetic intervention that, simultaneously, can protect
against various diseases, like diabetes and cancer, and that can
increase the life-span in mammalians [11]. CR can consist of
feeding once daily or thrice weekly over a range of restricted
food amounts [12]. Also, it seems to cause a large number of
benefits by reducing cardiovascular risk factors [13], improving
insulin sensitivity [14], enhancing mitochondrial function (also
inducing the generation of new mitochondria) [15], increasing
cellular quality control through autophagy [16, 17], and reduc-
ing oxidative damage in both DNA and RNA [18].
The above considerations demonstrate that fasting or CR
could be applied to protect patients from toxic side effects of
chemotherapy. However, in vivo preclinical studies showed
that several months may be necessary for people under CR to
reach a protected state and, accordingly, these two types of
approaches are not feasible for patients already prone to
weight loss because of cancer itself or chemotherapy [19].
In this regard, another dietary approach that could generate
similar biological changes, such as fasting and calorie restric-
tion, seems to be more suitable. Short-term starvation (STS or
intermittent fasting) is considered as a limited exposure to
several nutrients, in which food is not consumed during de-
signed fasting periods but is typically not restricted during
designated feeding periods [11]. Other authors indicated it as
the period of time in which animals lose weight after initiation
of food restriction but prior to rebound or weight maintenance
[20]. Accumulating evidence suggests that STS can produce,
like CR, similar beneficial biological effects, including mod-
ulation of reactive oxygen species (ROS) and inflammatory
cytokines, and also antimutagenic, antibacterial, and anticar-
cinogenic effects [21, 22]. Moreover, it has been shown that
STS may be advantageous even after certain injuries. For ex-
ample, in rats, a day of fasting can promote recovery following
moderate but not severe damage in a controlled cortical im-
pact injury model [23].
This manuscript proposes to review literature data for a
better understanding of the correlation between the effects of
the dietary restriction and response to anticancer treatment.
Dietary restriction-induced molecular changes
Until now, the restricted available data do not point to a
single gene, pathway, or molecular mechanism underly-
ing the benefits of the different dietary approaches. It is
well known that the salutary effect is mediated in part
by the negative regulation of nutrient-signaling
pathways, including, in part icular, the growth-
promoting insulin-like growth factor 1 (IGF-1) receptor
and its downstream effectors, such as extracellular
signal-regulated kinase (ERK), c-Jun N-terminal kinase
(JNK), p38 mitogen-activated protein kinase (MAPK),
and phosphoinositide 3-kinase (PI3K), which are known
to regulate several detoxification enzymes [24] (Fig. 1).
The IGF-1 pathway influences both animal life-span and
oxidative stress sensitivity. IGF-1 receptor-deficient mice
showed a great resistance to oxidative stress [25]. The
Forkhead box protein O1 (FOXO1), a downstream target of
IGF-1/AKT signaling, is able to enter the nucleus, in the ab-
sence or reduction of IGF-1/AKT signaling, and to modulate
genes involved in oxidative stress resistance, metabolism, and
longevity [26–28].
Circulating IGF-1, in collaborations with other hormones
and growth factors, plays an important function in the regula-
tion of cell differentiation and proliferation and body size and
also exerts a tumorigenic effect on a variety of tumors by
promoting proliferation and inhibiting apoptosis [29, 30].
Consistent with the effect of calorie restriction and starva-
tion (short- and long-term) in reducing growth factor signal-
ing, fibroblasts isolated from mice deficient in the GH/IGF-1
pathway are resistant to oxidative stress, UV, heat, and
genotoxins [31]. On the other hand, exposure of murine hepa-
tocytes to IGF-1 reduces the levels of superoxide dismutases
and catalase activity [32].
Moreover, it has been shown that a fasting period of 24 h
does not alter the hepatic expression of many ABC family
members but induces the expression of Abca1 (involved in
cholesterol transport) and Abcg8 (involved in sterol transport)
[33].
Dietary restrictions (DRs) also suppress the inflammatory
response. Restricted rats have exhibited reduced mRNA ex-
pression levels of inflammatory cytokines and chemokines
(IL-1β, TNF-α, and MCP-1) in various tissues such as the
liver, kidney, and spleen [34]. Coherently, 4 weeks of DR
decrease signs of illness (fever, cachexia, etc.), mitigating
pro-inflammatory gene expression (for example, COX-2 and
leptin) and increasing anti-inflammatory gene expression
(e.g., SOCS3 and IL-10) [20].
Some researchers have submitted to serum starvation
primary human myotubes, rat L6 myotubes, and human
embryonic kidney cells for 24 h and assessed phosphor-
ylation changes in the energy-sensing AMP-activated
protein kinase (AMPK) and its downstream targets, in-
cluding acetyl-CoA carboxylase (ACC), ERK1/2, and
mammalian target of rapamycin (mTOR) pathway.
Additionally, the phosphorylation of AMPK, ACC, and
ERK1/2 reacted to serum starvation dynamically in a
time-dependent way. Changes induced in the mTOR
pathway after serum starvation can be associated with
growth factor deprivation [3].
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Different dietary approaches may regulate genes in-
volved in cellular proliferation, such as the insulin sig-
naling adaptor (Irs2) and mitogenic hormone prolactin
receptor (Prlr), in both normal and cancer cells [19]. It
has been demonstrated that the PI3K pathway is impor-
tant in determining the sensitivity of tumors to dietary
restrictions. In particular, mutations that make PI3K
constitutively active affect the response of cancer cells
to dietary restrictions [35]. Instead, studies showed that
STS had a greater effect in reducing glucose compared
to calorie restriction diets, even when the CR caused an
equivalent weight loss. This can be explained by the
fact that STS and calorie restriction diets have distinct
physiological responses. For example, short-term fasting
induced a 70 % decrease in blood glucose that occurred
within 60 h, while a 90 % CR diets caused only a
40 % glucose reduction after 96 h [21, 36].
Previous findings have clarified that serum starvation acti-
vates in cancer cells the ATM/Chk2/p53 pathway that sensi-
tizes them to chemotherapy with cisplatin, probably due to a
temporary loss of the coordination between cell proliferation
driven by oncogenic mutations and the growth stimulated by
growth factors [37].
Dong et al. [38] demonstrated, through in vitro studies
using A549 non-small cell lung cancer cell lines, that serum
starvation increases E-cadherin expression. E-cadherin is in-
volved in the pathobiology of several types of cancer: the loss
or dysfunction of E-cadherin is associated with increased lung
cancer cell proliferation and invasiveness [39].
Braun et al. [40] observed that starvation induces the in-
crease of p21 levels in MCF7 cell lines independently from
p53 and this mitigates the efficacy of the Puma/Bax-
dependent apoptotic signal (also induced by starvation). In
addition, the anti-apoptotic function exerted by p21 in starved
cells occurs upstream of mitochondrial permeabilization at the
level of the Puma interactions with Bcl-x. Therefore, p21 pro-
tects cells against starvation-induced apoptosis. Furthermore,
an important step for cellular apoptosis is the phosphorylation
of H2AX (a variant of the histone H2A family) that is medi-
ated byMAPK family proteins, such as JNK and p38. Several
data showed that serum starvation induces strongly the phos-
phorylation of p38 and H2AX at Ser139 in a time-dependent
Cell protection
Fig. 1 Insulin-like growth factor-1 (IGF-1) signaling pathway. IGF-1
insulin-like growth factor-1; IGF-1R insulin-like growth factor-1
receptor; SHC Src homology 2 domain-containing adaptor protein B;
SOS Son of Sevenless; GRB2 growth factor receptor-binding protein 2;
RAS rat sarcoma viral oncogene homolog; RAF RAF-1 proto-oncogene,
serine/threonine kinase; MEK1/2 mitogen-activated protein kinases 1/2;
ERK1/2 extracellular signal-regulated protein kinases 1/2; IRS1 insulin
receptor substrate 1; IRS2 insulin receptor substrate 2; p85
phosphatidylinositol 3-kinase 85-kDa regulatory subunit alpha; P110
PI3K phosphatidylinositol 3-kinase, catalytic, 110-kDa, alpha; PIP2
phosphatidylinositol 4,5-bisphosphate; PIP3 phosphatidylinositol 3,4,5-
trisphosphate; PTEN phosphatase and tensin homolog; PDK1 pyruvate
dehydrogenase kinase, isozyme 1; AKT V-Akt murine thymoma viral
oncogene homolog 1; BCL-2 B cell CLL/lymphoma 2; BAD BCL2-
associated agonist of cell death; FOXO1 Forkhead box O1; FOXO3a
Forkhead box 3a; TSC1 tuberous sclerosis 1; TSC2 tuberous sclerosis 2;
mTOR mammalian target of rapamycin (serine/threonine kinase); AMPK
AMP-activated protein kinase; SRC SRC proto-oncogene, non-receptor
tyrosine kinase; RAC Ras-related C3 botulinum toxin substrate; JNK c-
Jun N-terminal kinase
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manner. These results indicate that H2AX phosphorylation is
regulated by p38 during serum starvation. In addition, serum
starvation increased the level of activated caspase-3, resulting
in apoptosis stimulation [41].
Nutrient starvation puts cells in alarm and induces them to
autophagy, a conserved self-eating process in which intracel-
lular membrane engulf a part of cytoplasmic organelles for
lysosomal degradation. Autophagy is a way by which cells
under starvation condition transfer nutrients from unnecessary
to essential processes [42]. The stimulation of autophagy by
starvation needs the activation of poly(ADP-ribose) polymer-
ase (PARP)-1, a nuclear enzyme switched on by DNA dam-
age. During starvation, ROS that could induce the activation
of PARP-1 are produced [43]. PARP-1 seems to be involved
in the hydrolysis of ADP ribose: its lack, in fact, does not
reduce ATP levels as much as when it is present [44]. As
result, the permanence of AMPK in an inactive state and the
consequent absence of the signal for mTOR inactivation were
detected, leading to impaired autophagy. An interesting in
vivo study suggested that PARP-1 regulates autophagy and
makes available a link between the PARP-1 function and over-
all cellular response to nutrient starvation. Then, starvation,
ROS production, and DNA damage cause PARP-1 activation
that is required for starvation-induced autophagy [43]. It is
well known that ROS-induced DNA damage consists of dif-
ferent lesions, including single-strand breaks (SSBs), double-
strand breaks (DSBs), and oxidized DNA nucleotides, the
most common of which is 8-oxo-7,8-dihydroguanine (8-
oxoG). The latter type of damage requires the intervention
of the base excision repair (BER) system, involving the repair
enzyme 8-oxoguanine DNA glycosylase (OGG1). It has been
observed that nutrient availability affects BER causing the
loss of OGG1 both in vitro and in vivo. In particular, the
induction of autophagy showed no consequence on OGG1
expression without starvation [45].
Dietary restriction and cancer
Tumor cells are exposed to numerous cellular stresses, such as
oncogene-induced genotoxic [46], oxidative [47], and meta-
bolic [48] stresses to which normal cells are not subjected.
That is why tumor cells are more dependent on stress by
supporting pathways for survival than normal cells.
Malignant cells undergo a series of genetic and epi-
genetic alterations that allow them to be both self-
sufficient for growth and non-sensitive to anti-growth
stimulation. Cancer cells express oncogenes that can
continue to relay the effect of growth factor, while
healthy cells are unable to grow in the absence of stim-
ulation. This independence could be explained by the
autocrine production of growth factors or by mutations
that make constitutively active intracellular signal
transduction proteins or membrane receptors. For exam-
ple, factors overproduced by cancer cells are platelet-
derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), and IGF-1 [49]. Probably, the
most important contribution regards alterations in genes
coding for components of the Ras/Raf/MAPK and
PTEN/PI3K/AKT pathways. In fact, mutated Ras alleles
can render the cell proliferation independent from extra-
cellular signals found in approximately a quarter of all
cancers [50] and, in particular, in half of colon cancers
[51].
In vitro serum starvation and in vivo short-term star-
vation reduce the levels of growth factors in normal
cells [52, 53]. Furthermore, in the same cells, the de-
pletion of paracrine communication signal of growth
factors reduces the activity of proliferation signaling
pathways and also the basal cellular metabolism.
Consequently, cells enter in a proliferative/quiescent sta-
tus [3]. Unlike healthy cells, it has been suggested that
cancer cells cannot rapidly adapt to fasting and thus
STS determines a differential stress resistance. Malignant
cells, in fact, struggle to adapt to the loss of external growth
factors by regulating autonomous growth stimulation and
reprogramming their metabolism, thereby maintaining contin-
uous proliferation [49]. This fundamental difference between
healthy and unhealthy cells may explain why starvation con-
dition protects normal cells without interfering with the killing
of malignant cells [21, 54] (Fig. 2).
In vitro and in vivo studies demonstrated that fasting
alone can modulate cell proliferation and apoptosis in
different types of tumors by determining an increased
cytotoxicity when combined with chemotherapy, the
main treatment for tumor injuries. Several chemotherapy
drugs harm DNA and cause cell death in part by pro-
moting oxidative damage that involves not only tumor
cells but also normal tissues (especially with high-dose
chemotherapy) [55]. This increase in ROS may act syn-
ergically with fasting and chemotherapy [19]. It seems
that the different types of dietary restriction selectively
protect normal cells from chemotherapy toxicity, sensi-
tizing simultaneously tumors to therapy, and STS is
much more effective than calorie restriction or long-
term fasting [21].
STS is able to sensitize various cancer types to chemo-
therapeutic agents. Some authors, in fact, showed that
growth factors and glucose restriction slowed proliferation
and increased cell death in 3 different murine cancer cell
lines, while 24 h of fasting before and after drug treatment
sensitized 15 of 17 cancer cell lines. They also evaluated
the effect of fasting in a model of human metastatic can-
cer by applying five cycles of fasting for 48 h in immu-
nosuppressed nude mice xenografted subcutaneously with
human neuroblastoma cells and comparing the results with
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normally fed mice. After 34 days, fasting cycles and cy-
clophosphamide treatment reduced tumor size to less than
a half of the one achieved in the treatment with cyclo-
phosphamide or fasting alone [19].
STS followed by chemotherapy is not only safe and
feasible but also helps to attenuate the side effects re-
lated to chemotherapeutic drugs. Some studies have
shown that STS induces cardioprotective effects against
the injury caused by doxorubicin [56]. Moreover,
Raffaghello et al. [54] studied the effects of high-dose
etoposide, a chemotherapeutic drug with a non-specific
toxicity profile, in murine models undergone to fasting
for 48–60 h, before the administration of a high-dose
drug, and in a control group fed ad libitum. The latter
group, after the treatment, showed many of the signs
associated with the toxicity of etoposide, including the
reduced mobility and the ruffled and posture alterations,
while mice submitted to fasting showed no obvious
signs of stress or pain. The beneficial effect of fasting
was confirmed by comparing the mortality rate of mice
in the two groups (43 % of the animals in the control
group), and only one case in the fasting group died
from acute toxicity by etoposide. A second group of
mice was starved for 60 h and then treated with a dose
of etoposide four or five times higher than the maxi-
mum dose recommended for humans. While non-starved
mice died or showed toxicity, starved mice only lost the
40 % of their weight, which was regained after 1 week
of re-feeding.
There is also an evidence of the benefits of the STS
before chemotherapy in humans. Ten volunteers affected
by different types of tumors were starved for 48–140 h
before chemotherapy and 56 h after the treatment. All
patients showed decreased chemotherapy-induced side
effects [54]. A period of fasting after chemotherapy
treatment could be relevant, because the combination
of re-feeding and drug-induced DNA damage can in-
crease the growth of aberrant foci in the liver, colon,
and rectum. This can be explained by the hypothesis
that prolonged fasting induces cell death and atrophy
in the organs and thus cell proliferation stimulated by
re-feeding can lead to a DNA damage, if high levels of
toxins are present [57, 58].
Effects of dietary restrictions on the main tumors
During disease, the interactions between tumor and stroma
cells are modified, producing a microenvironment that favors
the primary tumor growth (remodeling, invasion, and angio-
genesis) and its spreading (metastasis). Tumor microenviron-
ment is heterogeneous and, in addition to the tumor cells,
includes macrophages, fibroblasts, adipocytes, and endotheli-
al cells that appear different from those of normal tissues [59].
Among these, adipocytes suffer the influence of dietary re-
strictions and physical exercise. This condition implies that
dietary restrictions could be an effective method to favorably
change the tumor microenvironment and its activities [60].
Adipocytes localized near the tumor mass are called
Bcancer-associated adipocytes^ and show a reduction of adi-
pose markers, such as HSL, APN, and resistin, and an in-
creased expression of inflammatory cytokines (e.g., IL-6 and
IL-1β) [61]. Adipocytes play an important role in cancer pro-
gression and may contribute to carcinogenesis and tumor in-
vasiveness, since they are a source of pro-inflammatory cyto-
kines, such as IL-6 and TNF-α, ROS, and matrix
metalloproteases [62–65]. Moreover, adipocytes are able to
secrete adipokines that increase angiogenesis, fibrosis, and
inflammation by recruiting macrophages and endothelial cells
inside the cancer microenvironment in a way mediated by NF-
KB [66]. Dietary restriction can modulate the function of the
tumor microenvironment by altering the size of adipocytes
[63] and, consequently, reducing adipokine secretion, such
as IL-6 [67]. Furthermore, dietary approaches are often asso-
ciated with an increased life-span in mammalian and a better
response to chemotherapy in various types of cancer. It is well
known, in fact, that the bioavailability of several anticancer
oral drugs changes because of food exposure. Chemotherapy
Chemotherapy
Tumor cells
Drug-induced
cytotoxic effects
Dietary
Restriction
Healthy cells
Fig. 2 Effects of dietary
restrictions on effectiveness of
chemotherapy in cancer cells
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drugs are not the only cytotoxic strategy used for the treatment
of cancer. Evidences suggest that caloric restriction might also
be associated with radiation therapy (RT). Champ et al. [68]
reported that CR can modulate pathways involved in resis-
tance to treatment (such as IGF-1) and make cancer cells more
sensible to cytotoxicity induced by radiotherapy.
The standard chemotherapy can enhance cellular metabo-
lism by creating a tumor microenvironment rich in glucose
and glutamine. Recently, as an alternative to standard treat-
ment, metabolic therapies aimed to target metabolic alter-
ations present in all tumor cells and which give a benefit to
normal cells have been developed. For example, among the
metabolic therapies that improved the prognosis of patients
with glioblastoma multiforme and brain cancer, there is the
calorie-restricted ketogenic diet (KD-R), which shows anti-
angiogenic, anti-inflammatory, and anti-apoptotic effects [69].
Belowwe discuss some data in the literature concerning the
effects of dietary restrictions on the main tumors.
Breast cancer
Breast cancer is the most common cancer and represents the
first cause of the cancer death in women worldwide [70]. A
case report has shown the effect of a fasting period on
Caucasian women affected by breast cancer. The first case
was that of a 51-year-old woman (stage IIA) who has received
adjuvant chemotherapy (docetaxel and cyclophosphamide)
and has been subjected to fasting 140 h before and 40 h after
treatment. During fasting-chemotherapy cycle, the patient
showed no side effects in contrast to when she has undergone
chemotherapy alone. Even the complete blood count (CBC)
appeared best if the treatment was preceded by a period of
fasting. Another case was that of a 53-year-old woman (stage
IIA, HER2+) who has been exposed to four chemotherapy
cycles (with docetaxel and cyclophosphamide) and fasting
for 64 h before and 24 h post chemotherapy. Negligible side
effects were observed, including only mild weakness and
short-term memory impairment. The third case was represent-
ed by a 48-year-old woman treated with four cycles of doxo-
rubicin and cyclophosphamide followed by paclitaxel and
trastuzumab. During treatment, the patient was subjected to
fasting for 60 h prior and 5 h post drug administration, show-
ing no side effects associated with these drugs. The last report-
ed case was that of a 78-year-old woman (HER2+) submitted
to mastectomy and to six cycles of chemotherapy with
carboplatin, docetaxel, and trastuzumab. The patient adopted
fasting periods of variable lengths during therapy and, despite
this, has not been reported severe side effects [71]. Therefore,
it becomes apparent that a short period of fasting in associa-
tion with chemotherapy treatment improved patient’s tolera-
bility, reducing side effects even if underlying molecular
mechanisms are unclear. Factors related to the DNA repair
systems or apoptosis may be involved [72]. One of these is
REV1, a DNA polymerase involved in DNA repair, whose
role is to control cell metabolic fate. In a recent work, REV1
was indicated as a binding partner of p53 and, consequently,
as a regulator of its activity. Under fasting conditions,
SUMO2/3 (small ubiquitin-like modifier) induces changes in
REV1 by increasing the apoptotic effects of p53 on breast
cancer cells. The regulation of REV1 could be used as a
non-toxic strategy to increase p53-mediated cell death and
thus to improve the effectiveness of treatment [73].
Ovarian cancer
Ovarian cancer is the third most common gynecological can-
cer worldwide [74]. In vitro studies suggested that serum star-
vation reduces cell proliferation by inducing G1 arrest in hu-
man ovarian cancer cells (SK-OV-3), through the suppression
of Skp2-dependent CDK2 activity and Skp2-independent
CDK4 activity. Skp2 is an ubiquitin ligase that positively reg-
ulates cell cycle by inducing degradation of p27, resulting in
CDK2-induced progression from G1 to S phase [75].
A clinical study reported the case of a 44-year-old
Caucasian woman affected by ovarian cancer who, after a
series of drug resistances, has been treated with antineoplastic
drugs in combination with a fasting period of 62 h prior and
24 h after treatment. STS has been shown to improve the CBC
[71].
Colorectal cancer
Colorectal cancer (CRC) is the third most common can-
cer in men and the second in women worldwide [74].
Among the initial modifications causing the CRC onset,
there is the suppression of the serotonergic system that
seems to be related to a high-fat diet [76]. Moreover,
this type of diet enhances the formation of preneoplastic
lesions and consequently promotes CRC tumorigenesis
[77]. However, it has been shown that, during the ad-
vanced stages, the disease can induce a reduction of
serum total cholesterol levels [78]. Kaska et al. [79]
had evaluated the effects of a preoperative fasting peri-
od in CRC patients, observing no clinical benefit.
Conversely, intake of nutrients seems to be a protective
factor against surgical trauma. However, results about
the beneficial effects of dietary restrictions are conflict-
ing. Indeed, some authors reported that nutritional defi-
ciencies promote tumorigenesis because the lack of cer-
tain nutrients increases chemically induced carcinogene-
sis in preclinical models [80]. Furthermore, another
study evaluated the combined influence of a carcinogen
(1,2-dimethylhydrazine or DMH) and food deprivation
regimen in murine models. Food deprivation has been
shown to induce an increase of the lipid peroxidation
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processes in liver and colon tissues, suppressing the
serotonergic system in the colon [81].
Lung cancer
Lung cancer represents the most common cause of cancer
death worldwide [82]. The therapy of choice for patients with
locally advanced or metastatic non-small cell lung cancer
(with or without epidermal growth factor receptor (EGFR)
mutation) involves the use of erlotinib (an EGFR tyrosine
kinase inhibitor). Currently, its recommended dose is
150 mg daily, either 1 h before or 2 h after a meal. Katsuya
and colleagues [83] observed that these two types of fasting
determine a different drug absorption, resulting in increased
therapeutic effectiveness when drug administration occurs 2 h
after meal. Also, the authors found no major differences in
terms of toxicity or bioavailability between the two conditions
[83]. An interesting clinic case is represented by a 61-year-old
Caucasian woman with poorly differentiated non-small cell
lung cancer. During chemotherapy cycles, the patient experi-
enced numerous side effects that have been attenuated after
the implementation of fasting 48 h before and 24 h after che-
motherapy [71].
Prostate cancer
Prostate cancer is the second most common cancer in
men and the fifth leading cause of cancer death [74]. A
high-fat diet and a sedentary lifestyle can be considered
risk factors for the onset of prostate cancer by changing
the amount of hormones and growth factors in the se-
rum. An interesting study has recruited men with pros-
tate cancer randomly divided into two groups: one
group fed with a low-fat diet and the other without
restrictions. After 4 weeks, the serum was collected
from the patients and cultured with LNCaP prostate
cancer cells. The serum of both groups was not differ-
ent in terms of serum prostate-specific antigen (PSA),
sex hormones, insulin, IGF-1 and IGF-2, and insulin-
like growth factor-binding proteins, but serum triglycer-
ide and linoleic acid (omega-6) levels were decreased in
the low-fat diet group (in which omega-3 levels were
increased). It was observed that LNCaP cells in contact
with the serum of patients with low-fat diet grew very
slowly. Thus, a reduction in serum fatty acid levels may
induce a decrease in human LNCaP cell growth [84]. A
case report described the effect of a fasting period on
the response to an antineoplastic treatment in two
Caucasian men affected by prostate cancer. The first
case was that of a 74-year-old man with stage II pros-
tate adenocarcinoma and submitted to prostatectomy.
After therapy failure and severe side effects, the patient
was submitted to 60 h of fasting prior and 24 h post
chemotherapy. As result, a reduction of side effects and
PSA levels was observed compared to previous cycles
without STS. Similar results were obtained in a 66-year-
old man with prostate adenocarcinoma subjected to
fasting for 60–66 h prior and 8–24 h after chemothera-
py [71].
The beneficial effect of STS may be also observed
when the natural compound Guttiferone F (a prenylated
benzophenone derivative) is used. Guttiferone has been
shown to inhibit cell proliferation in prostate cancer cell
lines (LNCaP and PC3) submitted to serum starvation.
In this case, the compound leads to DNA fragmentation;
causes the entry of cells in the G1 phase; stimulates
mitochondria-dependent apoptosis, by regulating the
Bcl-2 family proteins; attenuates the androgen receptor
expression and ERK1/2 phosphorylation; but activates
JNK and calcium ion flow. The authors hypothesized
that the combination of dietary approaches and
Guttiferone F could increase the antitumor effect with-
out causing cytotoxicity in vivo [85].
In vivo studies investigated the effects of intermittent cal-
orie restriction (ICR) on mice xenografted with prostate can-
cer cells or transgenic adenocarcinoma mouse prostate
(TRAMP) models. Bonorden et al. [86] observed that ICR
(with a CR of 50 % lower than the classic feed) delays the
onset of cancer in TRAMPmice. If future studies will confirm
this data, STS could become an interesting strategy for pros-
tate cancer treatment.
Conclusions
Since dietary approaches represent an easy tool in delaying
aging, healing from damages, and preventing the onset of age-
related diseases, they may become efficient allies for
cooperating in the treatment of tumors, even though STS
seems to be more tolerated by sick patients. It is essential to
understand each change or hidden feature induced by the pro-
cesses described above to reap the benefits related to fasting.
The currently available data have associated the various
dietary approaches to numerous biological processes (from
cellular proliferation and vitality to inflammatory response)
and to the response to the chemotherapy. Recent studies have
reported that dietary restriction induces molecular changes in
genes, including IGF-1 and its receptor, as well as down-
stream effectors. The modification regards also inflammatory
cytokines and chemokines, such as IL-1β and TNF-α, and
elements associated to apoptosis (Bax/Bcl-x). However, addi-
tional insights are needed. Moreover, it might be interesting to
get more results in humans in order to ascertain the effect of
fasting and create standard protocols that are able to correlate
dietary approaches with chemotherapeutic treatments.
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Abstract Breast cancer is the most frequent carcinoma and
second most common cause of cancer-related mortality in
postmenopausal women. The acquisition of somatic muta-
tions represents the main mechanism through which cancer
cells overcome physiological cellular signaling pathways
(e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis
and metastasis monitoring is mainly carried out through tissue
biopsy and/or re-biopsy, a very invasive procedure limited
only to certain locations and not always feasible in clinical
practice. In order to improve disease monitoring over time
and to avoid painful procedure such as tissue biopsy, liquid
biopsy may represent a new precious tool. Indeed, it repre-
sents a basin of Bnew generation^ biomarkers that are spread
into the bloodstream from both primary and metastatic sites.
Moreover, elevated concentrations of circulating tumor DNA
(ctDNA) as well as circulating tumor cells (CTCs) have been
found in blood plasma of patients with various tumor types.
Nowadays, several new approaches have been introduced for
the detection and characterization of CTCs and ctDNA,
allowing a real-time monitoring of tumor evolution. This re-
view is focused on the clinical relevance of liquid biopsy in
breast cancer and will provide an update concerning CTCs
and ctDNA utility as a tool for breast cancer patient monitor-
ing during the course of disease.
Keywords Liquid biopsy . Breast cancer . Circulating tumor
cells . CTCs . Circulating tumor DNA . ctDNA
Introduction
Breast cancer is the most common carcinoma and one of the
leading causes of cancer-related deaths in women aged be-
tween 35 and 75 years [1, 2]. Although breast cancer seems
to be most often sporadic, about 5–10 % of new cases are
hereditary. Indeed, about half of these would be associated
with germline mutations occurring on codifying DNA se-
quences which determine a high risk of developing the disease
during life and for this reason called Bsusceptibility genes^ [3,
4].
The two major identified susceptibility genes are the tumor
suppressor genes BRCA1 and BRCA2 involved in DNA dou-
ble strand break repair trough the homologous recombination
(HR) pathway. Germline mutations in these genes cause ge-
netic instability that enhance the development of additional
mutations in other pivotal genes involved in cell cycle control
and many others cellular processes [4–7]. Gene expression
profiling studies, performed bymicroarray analysis, highlight-
ed the molecular heterogeneity of breast cancers, allowing the
identification of different molecular subgroups with similar
characteristics. Thus, based on the gene expression profiles,
they were classified into four distinct subtypes: luminal A,
luminal B, human epithelial growth factor receptor 2
(HER2) overexpressing, and basal-like [8]. Furthermore, im-
munohistochemical characterization of the aforementioned
subtypes on the basis of ER, PR, and HER2 expression is
shown in Table 1. Current ESMO guidelines on primary
breast cancer management consider this classification and im-
plement it with Ki-67 levels. The cutoff to distinguish high
from low levels of ki-67 is by 30 % [9]. Histologically, breast
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cancer can be divided into in situ and invasive carcinoma, both
of which can be further subclassified into ductal and lobular
carcinomas [10]. Triple negative breast cancer (TNBC) repre-
sents 15–20 % of all breast cancers. This unfavorable cancer
histotype lacks in the expression of estrogen, progesterone,
and human epidermal growth factor receptor-2 receptors.
Moreover, it usually presents at young age (age <50 years),
advanced stage at first diagnosis, unfavorable outcome, grade
3, high proliferative index, and higher risk of metastases [11,
12].
Even though breast cancer represents the second leading
cause of cancer-related death among women, a significant
proportion of patients can be treated by surgery only or sur-
gery and adjuvant systemic therapies. Despite the improve-
ments in disease management, mortality is still high due to
the emergence of distant metastasis. With the introduction of
new approaches, as well as next-generation sequencing
(NGS), it starts to be clear that clonal evolution occurs, among
a cell population, within the primary tumor and it is mainly
due to intra-tumor heterogeneity [13]. Furthermore, anticancer
therapies may also cause a selective acquisition of new genetic
alterations.
Another relevant drawback in luminal breast cancer is that
the metastatic event can appear years after first diagnosis. This
might be referred as Btumor dormancy,^ it means that cancer
cells may colonize earlier distant sites but stay dormant until
they do not accumulate enough genetic and/or epigenetic
modifications that allow their awakening from Bdormancy^
[14]. Two different possible scenarios can be forecasted for
explaining the metastatic event. According to the first scenar-
io, tumor cells leave the primary site to colonize distant organs
only if they acquire a totally competence to generate a meta-
static development. In the second case, Balmost normal epi-
thelial cells^ leave preneoplastic lesions earlier and evolve
simultaneously with the primary tumor cell population [15].
Currently in the clinical practice, it is very difficult to find a
reliable tool to follow tumor evolution over time, and this lack
is probably the main reason of treatment failure whether ad-
ministered at wrong time points during the course of disease.
Liquid biopsy may represent the solution to the aforemen-
tioned problems. Recent findings demonstrate that circulating
tumor cells (CTCs) and circulating tumor DNA (ctDNA) are
detectable in blood samples even at early stage disease.
Moreover, technological improvements in CTCs and ctDNA
isolation, detection, and analysis are paving the way for their
introduction in the current clinical practice. Moreover, new
insight into the nature and severity of breast cancers could
arise from small extracellular vesicles. Among the extracellu-
lar bodies, the interest of the scientific community in
exosomes biology is daily growing. Indeed, exosomes are
small vesicles (diameter 40–100 nm) involved in mediating
a cross-talk between the extracellular matrix and the cell act-
ing as a shuttle of many compounds as nucleic acids and
proteins [16, 17]. Indeed, these could represent a new intrigu-
ing diagnostic marker because of their possible involvement
in a multitude of cellular processes as well as the event of
tumor growth, metastasis, and not less notable, drug resistance
as effect of anticancer drugs removal from the breast cancer
cells [17, 18].
Few data have been available yet about the assessment
of serum microRNAs in breast cancer as it has been car-
ried out in other malignancies. The development of
microRNA panels in serum would add relevant informa-
tion for breast cancer classification along with messenger
RNA (mRNA) expression levels in tissue and ctDNA
panels in serum [19–22].
The review is focused on the clinical relevance of liquid
biopsy in breast cancer. We will provide an update concerning
CTCs and ctDNA utility as a tool for breast cancer patients
monitoring during the course of disease.
An overview on main signaling pathways involved
in breast cancer
Mutation gain in somatic cells is the pivotal mechanism
through which cancer cells alter normal signaling pathways
[23], in addition to other modifications such as epigenetic
variations which are primarily influenced by the local micro-
environment and germline genetic variations.
Cancer whole-genome studies highlighted a still growing
number of involved somatic mutations, most of which have
not yet a known biological function. The accumulation of
mutations within a cancerous and/or precancerous cell popu-
lation is a dynamic process not fully understood, and until
now, several pathways have been identified as responsible
for the process of mammary carcinogenesis.
The evaluation of estrogen, progesterone, and epidermal
growth factor type 2 receptors (ER, PgR, and HER2, respec-
tively) is widely used in clinical practice in order to obtain
prognostic and predictive information [24]. Also, several other
markers, such as B-cell lymphoma 2, androgen receptor, EGF,
phosphatase and tensin homolog (PTEN), and phos-
phatidylinositol 3-kinase (PI3K), may have prognostic value
in breast cancer. Several studies have reported that mutations
in PI3K are associated with lower recurrence and mortality
Table 1 Immunohistochemical profile of breast cancer subtypes
Luminal A Luminal B HER2+/ER− Basal like
• ER+ • ER+ • ER− • ER−
• and/or PR+ • and/or PR+ • PR− • PR−
• HER2− • HER2+ • HER2+ • HER2−
ER estrogen receptor, PR progesterone receptor,HER2 receptor type 2 for
EGF
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rates [25, 26]. PI3K/Akt/mTOR pathway is often altered in
patients with breast cancer. This pathway controls several bi-
ological activities within the cell, and its activation is one of
the fundamental downstream molecular events following ty-
rosine kinase growth factor receptor activation [27]. The first
event is the activation of PI3K, which, when not inhibited by
PTEN, phosphorylates and activates AKT localizing it in the
plasma membrane [28]. AKT can have a number of down-
stream effects by activating different substrates such as the
mammalian target of rapamycin (mTOR) whose substrate is
S6 Kinase 1 (p70S6K) [29–31] (Fig. 1).
PI3K mutations are more frequent in node-negative (not
spread to nearby lymph nodes), ER-positive, and Her2- neg-
ative patients, and are generally related to a favorable clinical
outcome. Several studies have reported that mutations in PI3K
are associated with lower recurrence and mortality rates [25,
26]. PI3Kmutations are very high recurrent genetic alterations
in breast cancers with a rate of 20–40 % in these cancers [32].
The PI3K/AKT/mTOR pathway plays a central role in regu-
lating cell proliferation, growth, apoptosis, and motility. The
PI3K enzyme is a heterodimer composed of a regulatory (p85)
and a catalytic subunit (p110), and it is activated after the
dimerization and auto-phosphorylation of tyrosine kinase re-
ceptors, such as HER2. Following its activation, PI3K is able
to phosphorylate phosphatydilinositol 4,5-trisphosphate
(PIP2) in phosphatydilinositol 3,4,5-trisphosphate (PIP3) that
is the main actor for the activation of PKB/AKT [33, 34].
Under physiological conditions, the PIP3 levels are tightly
regulated by specific phosphatases, such as PTEN.
Alteration in the PI3K/AKT pathway, due to loss or gain of
expression as well as genetic changes of its members, is a
pivotal event toward a malignant transformation, as already
well described in literature. Several studies have demonstrated
that the gene encoding the PI3K catalytic subunit p110a
(PI3KCA) is mutated in different cancers [35]. Activating
mutations in the p110α catalytic subunit of PI3K has been
also described in 9–45 % of breast cancers [32]. The preferred
mutational Bhot spots^ for PI3KCA are predominantly exons
9 and exon 20; mutations of these exons determine the follow-
ing amino acid substitutions: H1047R, E545K, and E542K.
This mutations account for 70–80 % of PI3KCA alterations in
breast cancer [36]. These hot spot mutations are known to
Fig. 1 Activation mechanism of
PI3K/Akt/mTOR signaling
pathway
Tumor Biol. (2016) 37:4263–4273 4265
modulate the activity of the PI3K in the signaling pathway
regulating cell growth, motility, and other important cellular
functions [36, 37].
Also, PTEN and AKT are frequently altered in breast can-
cer. As widely highlighted in many forms of infiltrating breast
cancers, PTEN genetic alteration and in particular its loss of
expression yield a probability of incidence quantified in 4–
35 %, while mutations or variations in AKT expression levels
give a percentage of 6 and 15–41 %, respectively. Taken to-
gether, these genetic aberrations seem to play a pivotal role in
the deregulation of PI3K/AKT pathway, and consequently,
this possibly leads to disease progression and therapy resis-
tance [38].
Other relevant mutations in breast carcinogenesis are those
in TP53 gene. Indeed, 83% of basal-like tumors showed TP53
mutations compared to 15 % in the luminal, normal-like, and
HER2-positive tumors [39]. TP53 is a tumor suppressor gene
encoding a 393 amino-acid nuclear phospho-protein whose
role is to arrest propagation of genetically aberrant cells [40].
TP53 mutations also seem to play a role in the epithelial-
mesenchymal transition (EMT) through the inhibition of epi-
thelial markers such as E-cadherin and the transcriptional ac-
tivation of genes associated with a mesenchymal phenotype
such as Twist, ZEB-1, and ZEB-2 [41]. These molecular
events encourage cells to acquire a cancer stem cell-like phe-
notype and to promote tumor growth and metastatic spread.
TP53 expression is also tightly correlated with Ki67 expres-
sion and is negatively associated with histological grade, tu-
mor size, and co-expression of vascular endothelial growth
factor (VEGF), epidermal growth factor receptor (EGFR),
and type II topoisomerase (TOPO II). In addition to the afore-
mentioned genetic alterations, also point mutations, as well as
gene amplification in the ESR1 gene, even though at a low-
frequency, seem to play a role in metastatic breast cancer [32,
42]. Some of these identified mutations seem to lead to ERα
transcriptional activity in a hormone-free manner, promoting
resistance to hormonal treatments [43, 44].
Liquid biopsy
Diagnosis and metastasis monitoring is mostly carried out
through tissue biopsy and re-biopsy, a very invasive tech-
nique, limited, and not easily acceptable by the patients.
In order to obtain an efficient and painless management of
the disease over time, liquid biopsies may represent a precious
basin of Bnew generation^ biomarkers. These biomarkers are
released into the bloodstream from both primary and metasta-
tic sites, and thus, they can provide intriguing information on
tumor evolution. Indeed, elevated concentrations of circulat-
ing nucleic acids have been found in blood plasma or serum of
patients with various tumor types and were often associated
with unfavorable outcome in some clinical studies. These
findings could improve the actual approach to breast cancer
patients and might in the near future help clinicians in modi-
fying the treatment choices according to the tumor evolution.
Circulating tumor DNA: a general overview
Cell-free DNA (cfDNA) was firstly reported in 1948 by
Mandel and Metais in the blood of healthy individuals [45].
Cell-free DNA is a double-stranded nucleic acid with low
molecular weight than genomic DNA that circulate in the
bloodstream in short (between 70 and 200 base pairs in length)
or long fragments up to 21 kb. To date, the source of cfDNA is
still not completely understood, while a big contribute seems
to derive essentially from nucleated blood cells. In cancer
patients, a considerable proportion of cfDNA is thought to
origin from tumor cells although a proportion of fragments
is represented by wild-type DNA as well as in the plasma of
healthy controls. Given that somatic mutation occurs exclu-
sively in tumor cells, the identification of a mutation in
cfDNA can define the portion of circulating tumor DNA
(ctDNA) [46]. The possible reason for the high presence of
nucleic acids into the blood of cancer patients could be ex-
plained as a part of the cell death process (apoptosis and ne-
crosis) in cancer cells. Within the physiological clearance pro-
cess of an apoptotic and/or necrotic cell, macrophages take a
pivotal role in engulfing dead cells and in realizing the
digested DNA into the tissue environment [47]. Another hy-
pothesis is that ctDNA arises from the lysis of circulating
cancer cells or micro metastases, already into the bloodstream,
shed by tumor. The amount of ctDNA that derives from tumor
cells is also affected by specific tumor characteristics, i.e., the
size and the stage of the tumor as well as all the physiological
filtering events triggered into the blood and lymphatic circu-
lation [48].
Circulating tumor DNA levels are considerably lower in
earlier stage disease and consequently more difficult to detect
than in advanced or metastatic disease [49].
Targeted therapies have deeply changed the approaches
to treatment of cancer over the past 10 years. Indeed, al-
most all tumors acquire resistance to systemic treatment as
a result of clonal evolution and selection of resistant cells
within the tumor mass. This Bclonal process^ is tightly
dependent from the heterogeneous characteristic of a tu-
mor. Although genotyping is the most reliable method ap-
plied for classifying tumors for future clinical decisions,
tumor tissues provide only a snapshot and are often diffi-
cult to obtain. Therefore, methods are needed for a rapid,
cost-effective (less-expensive) and noninvasive identifica-
tion of biomarkers at various time points during the course
of disease. Since ctDNA is a potential surrogate for the
entire tumor genome, the use of ctDNA as a liquid biopsy
may represent a valuable tool for obtaining the genetic
follow-up data that are urgently needed.
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Some quantitative study reported differences in terms of
circulating DNA amount between breast cancer and healthy
individuals [50]. Furthermore, the levels of ctDNA in cancer
patients would represent a stable parameter whose fluctuations
during the course of the disease may be correlated with clin-
ical outcome. Indeed, it has been demonstrated that high levels
of ctDNA correlate with tumor size, lymph node involvement,
histopathological grade, and clinical staging [51].
The presence of specific mutations helps to differentiate
ctDNA from normal cfDNA. These somatic mutations, com-
monly single base pair substitutions, are present only in the
genomes of cancer cells and are never present in normal cell
DNA within the same individual. These features confer ele-
vated specific properties to ctDNA as a biomarker. One of the
most common somatic alterations in breast cancer are the mu-
tation in PI3K gene that occurs in 40 % of all breast cancers.
This high mutational frequency renders PI3K a highly inter-
esting circulating biomarker. In a recent study [52], the PI3K
mutations were detected in ctDNA of 13/46 (28 %) patients
with metastatic breast cancer, but no trace of the mutation was
found in patients with resectable breast cancer. These results
suggested that the detection of ctDNA mutations is lower in
the early stage disease compared to more advanced stage and
demonstrated the feasibility of detection of PI3K mutation in
plasma [53].
A more recent study highlighted the utility of ctDNA in the
clinical management of breast cancer patients. The study of
Dawson et al., conducted on 30 women with metastatic dis-
ease under chemotherapy, compared the radiographic mea-
surement of tumors with the molecular analysis of ctDNA as
well as CA 15–3 and circulating tumor cells. With respect to
CA15-3 and CTCs which showed not high detectability with-
in the sample, ctDNAwas identified in almost all 30 patients
(29/30) in whom mutations of TP53 and PI3K were already
characterized in tumor biopsy specimens. This assay proved
the high sensitivity of ctDNA for detecting presence of meta-
static disease and study tumor burden when compared to the
aforementioned biomarkers. Furthermore, the researchers
found that ctDNA levels are often associated with both treat-
ment efficacy and survival. In fact, patient with longer surviv-
al showed lower ctDNA levels if compared with patients who
showed early disease progression and shorter survival [54,
55].
Technical approaches for ctDNA
Nowadays, circulating tumor DNA represent a very high chal-
lenging and innovative analyte. Because of its very low con-
centration and degree of fragmentation in liquid samples, it
needs very sensitive detection methods. Moreover, it has been
demonstrated that plasma represents a better ctDNA source
than serum, although the amount of ctDNA in serum can be
2–24 times higher than in plasma [56]. Indeed, during the
ctDNA isolation process, it exists a high risk of cell contam-
ination, and for this reason, it has been recommended the use
of plasma as a source for the analysis of tumor-specific DNA.
Moreover, another benefit deriving from plasma ctDNA is the
lower concentration of background wild-type DNA [57]. One
of the main issues in ctDNA analysis is the assay specificity
and sensitivity. In fact, a major drawback of the ctDNA assays
is the low frequency of some mutations that occur in tumors
and the risk of interference bywild-type sequences [58]. There
are now many methods for assessing ctDNA including the
following:
& BEAMing a technology which combines emulsion PCR
with magnetic beads and flow cytometry for the highly
sensitive detection and quantification of tumor DNA
molecules
& Next-generation sequencing approaches
& Digital PCR platforms
Each technique is able to detect mutant alleles with a sen-
sitivity of at least 2 %. Unfortunately, costs and feasibility of
developing the aforementioned methods in the clinic practice
show several technical issues. However, the use of these strat-
egies would allow and help clinicians in monitoring the dis-
ease progression by quantifying the number of ctDNA copies
per milliliter of plasma (copies/mL) [59].
Circulating tumor DNA: applications
The application of new sensitive methods for very rare circu-
lating mutation is urgently needed. In fact, the feasibility and
potential utility of ctDNA for detection of PI3K mutations
have been already deeply highlighted in patients with meta-
static breast cancer [53, 60].
Recently, the detection of tumor DNA from tissue speci-
mens and paired plasma samples has been reported.
Moreover, the possibility to find mutations in ctDNA at early
stage breast cancer can acquire high value as a marker for
Bminimal residual disease^ (MRD) in those patients subjected
to curative surgery. In particular, a recent work published by
the group of Beaver et al. [61] investigated PI3K exon 20 and
exon 9mutational status through droplet digital PCR (ddPCR)
in both tissue and paired plasma samples. The ddPCR is a
new, highly sensitive, and cost-effective method that allows
the analysis of rare mutation in a background of thousands of
wild-type molecules. The aim of this study was to provide a
proof-of-concept on the potential role of ctDNA as a marker
for MRD. Nowadays, breast surgery represents the elective
treatment for localized breast cancer patients. Unfortunately,
to date, we do not have any marker to recognize patients
definitively cured from those who may still have residual dis-
ease and thus may benefit from adjuvant treatment [46].
Beaver et al. [61] have analyzed 29 presurgery plasma
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samples and compared the results obtained with paired post-
surgery samples with the aim to highlight differences in PI3K
fraction abundance among samples before and after resection.
They showed that PI3K (exons 9 and 20) mutation levels in
plasma differ among pre- and post-surgery withdrawal. These
results, although preliminary, are very intriguing and could
lead to a more personalized breast cancer management [61].
The feasibility of ctDNA analysis have been, not so far,
investigated by Higgins et al., by using a BEAMing approach.
This analysis was conducted within a double, retrospective
and prospective, cohort of metastatic breast cancer patients.
In the retrospective study, the aim was to verify BEAMing
feasibility for the detection of PI3KCA mutations in plasma
that was present in paired tumor tissue specimens. Themethod
resulted reliable in identifying the same mutations observed in
FFPE-derived tissue samples with a concordance of 100 %. In
the prospective analysis, a cohort of 51 metastatic breast can-
cers was studied for PIK3CA mutations both by sequencing
and BEAMing in tumor tissue and paired ctDNA. Also for
this cohort, a high concordance rate was highlighted [62].
Another interesting molecular marker is TP53 mutation
that can be evaluated from ctDNA as well as PI3K mutations.
In particular, Madic et al. have demonstrated that TP53 muta-
tions in plasmamay help in the management of triple-negative
breast cancer patients [63]. Mutations within TP53 sequence
were analyzed by using next-generation sequencing plat-
forms. TAm-Seq-based Illumina and 454 sequencing success-
fully allowed TP53mutation detection in 84% of tumor tissue
specimens. The double NGS approach confirmed the same
genetic alteration also in the paired plasma in 81 % of cases,
demonstrating the robustness of NGS as a method to detect
TP53 mutations [63].
CTCs: a general overview
Circulating tumor cells (CTCs)were first observed in the nine-
teenth century [64, 65]. Generally, CTCs have peculiar fea-
tures including a visible nucleus and cytoplasm, and are main-
ly characterized for the expression of cytokeratin and no
CD45 expression [66].
Since CTCs do not circulate in healthy patients and
have been detected in patients with almost all cancer
types, they acquire high relevance for studying the biology
of the early metastatic disease and for diagnosis of meta-
static patients [67].
Circulating tumor cells show a very low frequency in
bloodstream [68]. Indeed, the number of CTCs would provide
real-time information on the clinical behavior of many tumors,
and they could additionally predict clinical outcome in meta-
static patients [69, 70] as they seem to play a crucial role in
mediating metastatic spread [71].
In fact, metastasis is a multistep process starting with the
detachment of high malignant potential cells from the primary
tumor site that could flow in bloodstream or the lymphatic
system, and reach new distant sites. The final step for a circu-
lating tumor cell is to extravasate, implant, and then proliferate
generating a macroscopic, clinically detectable neoplastic
growths [72].
Since CTCs seem to play crucial roles not only in metasta-
sis but also in resistance to drug administration, it is funda-
mental to understand their clinical role during the early stages
of the disease [73, 74].
Indeed, CTCs can predict early recurrence as well as de-
creased overall survival in chemo-naive patients with
nonmetastatic breast cancer. These results confirm that the
assessment of CTC might provide important prognostic infor-
mation in these patients [75].
In a work by Franken et al. [76], a correlation study be-
tween stage and CTCs number was reported. The CTCs num-
ber evaluation was carried out using three cohorts of patients
in stages I, II, and III, respectively. The detection of ≥1 CTCs
in bloodstream was 16 % for breast cancer patients at stage I,
18 % for stage II, and 31 % for stage III. Therefore, CTC
number positively correlates to disease stage, and patients
with at least one CTC detected showed higher risk of recur-
rence than patients with no CTC detected. Furthermore, CTC
evaluation before surgery plays a pivotal role in predicting
disease-free survival (DFS) [76].
Furthermore, a massive presence correlates more
strongly with poor prognosis than single CTCs in meta-
static breast cancer patients [77]. On the basis of the dif-
ferent degree of epithelial and/or mesenchymal marker
expression, CTCs can be divided different subpopulations
[78, 79]. These subpopulations may also acquire general
cancer stem-like properties allowing them to act as not
differentiated cells by regulating several biological pro-
cesses as quiescence, self-renewal, asymmetric division,
drug resistance, resistance to radiation, and abilities in
surviving within a foreign microenvironment, resulting
then in metastasis. In fact, these stem-like breast cells
commonly show a CD44+/CD24− phenotype [80] or the
expression of aldehyde dehydrogenase 1 (ALDH1) [81].
Technical approaches for CTCs
CTCs are high malignant cells that circulate in bloodstream
at extremely low frequency. CTC number is even lower in
nonmetastatic disease [82, 83]. Current technical ap-
proaches for detecting CTCs can be mainly classified in
enrichment and detection steps on the basis of specific
capture properties (Fig. 2). Through enrichment methods,
CTCs are detected for their physical properties such as cell
size, density, and positive or negative immunoselection. In
fact, CTCs are 20–30 μm in diameter, while blood cells
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measure 8–12 μm [84]. Indeed, in order to discriminate
cells for their size, several filtration methods have been
developed [85]. Mononuclear cells and CTCs can also be
discriminated from other cells on the basis of their density
by performing a ficoll-gradient enrichment [86]. However,
the most commonly used techniques for CTCs enrichment
are the immuno-based approaches. The only FDA- ap-
proved automatized immunomagnetic enrichment is the
CellSearch system. It relies on the ability of magnetic
ferrofluids coupled to anti-EpCAM antibodies to recognize
and bind only epithelial tumor cells expressing EpCAM,
indirectly discriminating them from blood cells. Anti-
EpCAM antibodies are added to 7.5 mL of peripheral
whole blood [51]. EpCAM and members of the CKs family
(CK8, CK18, and CK19) have been identified as useful
markers for positive discrimination in patients with carci-
noma. In particular, positive markers for breast cancer en-
richment are considered EpCAM/CK, HER-2, Mammag
lobin, and MUC-1 for their high expression degree in can-
cer cells [87]. On the contrary, negative discrimination can
be carried out by using antigens as CD45, expressed in
leukocytes, and CD61, expressed in megakaryocytes and
platelets [88].
On the other hand, methods of CTC detection are divided
into the following:
1. Nucleic-acid-based approaches: it relies on specific DNA
or mRNA markers useful to identify and discriminate
CTCs as epithelial-specific genes (CK and EpCAM),
organ-specific markers (CEA, PSA [89], mammaglobin
[90], and MUC-1 [91]) and tumor-specific markers such
as the EGFR andHER-2 genes which are normally absent
in circulation [92].
2. Immunology-based assay: it represents an effective meth-
od for CTCs detection and isolation. It uses labeled anti-
bodies against epithelial or tumor-associated antigens
along with automated digital microscopy or flow cytom-
etry to identify and quantify CTCs.
3. Epithelial immunospot (EPISPOT) assay: it allows the
detection of tumor-specific proteins.
Circulating tumor cells: applications
CTCs represent a reliable therapeutic indicator for many
forms of cancer as indicated in recent evidences that sug-
gested a strong correlation between CTC number and out-
come with respect to PFS and OS [93, 94]. Many clinical
trials have been specifically drawn to demonstrate that
CTC identification and characterization may be used for
improving the management of breast cancer patients as
well for patients’ stratification. Indeed, metastatic breast
cancer patients showing a ≥5 CTCs number after 3–
5 weeks from systemic and hormone- therapies correlate
with shorter PFS than patients with less than five CTCs.
Moreover, this strong correlation has been also demon-
strated between CTCs counts and radiographic disease
progression in patients treated with chemotherapies and
hormone therapies [95]. Therefore, CTC isolation could
be used in addition to standard methods for monitoring
disease status in metastatic breast cancer [96]. A few stud-
ies suggest that CTC number may have a potential prog-
nostic role in early-stage patients. Indeed, CTCs are de-
tectable in 20–40 % of patients with early-stage breast
cancer according to the aforementioned PCR-based assays
and almost 10 % of early-stage patients according to the
CellSearch system [93, 94, 97]. With respect to the main
genetic alteration involved in breast carcinogenesis,
Fernandez et al. [98] showed the feasibility of using
CTCs for TP53 mutation detection as a noninvasive meth-
od. In particular, CTCs from two triple negative breast
cancer patients were enriched using CellSearch system
and single cell selected by DEPArray™. Distinct CTC
populations were found, some of which harboring the
same TP53 mutation (R110 delG), and also confirmed in
the paired tumor samples, while some other showed either
a different TP53 mutation (TP53 R110 delC) or the wild-
type allele. These results indicate that CTCs could repre-
sent a noninvasive source of cancer cells for the determi-
nation of disease progression and the identification of new
potential therapeutic targets [98].
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Conclusions
In the last few years, we have experienced an increased
interest of genetic aberration role in carcinogenesis. In
fact, the use of molecular biomarkers in the next future
would probably help clinicians in evolving their actual
approach to patients’ management for different forms of
cancer (i.e., c-KIT and PDGFRA in GIST, EGFR in lung
cancer, BRAF in melanoma, RAS in colorectal cancer,
PTEN and TP53 in breast cancer). Moreover, the intro-
duction in clinical practice of many new generation ap-
proaches is day-by-day increasing the spectrum of gene
mutations whose involvement in cancer would drive on-
cologist to new personalized treatments delivering.
Despite this wide range of new acquired knowledge, mor-
tality rate is still high. This is mainly caused by the de-
velopment of metastasis due to cancer cell detachment
from the primary tumors. It is now widely demonstrated
that metastasis and primary tumors are biologically differ-
ent. Therefore, these heterogeneity characteristics give to
the metastatic disease the reason for considering it as a
world apart to be still completely discovered. Thus, char-
acterizing new lesions through a re-biopsy appears to be
fundamental. Unfortunately, re-biopsy is not always indi-
cated due to many reasons, first of all the extreme inva-
siveness that limits the procedure only to certain loca-
tions. In order to overcome these issues, the possibility
of using liquid biopsies plays a primary role. CTCs and
ctDNA have been well characterized as useful new and
noninvasive biomarkers that can be used routinely be-
cause of their ease of access within many body fluids.
Circulating tumor DNA is a double-stranded nucleic acid
with low molecular weight that has been detected in the
plasma and serum of cancer patients as well as in that of
healthy controls. In cancer patients a considerable propor-
tion of plasma DNA seems to originate from tumor cells,
although another amount seem to derive from circulating
cancer cells lysis as well as micro metastases. Moreover,
ctDNA amount strongly correlates with tumor stage and
size. The use of ctDNA as a liquid biopsy may help to
obtain the genetic follow-up data that are urgently needed.
Regarding CTCs analysis, at present, their role can be
mainly limited to prognostic purposes, but there is an
increasing interest in the development of new techniques
for their molecular characterization. CTCs are cells that
escape from the primary tumors and migrate through the
circulation until they colonize a new district. It is well-
known from recent clinical studies that their count is pro-
portional to a poorer prognosis in various tumor types.
Following this consideration, the growing interest in the
last few years by the scientific community to liquid biop-
sies gives hope for their routinely application in clinic
practice. Even if the road seems to be long and winding,
new efforts and investments are needed to bridge the gap
still existing.
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Microtubules are dynamic and structural cellular components involved in several cell functions, including cell shape, motility, and
intracellular trafficking. In proliferating cells, they are essential components in the division process through the formation of the
mitotic spindle. As a result of these functions, tubulin and microtubules are targets for anticancer agents. Microtubule-targeting
agents can be divided into two groups: microtubule-stabilizing, and microtubule-destabilizing agents. The former bind to the
tubulin polymer and stabilize microtubules, while the latter bind to the tubulin dimers and destabilize microtubules. Alteration of
tubulin-microtubule equilibrium determines the disruption of the mitotic spindle, halting the cell cycle at the metaphase-anaphase
transition and, eventually, resulting in cell death. Clinical application of earlier microtubule inhibitors, however, unfortunately
showed several limits, such as neurological and bone marrow toxicity and the emergence of drug-resistant tumor cells. Here
we review several natural and synthetic microtubule-targeting agents, which showed antitumor activity and increased efficacy in
comparison to traditional drugs in various preclinical and clinical studies. Cryptophycins, combretastatins, ombrabulin, soblidotin,
D-24851, epothilones and discodermolide were used in clinical trials. Some of them showed antiangiogenic and antivascular activity
and others showed the ability to overcome multidrug resistance, supporting their possible use in chemotherapy.
1. Introduction
Microtubules are dynamic and structural cellular compo-
nents, typically formed by 13 protofilaments, which constitute
the wall of a tube; each of the protofilaments consists of
a head-to-tail arrangement of 훼/훽 tubulin heterodimers
[1]. They are involved in several cell functions, includ-
ing cell shape, motility, and intracellular trafficking. In
proliferating cells, they are one of the essential compo-
nents in the division process through the formation of the
mitotic spindle. This event can take place because of the
dynamic nature of microtubules through polymerization
and depolymerization cycles [2]. As a result of these func-
tions, tubulin and microtubules are targets for anticancer
agents [3, 4]. Microtubule-targeting agents can be divided
into two groups: microtubule-stabilizing and microtubule-
destabilizing agents.The former bind to the tubulin polymer
and stabilizemicrotubules, while the latter bind to the tubulin
dimers and destabilize microtubules [5, 6].
Despite these differences, alteration of tubulin-
microtubule equilibrium leads to the same final result:
it disrupts the mitotic spindle, halting the cell cycle at the
metaphase-anaphase transition and eventually resulting in
cell death [7] (Figure 1).
Clinical application, however, has unfortunately shown
several limits, such as a high level of neurological and bone
marrow toxicity and the emergence of drug-resistant tumor
cells due to the overproduction of P-glycoprotein (Pgp),
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Figure 1: The dynamic nature of cytoskeleton is due to cycles
of microtubule catastrophes. (a) Model structure of assembled
cytoskeleton. The variety of shapes and sizes of the microtubule
cytoskeleton is as great as the number of different cell types. In
interphase, microtubules are long and stable because there are
almost no catastrophes. (b) In mitosis, catastrophes are relatively
frequent, resulting in highly dynamic microtubules that reach a
steady-state length after a few minutes of growth (c). (d) After
the segregation of chromatids, a new cycle of depolymerization
and polymerization begins, resulting in a new stable microtubule
cytoskeleton in daughter’s cells (d). Blue and red arrows indicate
effects of stabilizing and destabilizing agents, all resulting in cell
cycle arrest.
an ATP-binding cassette (ABC) transmembrane transporter
[8], the overexpression of different beta-tubulin isotypes,
including 훽III-tubulin [9, 10], or tubulin mutations [11].
Several natural and synthetic microtubule-targeting
agents, exhibiting antitumor activity and increased efficacy
in comparison to traditional drugs in various preclinical and
clinical studies, have been discovered and their mechanisms
have been elucidated [12, 13]. Apart from the well-known
antimitotic function, for some of these drugs antiangiogenic
and antivascular activity were demonstrated; for others the
ability to overcome multidrug resistance was found. Many of
these new generation microtubule-targeting agents are still
under evaluation for clinical use. Some of them showed good
tolerability and antitumor activity in particular cancers.
This review provides an overview of those microtubule-
targeting drugs which are to date under clinical evaluation.
A particular attention will be paid to the translation of
preclinical data into the design of clinical trials.
2. Microtubule-Destabilizing Agents
Colchicine and Vinca alkaloids are two of the first
microtubule-destabilizing agents to be discovered.These two
compounds depolymerize microtubules by interacting with
various 훽-tubulin sites. In particular, Vinca alkaloids interact
with tubulin at specific binding sites which differ from those
of other agents, including colchicine or taxanes, interfering
with microtubule dynamics, blocking polymerization at
the end of the mitotic spindle, and leading to metaphase
arrest. Thanks to their peculiar mechanism of action, Vinca
alkaloids have beenwidely used in anticancer therapy, usually
in combination with other chemotherapeutic agents which
do not have cross-resistance with them. First-generation
Vinca alkaloids such as vinblastine have been included in
the treatment protocol of both Hodgkin and non-Hodgkin
lymphomas and testicular carcinoma, while vincristine
has been approved for several years in the treatment of
hematological tumors such as acute leukemia and multiple
myeloma but also of rare tumors such as rhabdomyosarcoma
and neuroblastoma. However, vincristine treatment was
associated with a severe neurotoxicity, while the suppression
of the bone marrow was more frequently reported during
vinblastine therapy [14]. Second-generation semisynthetic
Vinca alkaloids, vinorelbine and vindesine, have shown a
broader spectrum of antitumor activity in vitro, along with a
decreased neurotoxicity. Vinorelbine was approved as single
agent and in combination therapy for the treatment of both
hematological and solid tumors, including lung cancer, breast
cancer, and gynecological tumors [15]. Recently, another
synthetic Vinca alkaloid, vinflunine, has been approved in
Europe for the second-line treatment of metastatic urothelial
carcinoma. It is the first fluorinated microtubule inhibitor,
which was associated with a higher antitumor activity than
other Vinca alkaloids, showing also an excellent safety profile
[16].
In order to overcome the clinical limits of these agents,
in the last years attention has been focused on natural and
synthetic compounds with a different structure but which act
in a similar way [7, 17] (Table 1).
2.1. Cryptophycins. Cryptophycins are synthetic derivatives
of macrocyclic depsipeptides, isolated by Nostoc sp. [18].
They block cell division and prevent the correct formation
of the mitotic spindle, by inhibiting tubulin polymerization,
probably at the binding site of the Vinca alkaloids [19]. In
particular, C-52 and C-55 induce apoptosis by means of Bcl-
2 hyperphosphorylation and inactivation [20–22] (Figure 2).
These compounds are able to induce this phosphorylation at a
greater extent than othermicrotubule inhibitors [23].Thefirst
form discovered was epoxide cryptophycin 1, which showed
antitumoral activity both in preclinical in vitro (colon, breast,
ovarian, lung, and nasopharyngeal carcinomas) and in vivo
(lung, breast, and prostate tumors) models. This has led to
isolation and synthesis of cryptophycin analogs, divided into
epoxides, chlorohydrins, and glycinate chlorohydrins [24]
(Figure 3).
Cryptophycin 8 is the first C-1 analog synthesized in order
to improve its antitumoral efficacy by means of conversion
of the epoxide group into chlorohydrin. Its activity has been
shown both in murine and human tumors. Although it is
not as powerful as C-1, it is more soluble in water and has a
stronger therapeutic effect.Nevertheless, it is still too unstable
in solution to be considered clinically relevant [25].
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Table 1: Microtubule-destabilizing agents.
Chemical lead Properties and effects Clinical trial/status References
Cryptophycins Apoptosis induction. Synergistic withchemotherapy and radiation.
Phase II clinical trials in
platinum-resistant ovarian cancer and in
NSCLC (C-52) but withdrawn due to
peripheral neuropathy.
[26, 28, 31, 32, 36]
Combretastatin A-4-P
Antivascular and antiangiogenic activity.
Synergistic with radiation, hyperthermia,
chemotherapy, and immunoradiotherapy.
Phases II and III clinical trials in
advanced solid tumors (lung and thyroid
cancer) and in combination with
carboplatin.
[63, 64, 66–70, 72, 73]
Combretastatin A-1-P
Antivascular and antitumoral activity
superior to CA-4-P. Synergistic with
chemotherapy.
Phase I clinical trials in solid tumors and
in acute myelogenous leukaemia and
myelodysplastic syndromes.
[78, 79]
Ombrabulin
Antivascular and antitumoral activity
superior to CA-4-P. Synergistic with
chemotherapy.
Phase I clinical trials as a single agent or
in combination; phase III clinical trial in
advanced soft-tissue sarcoma.
[86]
Soblidotin
Apoptosis induction. Antivascular
activity. Antitumoral activity in tumors
resistant to vincristine, docetaxel, and
paclitaxel.
Phase II clinical trials in advanced solid
tumors (soft-tissue sarcoma, NSCLC). [99–105]
D-24851
Curative at nontoxic doses in rat tumor.
No neurotoxic effects. Oral applicability.
Activity versus MDR cell lines.
Phase I/II clinical trials in advanced solid
tumors. [140, 141]
Pseudolaric acid B
Antiangiogenic activity. No neurotoxic
effects in tested animal. Activity versus
MDR cell lines.
Preclinical phase. [148, 149]
Embellistatin Antiangiogenic activity. Preclinical phase. [150]
Induce Bcl-2 phosphorylation
Cryptophycins
Inhibit polymerization
Bcl-2
inhibition
Apoptosis
in G2/M
Mitotic arrest
and destabilize microtubules
Figure 2: Mechanism of action of cryptophycins.
Cryptophycins
Epoxides
Chlorohydrins
Glycinate
chlorohydrins
C-1, C-52, C-292
C-8, C-55, C-296, C-283
C-249, C-55gly, C-309, C-283gly
Figure 3: Classification of cryptophycins.
2.1.1. Cryptophycins 52 and 55. Cryptophycin 52 (LY355703)
is a synthetic epoxide, used in phase II clinical trials, which
presents a cytotoxic effect 400 times stronger than paclitaxel
and Vinca alkaloids [26, 27]. It shows in vitro antitubulin,
antimitotic, and cytotoxic activity which is dose-dependent
against tumor cells. Furthermore, its activity has been eval-
uated both in murine tumor models and in human tumor
xenografts [23]. C-52 resulted to be also effective against
multidrug-resistant tumors [26, 28, 29].
Paclitaxel and the Vinca alkaloids are sensitive to the
multidrug resistance (MDR) transporters P-glycoprotein (P-
gp, MDR-1) and/or MDR-associated protein (MRP-1). Cryp-
tophycin 52 was tested for its sensitivity to multidrug resis-
tance in several paired cell lines in which a sensitive parental
line was matched with a multidrug-resistant derivative line.
Compared to other antimitotic agents (paclitaxel, vinblas-
tine, and vincristine), the potency of cryptophycin 52 was
shown to be minimally affected in multidrug-resistant cells
compared to their sensitive parental lines [30]. Cryptophycin
52 fragment A analogues was synthesized to improve the
potency and the aqueous solubility of the molecule allowing
for the modification of its formulation. However, the same
functional groups that rendered these analogues more potent
and more water soluble also contributed to making them
better substrates of the Pgp efflux pump. It is an unacceptable
feature in the development of a clinically relevant antitumor
agent [29].
Preclinical toxicological studies on animals (rats and
dogs) have shown that above a certain concentration level C-
52 causes secondary effects such as neutropenia and gastroin-
testinal problems but not neurotoxicity. These studies have
allowed evaluating the optimum phase II dosage and tracing
the plasma pharmacokinetic profile [26]. Furthermore, phase
I clinical trials identified 1.5mg/m2 as a well-tolerated dose
level of C-52. It was delivered as a 2-hour i.v. infusion on
day 1 and day 8 repeated every 3 weeks [31]. This schedule
was employed in a phase II study to determine the activity
of C-52 in non-small cell lung cancer (NSCLC) patients
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previously treated with platinum-based chemotherapy and
to characterize its toxicity profile. A good rate of disease
stabilization and an unacceptable toxicity was found in this
setting [32]. Also, a multicenter trial was performed to
evaluate the same schedule of the drug in patients with
platinum-resistant advanced ovarian cancer. A considerable
clinical benefit without serious adverse events was achieved
[28]. Afterwards, these phase II clinical trials were terminated
due to significant neurological toxicity [12].
Cryptophycin 55, a C-52 chlorohydrin, shows higher
cytotoxic activity and therapeutic efficacy than its epoxide
precursor, but its low stability in solution has delayed its
clinical application [33]. This problem has been overcome,
however, by means of the synthesis of glycinate esters (C-
55gly, C-283gly, and C-309) which show not only an in vivo
activity similar to their precursors but also a high level of
stability [34].
Treatment with C-52 and C-55 combined with other
chemotherapy agents has produced synergic effects without
increased toxicity, bringing about a greater survival rate
in ovarian carcinoma murine models [23, 28]. The use of
human tumor xenografts has made it possible to evaluate C-
52 and C-55 activity combined with cisplatin, carboplatin,
and oxaliplatin in different tumors. C-52 showed a synergic
effect only when associated with cisplatin, whereas C-55
showed increased activity with all the platinum compounds
[35]. In vivo antitumoral activity of C-52 and C-55 has
been assessed in combination with radiotherapy (2훾) or
with 5-FU in tumor xenografts, showing an increased effect.
Pharmacokinetic analyses performed in murine models have
demonstrated that C-52 concentration in the tumor increased
after administration and remained high for 24 hours. The
mean life of C-55 was the longest in the liver, intermediate in
tumor tissue, and less in plasma. After C-55 administration,
the mean life of C-52 was the longest in tumor tissue, less
in plasma, and even less in the liver, suggesting almost total
conversion of C-55 into C-52 in the tumor.The greater C-52
accumulation in tumor tissue depends on the bioconversion
of C-55 in C-52 and different binding affinities towards
different tissue proteins. The use of C-55 to deliver C-52
increased the retention of C-52 in tumor tissue and reduced
its presence in all studied normal tissues. Furthermore,
extracellular acid pH of the tumor increased C-55 stability,
whereas intracellular basic pH encouraged bioconversion by
stimulating its pharmacological activity [36].
The obtained results indicated that C-52 and C-55 ful-
filled all the criteria required by ideal chemotherapy agents,
since they showed an action mechanism against a specific
target and considerable activity against drug-resistant cells.
However, the lack of response observed in some tumors
and peripheral neuropathy have been limiting factors in the
development of these agents leading to termination of their
study.
2.1.2. Second-Generation Cryptophycins. C-309, C-249, and
C-283 are second-generation candidates for clinical use.The
first two are glycinate esters, synthesized in order to provide
a higher chemical stability and more solubility in water. C-
309 is a derivative of C-296 which has proved to have more
therapeutic activity than C-55, C-283, C-249, and C-296; it is
able to bring about a complete or partial regression of murine
tumors at lower doses than those of other glycinate analogs.
C-249 derives from C-8 and is active against MDR tumors.
Moreover, it has the advantage of being easier to synthesize.
These second-generation analogs have proved to be up to
1000 times as active as those of the first clinical candidates
(C-52) but with the same or even less toxicity [34].
2.2. Combretastatins. The combretastatins, isolated from
Combretum caffrum, are molecules structurally related to
colchicine which have been extensively developed since the
late 1990s as vascular-disrupting agents (VDAs) [37]. The
vascular-disrupting effect of these compounds is present well
below the maximum tolerated dose, with a wide therapeutic
window [38]. A number of combretastatins are currently
in clinical trials: combretastatins A4- and A1-phosphate,
verubulin, crolibulin, plinabulin, and ombrabulin [12].
2.2.1. CA-4-P. Combretastatin A-4 interacts with tubulin
at the colchicine binding site but not in the same pseu-
doirreversible manner. It is used as a combretastatin A-
4 3-O-phosphate (CA-4-P), a prodrug which is soluble in
water and transformed into its active form by endogenous
phosphatases [39]. It showed cytotoxicity in tumor cell lines
and in human endothelial cells, HUVEC, which are sensitive
to the drug only if they are actively proliferating, suggesting
a potential use as an antiangiogenic agent [38]. By interfering
with microtubule polymerization and with mitotic spindle
assembly, CA-4-P induces G2/M arrest, thus bringing about
cell death by either mitotic catastrophe or apoptosis [38, 40,
41].
Recent computational studies, using fluorescence spec-
troscopy, identified a potential binding site on 훾-tubulin
for both CA-4-P and colchicines [42]. Since high levels of훾-tubulin have been reported in poorly differentiated and
aggressive brain tumors, such as human glioblastoma and
medulloblastoma [43, 44] and lung [45] and breast cancer
[46], the discovery of a potential site interaction on this
molecule would offer the possibility of targeting inhibition
with a new class of chemotherapeutic agents. However, the
experimental validation of such interesting observation is
underway.
CA-4-P (also known as Zybrestat or fosbretabulin) shows
a potent in vivo antivascular activity since it causes a rapid
and widespread reduction of the tumoral blood flow and
an increased vascular resistance, effects which are extremely
reduced in the normal tissues [47]. At a dose of 1/5–1/10
of the maximum tolerated dose (MTD), the central area
of the tumor undergoes hemorrhagic necrosis, while a thin
peripheral ring of live cells remains [38, 48, 49]. On the con-
trary, colchicine and other drugs act only at approximately
MTD [50]. This constitutes an important advantage for the
therapeutic application of CA-4-P. An immediate effect of
CA-4-P treatment is an increased vascular permeability,
which is important for the reduction of blood flow through
vascular collapse, and an increased viscosity consequent to
fluid loss from the vasculature. However, endothelial barrier
function alterations and increased vascular permeability
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might contribute to hastening tumor cell extravasation,
causing progression to stages of greater malignancy, with
heightened invasiveness and, in some cases, increased distant
metastasis. It is no coincidence that susceptibility of tumors
to CA-4-P showed a positive correlation with tumor vascular
permeability [51]. Experiments conducted on HUVEC cells
have shown that the CA-4-P-inducted microtubule depoly-
merization triggers off the actin reorganization through Rho
activation and MLC (Myosin Light Chain) phosphorylation,
thus causing rounding and retraction of cells and mem-
brane blebbing. These events are associated with increased
permeability, while the morphological cell change might
contribute to determining the effects observed in vivo by
means of vascular constriction [52, 53]. Furthermore, since
CA-4-P interferes with the formation of stress fibers, it
inhibits the VE-cadherin/훽-catenin complex, thus leading
to the destabilization of cell-cell junctions and increasing
endothelial permeability [54].
The ex vivo perfusion of animal tumors highlights a
lower increase in vascular resistance to that found in vivo,
suggesting that the blood might also contribute towards the
antivascular action of the drug [48]. It has been demonstrated
that CA-4-P induces increased expression of endothelial
CAM, responsible for the observed neutrophil recruitment
which in vivo probably contributes both to vascular damage
and to tumor cell death [55].
Apart from being an antivascular agent, CA-4-P inhibits
the formation of new blood vessels, both in vitro and in
vivo, presumably through inactivation of the VE-cadherin/훽-
catenin complex and Akt, all proteins required for cell
adhesion, survival, and proliferation during neoangiogenesis.
The same study has shown that smooth muscle cells, which
are resistant to the drug, interfere with its antiangiogenic
activity in vitro, suggesting that they may confer resistance
to the endothelium by stabilizing cell-cell junctions [54]. CA-
4-P selectivity towards the neoplastic tissue might therefore
depend on the immaturity of tumor vessels, together with
the proliferative status of tumor endothelial cells. Moreover,
CA-4-P reduces in vitroHIF-1 expression (Hypoxia Inducible
Factor-1) under hypoxiamainly in endothelial cells compared
to that in cancer cell lines, suggesting a further possible
mechanism of action for the drug [56] (Figure 4).
However, the effects of CA-4-P on tumor growth are
not particularly significant, probably because of the per-
sistent presence of vital peripheral cells [50], although the
administration of several doses compared to the same total
dose of the drug does increase its antitumoral effect [57,
58]. Furthermore, CA-4-P activity is directly proportional
to tumor size [49]. This aspect, together with its capacity to
act on the tumor core, differentiates this drug from more
common therapeutic approaches, which target the peripheral
tumor area. These complementary properties, together with
the limited action of CA-4-P as a single agent, have led
to experimentation involving combined treatments. It has
been demonstrated that CA-4-P increases the response to
radiotherapy and hyperthermia in treated tumors [57, 59]
and, what is more, leads to a 90% increase in the retention
of the anti-CEA antibody marked with I131 in the tumor,
which is eradicated in 83%of the cases [60]. Similarly, CA-4-P
increases the effect of chemotherapy drugs such as cisplatin,
vinblastine, 5-fluorouracil, and irinotecan [57, 61].
The overall in vivo results obtained with CA-4-P have
led to its introduction in phase I clinical trials [12, 62–
66]. A phase I trial was performed to determine the MTD,
safety, and pharmacokinetic profile of CA-4-P. This study
showed absence of traditional cytotoxic side effects, with a
toxicity profile which seems consistent with a “vascularly
active” drug [67, 68]. The effects on tumor blood flow
were assessed using dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) techniques. Dosages < or =
60mg/m2, as a 10min infusion at 3-week intervals, define
the upper boundary of the MTD. Similar effects were seen in
other phase I clinical trials using a weekly and daily schedule
[69, 70]. Afterwards, a further phase I trial investigated
the combination of CA-4-P with carboplatin. A greater
thrombocytopenia was observed as a consequence of altered
carboplatin pharmacokinetics [63].
In order to improve its efficiency and reduce its side
effects, a specific therapeutic system has been realized,
based on the use of liposomes containing CA-4-P, carrying
superficial RGD-peptides able to bindwith the훼v훽3 integrins
overexpressed on proliferating tumor endothelium. In vitro
tests have demonstrated the specificity and stability of the
system, essential properties for its in vivo application [71]. To
date, phase II/III clinical trials in lung and thyroid cancer
are currently being evaluated [12]. These studies showed
that CA-4-P with or without carboplatin and paclitaxel
combination therapy was well tolerated in thyroid cancer
patients, although it did not meet statistical significance in
OS improvement [72]. Instead, preliminary data suggests
survival benefits and increased responses without significant
additional toxicity in NSCLC patients treated with CA-4-P in
combination with carboplatin, paclitaxel, and bevacizumab
compared to patients treated with carboplatin, paclitaxel, and
bevacizumab only [73].
2.2.2. CA-1-P. Combretastatin A1 phosphate (also known as
Oxi4503), a CA-1 water-soluble prodrug, shows a powerful
antivascular activity.Whenused inmurine and human tumor
xenografts at much lower doses than those required by CA-4-
P, CA-1-P brings about a drastic reduction of blood flow, with
resulting necrosis [74]. CA-1-P causes an increase in vessel
permeability, in VEGF production and apoptosis induction
in endothelial cells [75]. At high doses it is more easily
tolerated than CA-4-P and shows a much higher antitumoral
activity, leading to complete regression of human tumors
even at extremely low doses [74]. Excellent results have
been obtained with combined treatments involving several
chemotherapy agents [76].
In vitro pharmacokinetic studies have suggested that CA-
1-P is transformed into a more reactive metabolite than CA-
4-P, which is responsible for most of the antitumoral activity;
this has formed the basis for further clinical developments
of the drug as an antivascular and antitumor agent [77].The
drug has completed the phase I evaluation as a potential anti-
cancer drug at three different centres in the United Kingdom,
and it was studied in other phase I clinical trials [78, 79].
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Figure 4: Combretastatin A-4-P: mechanisms of action at tumor level.
Recently, a new series of combretastatin derivatives have
been synthesized and evaluated in seven cancer cell lines,
exhibiting good anticancer activity [80, 81].
2.2.3. Ombrabulin. Ombrabulin (also known as AC-7700)
is a serinamide hydrochloride, synthetic derivative of CA-
4-P, which inhibits growth in a large number of drug-
resistant animal tumors and carcinogen-induced tumors [39,
82]. Differently from CA-4-P, it does not act directly on
the tumor vessels but instead causes constriction of the
arterioles, resulting in complete downstream arrest of the
blood flow and tumor growth [83].These effects are obtained
at doses half of MTD and 100 times less than that of CA-
4-P [84]. Finally, the combination of AC-770 with cisplatin
increases the effect of both drugs in murine tumors, with
curative effects, and in human tumor xenografts [85]. In 2002,
AC-7700 was introduced into phase I clinical trials in the
United States and in Europe (AVE8062, Aventis Pharma).
Recently, ombrabulin in combination with cisplatin was used
in a phase III clinical trial for patients with advanced soft-
tissue sarcomas after failure of anthracycline and ifosfamide
chemotherapy, significantly improving progression-free sur-
vival. However, this improvement was not clinically relevant,
despite being statistically significant [86].
2.3. Dolastatins. Dolastatins are pseudopeptides isolated
from the sea hare Dolabella auricularia [50]. Dolastatins 10
and 15 showed antiproliferative activity.These agents induce
apoptosis through interactionwith tubulin [87]. Dolastatin 10
is a natural peptide able to interfere in microtubule assembly
bymeans of the noncompetitive binding to theVinca alkaloid
site [88]. A phase II trial investigated dolastatin 10 in NSCLC
patients. A low response rate was observed, even though
a good tolerability was achieved. Myelosuppression was
confirmed as the only noteworthy toxicity [89].
Other phase II clinical trials of dolastatin 10 were carried
out in patients with metastatic melanoma, advanced col-
orectal and breast cancers, recurrent platinum-sensitive ovar-
ian carcinoma, and hormone-refractory metastatic prostate
adenocarcinoma [90–94].These studies confirmed the same
results previously obtained in terms of tumor response and
toxicity. No activitywas found in advanced pancreaticobiliary
cancers and metastatic soft-tissue sarcomas [95, 96]. For
this reason, it was suggested to not pursue the clinical
development of this drug in further studies, not only because
of its side effects [97] but also because of the low mean
survival rate of the treated patients [95].
2.3.1. Soblidotin. Soblidotin (TZT-1027) is a synthetic ana-
log of dolastatin 10 which inhibits the growth of several
tumoral cell lines and induces caspase-3-dependent apopto-
sis. It shows in vivo antivascular effects in tumoral models
overexpressing VEGF and in murine colon tumors, with
an increase in vascular permeability, vessel closure, and
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widespread hemorrhage. Soblidotin also shows antitumoral
activity in vincristine-, docetaxel-, and paclitaxel-resistant
tumors, which makes it a potential chemotherapy drug for
use in tumors which do not respond to other microtubule
inhibitors [98].
The first two European phase I clinical trials identified a
recommended dose of soblidotin between 2.4 and 2.7mg/m2
for a 3-weekly administration with neutropenia, fatigue, and
a reversible peripheral neuropathy as the DLT. Moreover
neurological side effects seemed to correlate with previous
exposure to other neurotoxic agents such as platinum com-
pounds. No correlation was found with body surface area
suggesting possible use of flat dose regimen for next trials
[99, 100]. In a Japanese phase I clinical trialMTDof 1.5mg/m2
administered on days 1 and 8 in 3-week courses was found
[101]. A combination of this drug with carboplatin was also
tested.The recommended dose was 1.5mg/m2 for soblidotin
and AUC 5 for carboplatin and no pharmacokinetics inter-
action was observed [102]. In NSCLC patients a phase I trial
indicated a recommended dose of 4.8mg/m2, administered
every 3-4 weeks as recommended dose [103].
Phase II clinical investigations suggested activity in
advanced or metastatic soft-tissue sarcomas with prior treat-
ment with anthracycline-based chemotherapy. This study
confirmed tolerability profile, but objective response was
demonstrated in none of the patients [104]. Another phase II
trial showed no anticancer activity for soblidotin in NSCLC
patients previously treated with platinum-based chemother-
apy [105].
2.3.2. Dolastatin 15. Dolastatin 15 is very similar to dolastatin
10. It was demonstrated by chromatography that the binding
domain is the same as Vinca alkaloids and antimicrotubule
peptides. The site of the binding is not a well-defined locus
but a series of overlapping domains [106].This drug showed
an effect on growth and differentiation in leukaemia cell lines
[107], induction of apoptosis through Bcl-2 phosphorylation
in small cell lung cancer cell lines [108], and G2/M cell
cycle arrest in human myeloma cell lines [109]. Romidepsin
(Istodax), a dolastatin 15 analog, which also possesses activity
as a histone deacetylase inhibitor, was found to be active in
cutaneous T-cell lymphoma with a 34% objective response
rate and for this it was approved in 2009 [110, 111]. Other
two analogues of dolastatin 15 are used in clinical trials:
cemadotin and tasidotin.
2.3.3. Cemadotin. Cemadotin (LU103793) exerts its effect by
inhibition of microtubule polymerization [112]. This drug is
not able to inhibit the binding of vinblastine to tubulin and it
can suppressmicrotubule growthwithout a significantmicro-
tubule depolymerization [113].This agent was first evaluated
in three phase I clinical trials for advanced refractory solid
tumors with different schedules. Daily 5-day every 3 weeks
schedule identified a recommended dose of 2.5mg/m2 per
day. It was associated with neutropenia, peripheral edema,
and liver function test abnormalities as DLTs. This dose
showed lack of prohibitive cardiovascular effects. Acceptable
general toxicity profile has allowed prompting phase II
trials [114]. Meanwhile, cemadotin was studied for 24-hour
intravenous (i.v.) continuous infusion every three weeks.
15mg/m2 was the recommended dose for this schedule.
Hypertension was highlighted as the DLT, even if its nature
remained unclear [115]. Even 5-day continuous intravenous
(CIV) infusionwas investigated.MTDwas 12.5mg/m2.There
were moderate nonhematologic toxicities and no evidence of
the cardiovascular toxicity [116]. Pharmacokinetic analysis in
these phase I trials suggested that cardiovascular toxicity may
be associated with the magnitude of the peak blood levels of
cemadotin or its metabolites, whereas myelotoxicity depends
on the duration of time that blood levels exceed a threshold
concentration.
The first phase II clinical trial which used this drug
at 2.5mg/m2 daily 5-day schedule repeated every three
weeks obtained clinical activity with durable response in
chemotherapy-naı¨ve patients with metastatic melanoma.
Toxicity profile previously determined for this schedule was
confirmed [117]. In contrast, no activitywas observedwith the
same schedule in metastatic breast cancer patients previously
treated with two lines of chemotherapy and in untreated non-
small cell cancer patients [118, 119].
2.3.4. Tasidotin. Tasidotin (ILX651) is a third-generation
dolastatin 15 analogue that is metabolically stable through its
resistance to hydrolysis [120]. It demonstrated in vitro cell
cycle arrest in the G2 and M phases and inhibition of tubulin
polymerization similar to cemadotin and the Vinca alkaloids.
It can inhibit the extent of microtubule assembly even at low
concentrations [121]. In vitro study with MCF7/GFP breast
cancer cells and in vivo pharmacokinetic analysis through
LOX tumors xenografts proposed that tasidotin is converted
in tasidotin C-carboxylate, a functionally active intracellular
metabolite, 10 to 30 times more potent [122]. Capability
of inducing apoptosis was observed in Ewing’s sarcoma,
rhabdomyosarcoma, synovial sarcoma, and osteosarcoma
cell lines. Preclinical xenograftmodels of pediatric sarcomas
showed antitumor activity [123].
Like cemadotin the schedule indicated for clinical use
is daily administration for 5 days every 3 weeks. The
recommended dose for investigation in phase II trial was
27.3mg/m2/day. The toxicity profile was favourable and
antitumor activity was found in melanoma patients [124].
The other two schedules were evaluated in phase I trial:
34.4mg/m2 d1,3,5 q3wk and 46.8mg/m2 d1,8,15 q4wk [125,
126]. Tolerability was similar with these schedules.
2.4. Rhizoxin. Rhizoxin (NSC 332598) is a macrolide antitu-
mor antibiotic extracted from a pathogenic fungus, Rhizopus
chinensis. It is known for its antifungal activity, but it is
also studied for cytotoxic activity in a variety of human
tumor cell lines, including melanoma, leukaemia, sarcoma,
and some human tumor xenografts of melanoma, lung, and
breast cancer [127].The drug can bind to tubulin and inhibits
microtubule assembly, blocking the cell cycle at the G2-M
phase [128]. It is a more potent cytotoxic compound than
vincristine in vitro, and, in addition, it showed activity in
vincristine-resistant cells [129].
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A recommended dose of 2.0mg/m2 administered by i.v.
bolus injection at 3-week intervals was identified through
phase I trial because of its good tolerability with mucositis
and neutropenia as the main toxicities [130]. Minimal or
absent antitumor activity was found in phase II studies for
patients with various advanced solid tumors [131–134]. A
pharmacological study demonstrated the rapid and variable
elimination of rhizoxin. These data could explain the low
levels of systemic toxicity and the little response rates [135].
For this reason, alternative dosage and schedule were studied
in phase I trial. A 72-hour continuous i.v. infusion indicated
the dose of 1.2mg/m2/72 hours as the MTD. The toxicity
profile was similar to that obtained with brief infusion, but
yet no antitumor responses were found [136].
2.5. D-24851. D-24851 (N-(pyridin-4-yl)-[1-(4-chlorbenzyl)-
indol-3-yl]-glyoxyl-amid) is a synthetic compound which
has been selected by a cell-based screening assay by ASTA
Medica AG, Germany. This drug destabilizes microtubules
by interacting with a binding site that does not overlap
with those of known microtubule-destabilizing agents like
vincristine or colchicine [137, 138].
D-24851 (also known as indibulin) induces Bcl-2 and
Bax-mediated apoptosis in both p53wt and p53−/− cell lines
[137, 139]. It produces in vivo curative effects in rat sarcomas
at nontoxic doses, is suitable for oral use, does not give
rise to neurotoxic effects at curative doses, unlike vincristine
and paclitaxel, and is effective in MDR tumor cells, so that
it is an excellent candidate as a chemotherapy agent [137].
In 2004, an LC/MS/MS (liquid chromatography/tandem
mass spectrometry) system was proposed for quantitative
analysis of D-24851 in human plasma and urine in phase I
clinical trials. Indibulin was used in phase I/II clinical trials
of patients with advanced solid tumors (metastatic breast
cancer) [27, 140, 141]. In a phase I clinical trial indibulin was
studied for oral administration once daily for 14 days every 3
weeks in patients with various solid tumors. Pharmacokinetic
analysis showed a better tolerability under feeding condition.
The recommended dose identified for further studies was
60mg daily for 14 days. Dose-limiting toxicities were nausea
and vomiting, which seemed to be related to solvent lactic
acid [141].
Furthermore, the effects of two N-heterocyclic indolyl
glyoxylamides derivatives of D-24851, BPR0C259, and
BPR0C123 were investigated in NSCLC cells. The obtained
results showed that these compounds can suppress the cell
proliferation, by inducing p53-independent apoptosis and
G2/M phase arrest, and potentially increase radiosensitivity
of human lung cancer cells in a p53-independent manner
[142].
2.6. Pseudolaric Acid B. Pseudolaric acid B (PAB) is a
diterpene isolated from Pseudolarix kaempferi Gordon which
is able to selectively inhibit the growth of actively proliferating
cancer cells. It induces apoptosis through the intrinsic path-
way, involving JNK/SAPK and p53. Nevertheless, its cytotoxic
effectswere found also in p53−/− cell lines, which is interesting
for its therapeutic use [143, 144].
It interacts with a different binding site on tubulin com-
pared with those of colchicine and vinblastine [143] and, both
in vitro and in vivo, inhibits endothelial cells proliferation
and VEGF-dependent formation of blood vessels. In fact,
PAB antagonizes VEGF-mediated antiapoptotic activity by
inhibiting the phosphorylation/activation of KDR, the VEGF
receptor implicated in mediating this effect [145]. Further-
more, at nontoxic doses, PAB inhibits VEGF secretion from
tumor cells by reducing its HIF-1-dependent transcription.
PAB, in fact, acts by accelerating the proteasome-mediated
degradation of HIF-1훼, by means of a mechanism so far
unknown [146]. PAB also induces endothelial cell retraction,
intercellular gap formation, and actin stress fiber formation,
effects which can be attributed to disruption of tubulin
cytoskeleton and which contribute to its antiangiogenic
action [147]. Moreover, PAB circumvents P-glycoprotein
overexpression-induced drug resistance and the doses used
are well tolerated and nontoxic and have not proved lethal
on tested animals [143]. PAB showed significant inhibitory
effect and an additive inhibitory effect in combination with
adriamycin on the growth of gastric cancer in vivo [148, 149].
2.7. Embellistatin. Embellistatin is a ketone isolated from
Embellisia chlamydospora which inhibits microtubule poly-
merization and shows a strong antiangiogenic activity. It
inhibits in vitro bovine endothelial cells (BAEC) prolifera-
tion through p53 and p21 activation, thus inhibiting bFGF-
induced formation of vessels.This antiangiogenic activity has
been confirmed in vivo on murine models. Similar effects
have been found in human tumor cell lines, suggesting that
it could be suitable for use in the development of new
anticancer drugs [150].
2.8. CI-980. CI-980 (mivobulin) acts at the colchicine bind-
ing site and it appears to have significantly less vesicant
activity than vinblastine [151]. It is a mitotic inhibitor with in
vivo and in vitro activity against murine multidrug-resistant
sublines. Its interactions with microtubules in vitro are
similar to other drugs, but cellular microtubule and mitotic
inhibition is more potent [152]. The uptake of CI-980 is not
temperature or energy dependent, and its passive diffusion
is followed by a significant but largely reversible binding to
intracellular or membrane components [153].
Mivobulin was tested in a phase I trial using 24-hour
infusion repeated every 3 weeks. MTD was 14.4mg/m2. The
main toxicities were neutropenia, dose-dependent but not
dose-limiting, and early and reversible neurotoxicity char-
acterized by dizziness, headache, loss of coordination, loss
of consciousness, nervousness, and other symptoms. Tumor
responses and tumor marker reductions were observed in a
colon cancer patient and two ovarian cancer patients, respec-
tively [154].The same toxicity profile was confirmed in other
studies [155, 156]. A continuous 72-hour infusion of MTD
4.5mg/m2/day every 21 days was associated with reduced
neurotoxicity but dose-limiting neutropenia [157]. For this
reason, it was used in phase II clinical trials. A similar toler-
ability profile was found. CI-980 seems inactive in metastatic
colorectal carcinoma, advanced soft-tissue sarcomas, treated
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and untreated melanoma, hormone-refractory prostate can-
cer, and malignant gliomas [158, 159]. Minimal activity was
observed in platinum-refractory advanced epithelial ovarian
carcinoma [160].
2.9. T138067. T138067 is a synthetic compound which irre-
versibly disrupts microtubule assembly by a selective and
covalent binding to beta1, beta2, and beta4 isotypes of beta-
tubulin at a conserved cysteine residue (Cys-239). Its action
results in cell cycle arrest at G2/M and induction of apoptosis.
It exhibits cytotoxic activity in tumor cell lines resistant to
various antimicrotubule agents (vinblastine, paclitaxel, etc.)
and in multidrug-resistant human tumor xenografts [161].
The covalent interaction of T138067 with 훽-tubulin may be
proposed as a new way to overcome MDR. In vivo studies
showed that this drug can cross the blood-brain barrier in
mice, suggesting a possible use for brain tumors [162].
Phase I trials of T138067 were conducted by using a
3-hour infusion of drug given weekly or every 21 days
with a recommended dose of 330mg/m2 per week. DLTs
were neutropenia and neurological effects, consisting of
encephalopathy, headache, hearing loss, and ataxia [163, 164].
This weekly dosage was used in two phase II clinical trials
for patients with malignant glioma and metastatic colorectal
cancer previously treated with irinotecan and 5-fluorouracil,
respectively.The good toxicity profile was confirmed in both
studies. No clinical activity in terms of antitumor responses
was observed in both cases [165, 166].
2.9.1. T900607. T900607 is similar to T138067 for the kind of
binding to tubulin in Cys-239 residue, but it is distinguished
for a reduced ability to cross the blood-brain barrier.
A phase I trial indicated a recommended dose of
130mg/m2 delivered in i.v. infusion over 60 minutes on
a 21-day cycle. No objective responses were observed but
stable disease was reported in 7/20. Cardiac toxicity is the
main drug-related side effect with this schedule. A different
schedule consisting of weekly administration of T900607
identified MTD of 100mg/m2. This schedule was used in a
phase II clinical trial for untreated patients with unresectable
hepatocellular carcinoma. It showed good tolerability and
moderate activity in some of these patients [167].
2.10. ABT-751. ABT-751, also known as E7010, is a sulfon-
amide able to impair microtubule formation and inhibit
cell growth. Its binding characteristics seem to be different
from that of colchicine and Vinca alkaloids. This agent
has antiproliferative effects in many tumor cell lines which
are drug-resistant due to the P-glycoprotein overexpression
[168]. It showed a broad spectrum of activity against a
variety of tumors inmice and human tumor xenografts, when
administered orally [169]. Beta3 isotype is the preferential
binding target. ABT-751-resistant cells were characterized by
decreased expression of this tubulin isotype [170]. A warning
derived from an in vivo study, which shed light on a possible
testicular toxicity related to this drug administration in mice.
It consisted of loss of seminiferous epithelial cells due to apop-
tosis of meiotic spermatocytes [171]. This drug selectively
reduces tumor blood flow through tumor necrosis, regardless
of a direct cytotoxic effect on tumor cells. Negligible is the
effect on normal vascular function [172].
In a phase I clinical trial ABT-751 was administered
as oral single or 5-day doses. The recommended dose for
phase II trials is identified at 320mg/m2 for single dose and
200mg/m2/day for 5-day repeated dose. Peripheral neuropa-
thy and intestinal paralysis were the DLTs. Gastrointestinal
toxicity was dose-dependent but hematological toxicity was
not dose-dependent [173]. Pharmacokinetic analysis of this
study suggested that activity of ABT-751 may be time-
dependent. For this reason a new schedule using a divided
dose in order to maintain the blood level of ABT-751 has
been formulated. The recommended dose in hematologic
malignancies is 175mg/m2/day orally for 21 days every 4
weeks [174]. In a phase I trial for a pediatric population of
patients with solid tumors ABT-751 was administered orally
once daily for 21 days, repeated every 28 days. The MTD
obtained for this schedule was 100mg/m2/day. DLTs included
fatigue, sensory neuropathy, transient hypertension, neu-
tropenia, thrombocytopenia, nausea, vomiting, dehydration,
abdominal pain, and constipation [175]. In a phase II clinical
trial, 21-day every 28 days schedule at the dose of 200mgdaily
was studied in taxane-refractory NSCLC patients. Toxicity
was acceptable. Median time to tumor progression and
overall survival was 2.1 and 8.4 months, respectively. The
objective response rate was 2.9% [176]. The combination
of this agent with other cytotoxic drugs was proposed for
future clinical studies. A phase IB study investigated clinical
antitumor activity of ABT-751 in combination with docetaxel
in patients with castration-resistant prostate cancer. Based
on the cumulative safety analysis, the recommended phase
II dose of ABT-751 is 200mg daily with docetaxel 60mg/m2
for this patient population [177]. Further phases I and II
clinical trials were carried out to evaluate activity of ABT-751
in combination with other drugs in advanced or metastatic
NSCLC patients [178, 179]. ABT-751 showed adverse effects,
although it has the advantage of being orally bioavailable.
3. Microtubule-Stabilizing Agents
Unlike the microtubule-destabilizing agents, there are other
compounds that enhance microtubule polymerization. One
of the most important classes of microtubule-stabilizing
chemotherapy agents is that of taxanes, which target the
cytoskeleton and spindle apparatus of tumor cells by binding
to the microtubules, thereby disrupting key cellular mech-
anisms, including mitosis. The first microtubule-stabilizing
agent used in anticancer chemotherapy [180] was paclitaxel.
Thanks to their peculiar mechanism of action, taxanes are
among the most effective chemotherapeutic agents used
in the treatment of multiple solid tumors, such as breast,
ovarian, lung, and prostate cancers. However, the occurrence
of resistance limits treatment options and creates a major
challenge for clinicians. Several potential mechanisms of
resistance to these drugs have been identified, occurring at
different pharmacodynamics levels. Besides the well-known
overexpression of Pgp, an ABC transmembrane transporter
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Table 2: Microtube-stabilizing agents.
Chemical lead Properties and effects Clinical trial/status References
Epothilones
Elevated water solubility, activity
versus MDR cell lines, and chemical
malleability.
Phase II/III clinical trials in
taxane-sensitive solid tumors (breast,
lung, and prostate).
[195, 196]
Ixabepilone
Epothilone B analog, superior
metabolic stability, and activity versus
MDR cell lines.
Approved in 2007 for metastatic breast
cancer; several ongoing trials in solid
tumors.
[194, 197]
Laulimalide
Activity versus MDR cell lines and
angiogenic activity, synergistic with
docetaxel.
Preclinical phase. [199, 201]
Dictyostatin Activity against MDR cell lines,synergistic with taxol. Preclinical phase. [205, 206]
which pumps the drugs out of the tumor cells [8], the
alterated expression of specific beta-tubulin isotypes, seems
to play an important role. Most notably, the increased expres-
sion of 훽III-tubulin isotype has been associated with resis-
tance to taxanes in several cancers, including ovarian, breast,
and lung cancer [9, 181, 182]. It was originally correlated to the
qualitative or quantitative modifications of the microtubule
complex, which represents the target of such agents, defini-
tively reducing the drug binding affinity [27]. However, the
aberrant expression of 훽III-tubulin can also interfere with
microtubule dynamics, increasing the dynamic instability
and counteracting the stabilizing effect of taxanes, with con-
sequences for drug sensitivity/resistance [183]. Recent studies
have suggested 훽III-tubulin as a prosurvival factor adaptively
expressed by cancer cells exposed to microenvironmental
stressors, such as hypoxia or deficient nutrient supply [184,
185]. The activation of the 훽III-tubulin-dependent pathway
in partnership with GTPases, such as guanylate-binding
protein 1 (GBP1), is associated with the incorporation of
PIM1 into the cytoskeleton of tumor cells, conferring a
survival advantage in a hostile microenvironment and ulti-
mately leading to the development of drug resistance [186].
Finally, a multitude of alterations involving the apoptotic
signaling pathways downstream the microtubule complex,
as well as aberrant expression of microRNA, have been also
found in resistant tumors. A better understanding of the
mechanism underlying the occurrence of acquired resistance
has led to the development of a new class of microtubule-
stabilizing agents, including epothilones, discodermolide,
sarcodictyins, eleutherobin, and laulimalide, which are more
readily modifiable, with different structures but a similar
mechanism of action [187] (Table 2). Epothilones, disco-
dermolide, eleutherobins, and sarcodictyins compete with
paclitaxel for binding to microtubules and bind at or near the
taxane site, whereas laulimalide seems to bind to unique sites
on microtubules (Figure 5). Recently, a novel generation of
paclitaxel derivatives have been designed, targeting a specific
intermediate binding site in the microtubule with differential
affinity, depending on the 훽-tubulin isotype expressed in the
tumor. Since 훽III-tubulin is overexpressed in the majority
of aggressive, resistant tumors, the design of a 훽III-tubulin
targeted agent was expected to enhance the drug activity,
reducing common toxicities. However, none of the new
molecules tested in breast cancer cell lines was superior to the
currently used taxanes [188].
3.1. Epothilones. Among several classes of microtubule-
targeting chemotherapy agents that may maintain activity
despite clinical resistance to taxanes, there are the epothilones
which have been isolated from the soil bacterium Solangium
cellulosum and have been studied most extensively in the
clinical setting [189]. They induce the formation of an
aberrant mitotic spindle, mitotic arrest, and apoptosis [190].
Their greater solubility in water and their activity in MDR
cells havemade them an alternative to paclitaxel in anticancer
treatment [191, 192]. Moreover, their simple structure makes
it easy to produce synthetic analogs during the clinical
experimentation phase [190]. There are 4 classes of natural
epothilones (A, B, C, and D). By means of the selection
of resistant or taxane-dependent cells, it has been observed
that tubulin 훽1 plays an important role in epothilone B
functionality [193].
Ixabepilone (Ixempra) is a semisynthetic analog of
epothilone B, selected because of its greater metabolic stabil-
ity and its simple preparation. It ismore powerful in vitro than
paclitaxel and also presents cytotoxicity against MDR cells.
It causes regression of MDR tumors and is more effective
than paclitaxel in a wide spectrum of pediatric tumors
[194]. Ixabepilone is currently the only approved epothilone
derivative and the most clinically advanced (phases II and III
clinical trials), showing efficacy in several patient subgroups
and in various stages of breast cancer.This analog is used for
the treatment of locally advanced or metastatic breast cancer
as monotherapy after failure of a taxane, an anthracycline,
and capecitabine, or in combination with capecitabine after
failure of a taxane and an anthracycline [195].
A great number of phase II clinical studies of epothilones
in cancer treatment have been reported, and significant
activity in taxane-sensitive tumor types (such as breast, lung,
and prostate cancers) has been observed [12, 17]. Response
rates in taxane-refractory metastatic breast cancer are rela-
tively modest, but ixabepilone and patupilone have shown
promising efficacy in hormone-refractorymetastatic prostate
cancer and in taxane-refractory ovarian cancer [196, 197].
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Figure 5: Similarities and differences between mechanisms of action and activity of microtubule-stabilizing agents.
3.2. Laulimalide. Laulimalide is a macrolide isolated from
marine sponge (Cacospongia mycofijiensis) which inhibits
cell proliferation, promoting assembly of the microtubules
and stabilizing them in a taxol-like way, but at a different
binding site located on two adjacent 훽-tubulin units between
tubulin protofilaments of amicrotubule [198–200].This agent
is also active in MDR cells which overexpress glycoprotein-P.
When administered below cytotoxic doses, the drug prevents
blood vessel formation and the VEGF-induced endothelial
cell migration [201]. Docetaxel and laulimalide possess a
synergic effect in these two processes, whereas they have
antagonistic effects towards cell proliferation.
Used at low doses, laulimalide inhibits events down-
stream of VEGFR-2 activation, such as FAK and paxillin
phosphorylation, VEGFR-2/FAK/Hsp90 interaction, and
integrin activation. Compared with docetaxel, laulimalide
has less effect on the VEGF-induced VEGFR-2/integrin 훼5훽1
interaction and is more effective with regard to phosphory-
lated paxillin levels. Furthermore, it inhibits RhoA/integrin훼5훽1 association, suggesting that synergic effects of the two
drugs might be explained by two different modalities of
action.
The low quantities of the drug found in nature, together
with its instability caused by its transformation into iso-
laulimalide, have led to the synthesis of the drug itself and
of several analogs. The removal of a electrophilic and/or
nucleophilic group, which prevents the substitution process,
leads to major functional stability of the drug [202]. In
preclinical phase, laulimalide so far showed poor efficacy and
systematic toxicity [12]. The macrolide peloruside A shared
many of the same properties of laulimalide, including its
binding site and synergistic effects with the taxanes [203].
3.3. Dictyostatin. Dictyostatin is a macrolactone produced
from sponges which induces in vitro tubulin assembly in
the same way of paclitaxel but more rapidly. Like disco-
dermolide, this drug possesses an antiproliferative action
against paclitaxel-resistant human tumor cells as a result of훽-
tubulin mutations [204]. Dictyostatin inhibits the binding of
discodermolide with microtubules and both drugs are able to
inhibit the binding of epothilone B and paclitaxel withmicro-
tubules [204]. Several discodermolide/dictyostatin hybrids
have been designed and have been found tomaintain antipro-
liferative activities against several taxane-resistant cell lines
[205, 206].
3.4. Eleutherobin. Eleutherobin is a glycosylate diterpene
isolated fromEleutherobia sp. [207], which inhibits cell prolif-
eration stabilizing microtubules. It binds at a site overlapping
that of paclitaxel [208]. There is another group of cytotoxic
agents, called sarcodictyins, which are structurally and func-
tionally correlated to eleutherobins but not so toxic [209]. A
form of cytotoxic diterpene, known as (Z)-sarcodictyine A,
has been isolated from Bellonia albiflora; this exhibits a high
level of toxicity towards humanHeLa cells of the cervix [210].
Eleutherobin and the sarcodictyins have not been pursued
clinically likely due to their susceptibility to Pgp-mediated
transport [211].
4. Clinical Implications
In the last few years, a great amount of efforts has been put
into the identification of new microtubule-targeting agents
for use in anticancer therapy [212]. These last generation
agents are also active in MDR tumors, which are resistant
to the traditional antitubulin drugs used in chemotherapy,
such as Vinca alkaloids and taxanes. Furthermore, these
compounds have shown significant antivascular and antian-
giogenic activity, leading to the possibility of using them
both as alternatives to or in combination with preexistent
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drugs, as already indicated in several published studies [213].
A lot of clinical trials were conducted to study microtubule-
targeting agents. In particular, epothilones are in advanced
phases of clinical development [214, 215]. In cancer therapy,
microtubule-targeting agents can target angiogenesis, cell
migration, and intracellular trafficking to prevent tumor
growth and induce cancer cell apoptosis. These new agents,
which impair or enhance tubulin polymerization, can be clas-
sified in two groups: natural and synthetic drugs.The natural
compounds are derived from different species of uni- and
multicellular organisms. To improve their pharmacodynamic
and pharmacokinetic features some of these compounds
are transformed in semisynthetic molecules. Other agents
are produced by a totally synthetic procedure. The great
diversity of natural and synthetic compounds capable of
interactingwithmicrotubules represents an important source
for developing of novel potential anticancer agents. However,
the effectiveness of these agents in cancer therapy has been
impaired by various side effects and drug resistance. Phase I
trials have allowed identifying more tolerable schedules with
the most frequent toxicities represented by neutropenia and
neurological, cardiovascular, and gastrointestinal effects.The
main way of delivery is the i.v. infusion. Oral assumption
was studied for the synthetic compounds D-24851 and ABT-
751. The most evident efficacy was observed for rhizoxin,
above all in NSCLC. For the other agents only minor or no
responses were obtained.The identification of new schedules
or the transformation in more potent analogues should allow
overcoming these hurdles in their clinical advancement.
5. Conclusions
Data obtained up till now have allowed introducing some
of these microtubule-targeting drugs into the clinical exper-
imentation phase, whereas others, still in their preclinical
phase, represent excellent candidates for a future use in
cancer treatment, thus opening new roads towards the
development of new, individual, and efficient therapeutic
approaches.
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